posit
full list rate price target
earn chang report pleas see
tabl page
prep book move neutral
sector viewstock select
 prep upcom meet book youll need
downgrad sector neutral feel us almost good get
regulatori reimburs environ conduc innov
lead increas new product turn led acceler sale
growth rate capit market low interest rate provid compani
ampl access capit rel sector polit rhetor
benign make med-tech healthcar safe fact recent med-tech
move favor light devic tax repeal decemb rel pe
move histor low match achiev
clinton healthcar reform closer histor high
today us hard see els get materi better convers
view stock select key larg cap see upsid opportun
value-ori name identifi catalyst valu creation
rate overweight/ow continu rate ow see growth
in-lin earn believ pe expans current level
limit smid continu rate ow
make top pick pt rais prior reiter overweight
next chapter begin believ chapter one
improv execut innov growth catalyst nearli everi
month give investor greater appreci pipelin make
acceler growth real turn expand pe multipl closer peer
pt reflect prior calendar ep
still see favor risk/reward fundament reiter overweight
recent talc news flow posit believ much discount still
built pharma continu growth opportun exist portfolio
formid pipelin manag medium-term patent expir devic
 consum day bring confid improv outlook
downgrad equal weight ow valuat pt remain
stock near pt downgrad equal weight believ becton
good oper fundament manag howev stock
perspect absenc catalyst may limit opportun pe expans
chang reduc pt reflect vs pe
 ep recalibr base sector view updat
model see risk beyond outlook rais pt
reflect vs ev/ unchang sale multipl
refresh outlook still like opportun buffalo filter airseal
mark pt smid peer multipl trade also made model
chang updat market view
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
summari rate price target earn chang report chang shown bold
co
barclay research share price target price shown primari list currenc ep estim shown report currenc
current fiscal year estim barclay research fiscal year estim barclay research
wasnt long ago med-tech sector consid less-desir
healthcar sub-sector sector sale growth rate slow financi crisi
subsequ year healthcar demand prove elast coupl effect
challeng fda environ preced year well hospit push-back
new product result sector under-perform market gener
under-own view seri year investor med-tech known
thing start changeconsolid emerg pipelin
med-tech stock start receiv boost announc
april zimmer biomet announc intent merg june
covidien announc intent merg octob becton carefus
announc merger forth underli bid med-tech began
pipelin also start emerg fda start becom accommod
polici overal regulatori reimburs environ conduc
innov led lead increas new product turn led
acceler sale growth rate
capit market low interest rate provid compani ampl access
capit wherea mid-to-l fda conservat lack visibl
polit front rel sector rel benign
med-tech fact would argu actual favor past decemb
medic devic excis tax repeal
given littl surpris sector gener outperform
past sever year mani individu stock post handsom return
medtech notabl period out-performance rel
see figur last year healthcar equip suppli index
basic perform in-lin versu though
individu stock post fairli signific gain
return function improv earn major
recent stock appreci function expans price-to-earnings
valuat multipl figur rel pe med-tech move histor
low match achiev clinton healthcar reform
closer histor high
todaymov neutral industri view
us hard see els get materi better henc move
industri view neutral posit reflect belief industri coverag
univers fundamentals/valu steadi
see risk factor ahead polit environ market environ
could bring upsid and/or downsid sector prefer stock
value-bia identifi catalyst rate
 healthcar equip suppli index versu index
absolut rel pe ntm ep estim
composit includ ew well guidant biomet covidien bard st jude medic trade
welcom med-tech prep book
report find snapshot compani bull bear thesi
upcom event possibl questions/top manag team along
background inform hope find help resourc
prepar upcom meet
big-pictur topic focu manag team
sustain growth
think investor focu whether thing good get
med-tech sale growth rate acceler recent year owe solid underli
demand new product support favor fda environ continu
see gener favor environ unit state european medic devic
regul becom bit difficult costli would focu
compani product pipelin abil sustain ideal acceler sale growth
price remain headwind across med-tech sector stabl
modest hot topic biopharmaceut landscap would
ask manag discuss view price outlook could prompt
chang current price trend would focu reimburs dynam
unit state well global given signific amount sale across
industri deriv intern market
med-tech product typic high gross margin profil sale market support
 cost vari depend individu sub-sector net/net med-tech
compani gener attract oper margin profil past sever year
mani compani expand oper margin manag team
continu point expans opportun ahead would like know
confid achiev expans
capit deploy expect
 tax reform reduc effect corpor tax rate perhap importantli
provid increas flexibl use cash would focu capit deploy
particularli area avenu growth mani compani
relev medic industri confer
advanc technolog treatment diabet attd
medtron pivot data pump expect meet
confer cover varieti topic cardiolog vascular medicin
transcathet valv peripher intervent
healthcar inform manag system societi himss
one largest confer orthoped surgeon typic
orthoped manufactur host investor brief
american colleg cardiolog
confer focus diagnost therapeut pharmaceut
medic devic treatment cardiovascular diseas past
late break data releas confer typic
cardiolog compani host investor brief conjunct meet
associ periop regist nurs
societi intervent radiolog sir
societi american gastrointestin endoscop surgeon sage
confer focus minim invas surgeri includ robot
past medic devic compani host booth tour
and/or investor brief conjunct confer
intern symposium focus vascular therapi
american colleg obstetrician gynecologist acog
meet focus gastrointestin endoscopi space
host investor brief highlight product
meet focus rhythm disord target electrophysiologist
past medic devic compani host booth tour
and/or investor brief conjunct confer
meet relev urolift product also boston
scientif urolog product well axon
offici annual meet european associ percutan
cardiovascular intervent eapci one largest confer
focus intervent medicin past medic devic
compani host booth tour and/or investor brief conjunct
confer
meet histor focus pharmaceut therapi
increasingli integr devic pump cgm content past
medic devic compani host booth tour and/or investor
brief conjunct confer
societi robot surgeri sr world congress robot digit surgeri lake buena vista fl
european societi cardiolog esc
meet focus varieti topic cardiolog relev
pharmaceut well medic devic
heart failur societi america hfsa
meet focus heart failur left ventricular assist devic
american societi nephrolog kidney week
american societi radiat oncologist astro
european associ studi diabet easd
one largest medic confer intervent cardiolog topic
includ transcathet valv laa coronari stent cardiolog
compani typic host investor brief conjunct meet
one largest spine confer year spine compani
typic host meet and/or tour conjunct confer
american academi ophthalmolog
american colleg surgeon ac
american associ hip knee surgeon aahk
cardiolog meet mainli focus pharmaceut treatment also
includ content relev medic devic diagnost
meet design vascular surgeon intervent radiologist
intervent cardiologist vascular specialist
confer focus transcathet heart valv therapi
radiolog societi north america rsna
quarterli annual ep usd
consensu number bloomberg receiv gmt
price pe perform
abbott spun effect share appreci prospect improv growth abbott announc
divestitur develop market establish pharmaceut busi juli share trade sideway
attribut emerg market concern abbott announc two major acquisitionsaler februari st jude medic april
abbott close acquisit st jude januari share move higher underli sale growth trend
improv share appreci bug lag market believ stock held back view rel
premium valuat lesser extent concern around time approv freestyl libr continu glucos monitor
laboratori equip pe ntm estim pricepric lh rel pe barclay medic suppli devic
sale product categori mo end
sale geographi
major brand name includ similac isomil eleva pedialyt pediasur
includ adult nutrit brand ensur glucerna prosur zoneperfect
laboratori system includ area immunoassay clinic chemistri hematolog
transfus alin abbott latest famili instrument brand includ architect prism cell-dyn
instrument autom extract purif prepar dna rna detect measur
infecti agent abbott molecular instrument roll alinity-m
point
lab qualiti diagnost test system design rapid portabl includ handheld blood analyz
platform test target avail rapid diagnost busi point care acquir aler
brand gener pharmaceut includ therapeut gastroenterolog women health cardiovascular
pain central nervou system respiratori drug vaccin busi exclus emerg market
product includ pacemak system implant defibril cardiac resynchron devic confirmrx
divis includ product design correct monitor cardiac arrhythmia product includ ablat
cathet gener cardiac map system
product divis design monitor treat heart failur product includ heartmat left ventricl
assist devic also includ cardiomem pulmonari arteri sensor
abbott varieti product line includ drug-elut stent xienc coronari balloon cathet guidewir
imag solut
structur heart product includ devic design repair damag heart valv transcathet solut
product includ mitraclip mitral valv repair portico transcathet aortic valv replac amplatz
occlud surgic heart valv
spinal cord stimul deep brain stimul system rf ablat system
divis primarili reflect revenu freestyl libr continu glucos monitor cgm sensor system
also includ sale relat tradit blood glucos monitor meter test strip diabet product
establish barclay ical suppli devic
view good quarter organ sale growth reflect
strong growth across number divis product categori notabl diabet
core laboratori ep y/i in-lin streets/our estim
abbott expect close organ sale growth around
momentum expect continu view stock chang
maintain overweight rate abbott growth profil continu outpac peer
think stock still warrant premium valuat
addit detail quarter
million except per share data chang sale constant currenc organ basi unless otherwis note
organ sale growth ep rose y/i
diabet sale y/i driven libr report million
sale y/i
alin continu drive laboratori sale y/i
structur heart grew y/i led strong perform mitraclip mitraclip
sale total million y/i ww includ us growth
compani note see impact tariff geopolit
environ china busi
regard libr manag disclos work fda
hand open item work manag would
provid updat approv expect acknowledg misjudg
past past call manag character approv product
soon updat disappoint us like market
pediatr nutrit sale y/i us growth partial off-set
ou declin driven china manag note low birth rate
impact volum prompt competit china repres
littl less total nutrit sale
fx headwind sale quarter expect
molecular diagnost sale y/i diagnost sale
y/i busi impact sale africa
sale constant currenc organ basi
gross margin y/i lower due fx
sg margin y/i
 margin y/i
adjust tax rate flat y/i line mgmt full year guidanc
adjust ep in-lin street estim
abbott expect organ sale growth around organ basi expect follow division/product area
establish pharma epd high single-digit growth nutrit expect grow low-to-mid single-digit diagnost expect grow
mid-to-high single-digit medic devic expect grow similar reflect double-digit growth sever area fx expect
somewhat headwind gross margin expect approxim expect around sale
sg approach sale abbott expect ep reflect growth midpoint time earn
releas street estim
abbott tighten ep guidanc rang pre-releas street
manag provid formal guidanc comment last quarter view organ growth sustain
note deliv straight quarter growth moreov manag see anyth would chang
view momentum across board
actualsal laboratori management impact chang barclay medic suppli devic
abbott diversifi compani multipl driver
growth sale growth rate acceler recent year
given product pipelin peer growth
sustain in/around rate higher
abbott master destini compani
significantli de-lev financi flexibl
addit acquisit deal
plenti intern growth driver
stori well appreci reflect multipl
ceo mile white step robert ford take
white continu execut chairman
board unclear long remain chairman
ford somewhat unknown leader
revenu acceler come libr
continu good run-way growth
point anoth engin must come
view abbott high-qual growth asset believ compani favor mix
busi product well geograph perspect see medic devic busi
particularli diabet key driver sustain growth go forward believ growth
profil warrant premium valuat see stock appreci least line bottom line
growth double-digit
soon fda approv freestyl libr
jan result guidanc
feb advanc technolog treatment diabet attd meet
american colleg cardiolog meet
robert ford take ceo
possibl question topic manag
robert ford strateg prioriti may differ leadership strateg
appetit signific portfolio move sell spin nutrit
and/or establish pharmaceut pro con
manag think capit alloc current thought
put take particularli fx rate
one think sustain top bottom line growth rate compani
sustain believ sale growth rate els see drive growth
beyond libr alin mitraclip
time fda approv freestyl libr still expect icgm design
approv taken long
estim total address market libr competit
landscap posit therein especi vs dexcom what beyond libr
mani year would expect see market growth core diagnost driven
alin roll-out us ou region abl pre-sel alin us
opportun improv molecular rapid diagnost perform
cardiac rhythm manag vascular busi repres nearli total sale
flat declin opportun acceler growth
nutrit busi still consid core abbott one think longer
term growth outlook china busi
epd busi consid core sustain rate epd
possibl questions/top manag
possibl question manag
robert ford prioriti first day ceo
could abbott strategi differ robert ford leadership
appetit signific portfolio move sell spinning-off
nutrit establish pharmaceut pro con
robert ford thought capit alloc near term
chang medic devic busi one expect
leadership lisa earnhardt
mile white ceo abbott sinc januari novemb abbott
announc robert ford would take presid ceo effect march
view surpris ford appoint posit white
previous comment ford would key leadership role long time
investor read line white remain execut chairman
board long uncertain
ford join abbott within diabet busi held job increas
respons across compani includ diagnost nutrit busi prior
appoint serv execut vice presid medic devic
oversaw integr st jude medic integr launch
june abbott announc lisa earnhardt join abbott take role
evp medic devic intersect ent serv presid ceo prior
presid boston scientif cardiac surgeri divis prior
held varieti sale market role boston scientific/guid within
cardiac surgeri cardiac rhythm manag busi unit
strategi capit alloc
mile white activ portfolio manag creat valu investor
leadership white abbott extrem activ portfolio manag
abbott spun-off two companieshospira shape
portfolio acquisit well divestitur two recent notabl
acquisit st
presenc cardiovascular
neuromodul aler point care diagnost
investor debat whether would will one act portfolio manag
retir compani howev ceo announc seem
may tabl
abbott significantli de-lev transact financi flexibl
addit howev white comment seen anyth great
interest rather continu priorit intern invest build
capac freestyl libr expans alin invest structur heart
possibl question manag
put take particularli given fx rate movement
sustain believ sale growth rate els see
drive growth beyond libr alin mitraclip
double-digit growth still target bottom-lin driver
abbott organ sale growth profil improv last sever year mid-
to-high single-digit acceler mainli driven success freestyl libr
continu glucos monitor well alin mitraclip
abbott organ sale driven continu strong growth medic
devic driven diabetes/libr partial off-set establish pharm
diagnost nutrit
report dollar growth libr sale abbott organ sale growth rate would slightli underrepres
contribut overal growth rate
figur present abbott oper margin divis includ unalloc
incom non-report segment attribut diabet busi
shown follow figur
shown diabet contributor top-lin perspect
bottom line perspect well abbott volum libr improv believ
margin
division unallocated/diabet oper margin
abbott growth object aim peer
abbott manag start target organ growth rais
guidanc juli suggest new level sustain
growth call octob manag note averag around
organ rate past eight quarter see reason chang view
whether sustain rate growth driver usual suspectslibr
alin mitraclip
bottom line manag start year target double-digit ep growth fx
rate present challeng goal given compani broad intern exposur
particularli emerg market
possibl question manag
time fda approv freestyl libr still expect
icgm design hand open item work
approv taken long
us ramp freestyl libr progress rel expect
estim total address market libr
discuss partnership tandem omada sanofi
expect partnership well
futur plan freestyl libr beyond see
competit landscap evolv particularli dexcom
abbott diabet busi driver growth past sever year
nine month end septemb sale total billion repres total
sale constant currenc basi abbott still sell tradit
blood glucos monitor devic meter test strip repres
sale freestyl libr continu glucos monitor present sale
librelink app
nine month end septemb freestyl libr sale total billion
constant currenc basi view freestyl libr potenti
multi-billion-dollar product
courtesi abbott lab
libr navig
abbott develop continu glucos monitor call freestyl navig
receiv ce mark european approv june fda approv march
howev system suppli interrupt limit success led
discontinu product pursuit develop improv next
gener version would becom libr
abbott launch freestyl libr continu blood glucos monitor system
europ abbott receiv fda approv freestyl libr sensor system
septemb sensor system juli freestyl libr cgm
system includ handheld reader dispos sensor worn back
upper arm finger stick calibr requir
libr still wait us approval/clear
octob abbott receiv ce mark european approv freestyl libr
add option real-tim alarm function lack real-tim alarm view
competit disadvantag rel cgm system market
icgm stand integr
monitor part
compat medic
devic electron
interfac may includ
system insulin pump
freestyl libr yet approved/clear unit state expect
approv soon expect icgm design earn call
april abbott announc file expect receiv fda approv
freestyl libr icgm earn call novemb manag said
misjudg time libr approv hand open item
work fda
current futur cgm technolog
freestyl libr compet cgm system market
senseon abbott comment specif futur iter beyond libr
view cover abbott signific competitor latest
gener system dexcom system sensor also factor
calibr also work bring market next-gener devic
dexcom expect factori calibr extend wear like day
sensor fulli dispos smaller devic expect limit market releas end
broader market releas
also work addit iter guardian cgm system
includ work toward smaller devic one icgm design factori
calibr synergi sensor expect smaller guardian sensor
dispos design still requir day calibr expect submit
regulatori file fda timelin hold would lead year-
end calendar fda approv estim
senseon cover complet differ approach continu glucos
monitor implant sensor unit state sensor label
day europ label day compani work extend
us life day goal move sensor
abbott announc sever partnership wherebi integr freestyl libr flash
system includ bigfoot biomed inject infus pump-bas insulin
deliveri system develop novo nordisk insulin pen sanofi futur smart pen
insulin titrat app cloud softwar omada health digit health platform
coach integr slim insulin pump
past abbott partner integr abbott freestyl tradit
blood glucos monitor technolog person devic manag also
work integr abbott navig cgm technolog abbott continu
relationship though unclear whether extend libr
suspect like
possibl question manag
ultim expect impact us diagnost busi
mani year would expect see market growth core
diagnost driven alin roll-out us ou region inning
come realiz sale benefit alin
abl pre-sel alin us includ technolog
claus contract
outlook molecular diagnost busi statu
alinity-m enough make competit market
need acquir competit
growth outlook rapid diagnost still believ
acceler growth prospect franchis mid-singl digit
abbott diagnost divis repres total sale includ core laboratori
system molecular diagnost system point care system rapid diagnost
system product gener sold blood bank hospit commerci lab
clinic physician offic govern agenc altern care test site plasma
pama protect access medicar act pama chang medicar
pay clinic diagnost laboratori test clinic laboratori fee schedul
clf begin januari medicar payment amount test set
weight median privat payor rate reduc reimburs
estim put pressur lab
laboratori driver growth past two year constant
currenc sale growth growth approach
estim manag attribut market estim
around success roll-out next-gener diagnost systemsalin
alin integr famili next-gener diagnost system solut
common user experi design alin system includ alin ci-seri
integr clinic chemistri immunoassay system alin h-seri integr
hematolog system alin blood plasma screen also alin
molecular system relat sale includ molecular diagnost busi
core lab
instrument placement proceed intern market approv test
menu avail longer unit state roll-out underway
test menu expand critic mass howev believ abbott
abl recogn benefit new contract may alreadi includ technolog
upgrad program believ help drive market us
core laboratori growth past year
molecular diagnost smaller busi abbott see benefit
alin molecular system launch abbott exist busi includ
instrument test hiv hbv hcv hpv ct/ng well vysi fish product line
genomic-bas test busi pressur sale declin
point diagnost
point rapid diagnost remain two busi abbott
point includ legaci i-stat franchis next-gener i-stat alin
point care system cartridg blood analysi
rapid diagnost busi legaci aler point care diagnost busi
includ test infecti diseas test test flu strep rsv hiv malaria
drug alcohol cardio-metabol other time abbott acquir aler
slower growth busi manag believ could acceler overal growth
profil in-lin point care busi
possibl question manag
see potenti growth rate structur heart franchis
next year
outcom expect uk patent trial mitraclip patent
held decemb would will settl edward
royalti would view reason
size total address market mitraclip feel
competit posit ip asid rel edward pascal
provid updat transcathet mitral replac effort
mitral repair effort may underway
big view opportun tricuspid
beyond mitraclip new product within structur heart busi
excit
current statu amplatz amulet left atrial appendag
program expect fda approv believ
product compar boston scientif watchman flx percent
market share us expect gain first year launch
expect us approv portico strategi
launch given fourth entrant market physician
consid older gener product would will price
aggress quickli advanc navitor
abbott structur heart franchis deliv strong revenu growth past two
year today busi account total sale abbott hope
grow percentag growth outpac corpor sale growth sale includ
mitraclip percutan mitral valv repair system amulet left atrial appendag
occlud sold ou today abbott aim launch us amplatz
pfo occlud tissu mechan surgic heart valv portico transcathet aortic
valv solid ou today abbott aim us launch
courtesi abbott lab
mitraclip transcathet mitral valv repair system key contributor
structur heart sale growth mitraclip sale approxim million
surpass million track nearli million estim
mitraclip approv europ sinc march us sinc octob
us approv limit patient signific symptomat primari
degen mitral regurgit howev march fda approv
expand indic patient moderate-to-sever sever secondari function
mitral regurgit base coapt studi result abbott estim coapt result
doubl tripl us address popul
juli abbott announc us approv next-gener devic mitraclip
expand rang clip size four clip size altern leaflet grasp
courtesi abbott lab
featur allow physician grasp one leaflet procedur
facilit procedur assess real time
mitraclip competit edwardss pascal system similar system repair mitral
regurgit clasp leaflet togeth system includ spacer paddl
hold leaflet togeth pascal receiv ce mark european approv
commerci launch europ edward current enrol pivot studyth
clasp iid degen /iif function trial enrol estim patient
includ random abbott mitraclip system
abbott current su edward patent infring sever jurisdict alleg
pascal infring patent own abbott uk trial held decemb
judg expect issu rule end januari unit state trial
schedul may abbott deni preliminari injunct temporari
restrain order unit state germani district court trial schedul
juli abbott grant preliminari injunct switzerland
abbott portico devic acquir st jude medic acquisit portico
size first approv europ novemb subsequ size approv
entri us market taken longer expect us trial paus
period time investig higher rate subclin thrombosi rate
enrol continu along mandat ct-substudi abbott also chose extent
trial includ substudi evalu next-gener flexnav deliveri system well
us pivot data present septemb transcathet cardiovascular
therapeut tct confer trial enrol high risk extrem risk patient
random either portico valv commerci avail valv sever version
edward sapien valv medtron corevalv evolut etc trial met primari
endpoint non-inferior view physician seem struggl find reason
fit portico treatment regim first gener valv system
industri evolv next-gener product
abbott plan launch portico flexnav deliveri system unit state
abbott work next-gener system call navitor build
upon portico system includ inner cuff outer polyethylen fabric cuff
reduc paravalvular leak abbott aim start studi support ce mark fda
approv high extrem surgic risk patient would expect approv
product earliest
estim portico ou sale current million rang us launch
would help expand abbott share tavr market albeit forese modestli
portico first-gener product compet next-gener devic
courtesi abbott lab
abbott two mitral replac develop acquir
tendyn cephea
tendyn abbott acquir tendyn mitral valv replac program august
tendyn tri-leaflet porcin bioprosthet valv outer frame contour
mitral annulu tether connect apex heart via apic
pad valv deliv via transap approach abbott expect ce mark
european approv around end year plan launch product earli
europ abbott enrol us pivot studi summit trial includ
random cohort group mitraclip experiment arm receiv
tendyn devic estim primari complet date per clinicaltri gov june
would put fda approv date roughli one year thereaft
cephea abbott provid capit secur option purchas cephea
acquir compani januari devic design transept procedur
low profil surgical-lik design tct confer septemb
earli feasibl strategi develop
tricuspid valv right atrium right ventricl consid
anoth valv potenti transcathet repair abbott develop triclip
transcathet tricuspid valv repair system treatment sever tricuspid
regurgit system build mitraclip system
abbott expect receiv ce mark european approv around end
although receiv one thu expect receiv one earli abbott
initi us pivot trial trilumin septemb expect enrol
studi take least two year end-point earliest forese us
approv would late
courtesi abbott lab
left atrial appendag laa market million market potenti
exceed billion next five year boston scientif watchman devic
approv product unit state abbott compet intern
watchman amplatz amulet occlud devic receiv ce mark
abbott plan enter us market late amplatz amulet approv
support result amulet studi compar outcom
amulet watchman approv amulet compet boston scientif
next-gener watchman flx expect receiv fda approv
vascular franchis
possibl question manag
cardiac rhythm manag vascular busi flat declin
opportun acceler growth
product pipelin still next gener
icd/crt launch schedul
time updat nanostim leadless pacemak product
still work develop dual-chamb leadless pacemak
develop subcutan extravascular
thought risk associ ischemia trial
potenti impact stent franchis vascular busi broadli
latest updat percutan heart pump php potenti
timelin market
overal thought peripher busi feel
need add addit product acquir gain greater scale
see risk sale eros manta larg bore closur
launch impact perclos proglid franchis
abbott cardiac rhythm manag vascular busi combin repres nearli
sale end end market matur busi
within abbott flat declin thu anchor overal growth
defibril icd cardiac resynchron therapi crt devic implant
cardiac monitor icm latter offer opportun growth
market shift new technolog includ leadless pacemak
subcutan extravascular defibril regard abbott appear fall
behind view
abbott leadless pacemak program nanostim receiv ce mark european
approv howev issu devic led advisori
ultim halt sale devic intern first batteri
malfunct advisori dock button detach issu
understand abbott focus develop dual-chamb leadless pacemak
micra pacemak market address estim
pacemak popul plan launch micraav expand
address patient popul roughli boston scientif also work
develop leadless pacemak devic would work concert modular
subcutan system us trial expect start
vascular busi includ xienc famili drug-elut coronari stent
estim third vascular coronari balloon dilat product guidewir
starclos se perclos proglid vessel closur devic supera peripher stent
system carotid stent imag cathet well pressurewir ffr measur
system collect busi flat declin
abiom impella gener million sale fiscal year end march
year-over-year believ market opportun excess
abbott look enter market heartmat php percutan heart
design deliv blood flow mean flow stabil
european approv juli support patient undergo high-risk
percutan coronari intervent pci us pivot trial shield ii initi
howev abbott identifi small number clinic event associ pump
stoppag support high risk pci patient clinic commerci use
prompt abbott halt studi european sale abbott restart shield
ii studi stop restart primari endpoint studi
day primari complet date clinicaltri gov estim decemb
would put potenti approv sometim late
februari abbott announc sign agreement surmod
wherebi abbott obtain exclus world-wide commerci right surveil
paclitaxel drug-coat balloon use peripher applic time seem
like larg opportun abbott industry-wid paclitaxel concern emerg
late caus market paclitaxel coat balloon compress half
surmod submit regulatori file european notifi bodi howev
review file paus due on-going debate/review consid
long-term mortal signal therefor longer expect receiv ce mark
european approv around year-end receiv one timelin
provid approv
us trial transcend complet enrol patient one-year
data read-out avail late
said given concern paclitaxel opportun dcb smaller
seem abbott -- other
possibl question manag
overal strategi neuromodul franchis
chang made within neuromodul return
segment higher level growth
product pipelin
abbott neuromodul busi account total sale includ spinal cord
stimul proclaim elit prodigi mri proclaim drg design dorsal root
ganglion therapi infin deep brain stimul treatment
past coupl quarter abbott neuromodul busi deceler
declin singl digit year-to-d basi septemb
neuromodul sale reflect declin flat
septemb abbott receiv fda approv proclaim xr
neurostimul system patient chronic pain
recharge-fre
possibl question manag
nutrit busi sustain current level growth
plan address headwind chines market
still busi consid core abbott
abbott nutrit divis total sale includ pediatr adult nutrit
product brand market abbott includ similac infant formula isomil
nutrit zone perfect bar adult nutrit myoplex adult nutrit advantedg
adult nutrit product gener sold consum well institut
wholesal retail healthcar facil govern agenc
time spin-off nutrit busi consid driver
sale profit growth busi gener sale growth
respect
sale growth slow period respect
abbott face headwind intern market china
sale offset unit state
earn call abbott highlight challeng market dynam china
sale low birth rate impact volum lead price competit
year-to-d basi nutrit organ sale ou sale us
possibl question manag
level confid sustain growth mid-to-high
sensit epd market macroeconom trend countri
abbott establish pharmaceut divis epd total sale market
extens portfolio brand gener pharmaceut emerg market focu
key market india russia china brazil
abbott five broad therapeut area focu gastroenterolog product women
health product cardiovascular metabol product pain central nervou
system product respiratori drug vaccin brand gener drug
gener sold directli wholesal distributor govern agenc health care
facil pharmaci independ retail
epd sale oper basi year-to-d basi
epd sale organ led perform key emerg market
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight view share high-
qualiti growth asset believ compani
favor mix busi product
geograph perspect see medic devic
busi particularli diabet key driver
growth go forward believ growth profil
upsid case depend sever key factor
strong growth libr alin approv
adopt new product particularli within medic
devic abil drive margin expans
downsid case driven slower
libre/alin sale fx slowdown emerg
market inabl receiv product approv and/or
acquisit sentiment around likelihood
quarterli annual ep usd
consensu number bloomberg receiv gmt
avano formerli halyard health spun octob follow period post-spin euphoria stock trade lower
quarterli result live expect under-perform larg due continu poor peform ip segment
stock increas earli follow accret corpak acquisit subsequ sold follow minut segment paint
halyard surgic gown neg light stock later rebound follow improv quarterli result announc sale ip
busi novemb share increas dramat follow ip divestitur may howev supplier constraint key
drug neg impact on-q product sale caus compani lower full year guidanc stock price also
sale product categori mo end
digest health feed solut
sale geographi mo end
brand includ mic-key enter feed tube kit feed solut corpak acquisit
respiratori health product brand includ ballard airway suction system
pain manag two main franchis
acut pain product includ on-q surgic pain pump iv pain therapi game readi franchis
intervent pain solut includ standard rf ablat busi well compani coolief
system minim invas water-cool radio-frequ treatment chronic pain
sale street/our estim primarili driven
increas backord associ implement compani new
system unexpect distributor inventori drawdown chronic weaker
anticip intern revenu ep slightli street
estim slightli estim given headwind
anticip continu impact manag lower full-year sale
outlook includ acquisit benefit organ
adjust ep net/net view pullback share price
buy opportun believ number concern remain overhang
stock reiter underweight rate
addit detail quarter
million except per share data
coolief strong quarter growth manag highlight
recent hospit outpati reimburs rel propos keep
payment statu quo exist rate well futur growth
opportun spine procedur intern
sale miss street estim estim
manag note shortfal driven backord
relat system implement distributor de-stock within chronic
care weaker-than-expect intern sale due number issu
ep miss street expect
full-year constant currenc sale growth reduc
organ growth expect reduc
headwind anticip also impact like adjust ep
guidanc also lower
despit drug suppli return market on-q sale expect rel
flat take time market return steadi state
sale report constant currenc basi
gross margin y/i due downtim manufactur
site relat system implement increas distribut cost
relat allevi custom backord
sg sale y/i although due accrual
lower bonus due sale recalibr
 sale y/i
oper margin y/i driven declin gross
margin bonu accrual sg
adjust tax rate y/i
ep street estim estim
manag lower constant currenc sale growth outlook account potenti
continu backord near term organ sale growth guidanc lower manag expect
adjust tax rate given lower sale outlook adjust ep guidanc lower
gaap ep guidanc also lower
lrp manag firmli acknowledg like wont achiev long-rang plan goal outlin investor day last summer
on-q drug suppli recov manag expect
flat on-q sale could prove conserv
even though street number fall
estim still high
separ cost near end flow
improv leav compani capac
sale ebitda margin improv
stock inexpens ev/sal perspect
 capac reduc owe higher
separ cost reduc outlook avano cash
flow year avano net debt posit
global go-liv occur may result
believ compani right strategi redeploy ip proce medic devic
growth initi howev face numer headwind includ recent challeng
roll-out believ street ep outlook remain high believ stock like
jan commentari broker confer
feb result guidanc
possibl question topic manag
role new cfo michael greiner play organ term financi plan
corpor strategi function
philosophi upcom earn guidanc light recent
instal new cfo compani still plan give guidanc februari
report result key put take investor consid
manag chang may requir implement turnaround
restructur initi may need
see key risk next month compani continu
transit transit proceed
see compani core compet greatest strength see
greatest weak plan address
see compani strategi unfold next sever year might
avano look like year
investor view acquisit strategi one expect smaller deal similar
done larger transact
manag comment long-rang plan lrp target outlin investor day
june unlik achiev timelin specifi reason
target provid updat
still confid deliv million cost save increment
current run-rat drop bottom line reinvest
view near longer term outlook acut pain busi
comfort double-digit sale growth profil coolief
translat entir intervent pain franchis
possibl questions/top manag
new cfo manag chang
possibl question manag
role new cfo michael greiner play organ term
financi plan corpor strategi function
philosophi compani upcom earn
guidanc light new cfo compani still plan give
guidanc februari report result
manag chang may requir implement
turnaround restructur initi may need
april avanoss cfo steve voskuil notifi compani resign
compani effect may becom cfo hershey compani
announc made public april
decemb avano announc appoint michael greiner svp
cfo effect januari greiner join avano
serv evp cfo august departur octob
angiodynam manufactur peripher vascular vascular access oncolog devic
like avano compani view turnaround stori
greiner come one degre separ baxter formerli covidien ceo
presid medic devic busi almeida avano current ceo woodi
presid covidien vascular therapi busi angiodynamicss jim clemmer
presid covidien suppli busi
view appoint greiner posit believ bring right skillset
avanosexperi tradit cfo function importantli experi strategi
develop execut turnaround situat
august avano announc john tushar compani presid
global franchis would leav compani posit would elimin due
organ realign tushar join avano march recent
posit presid gener manag teleflex surgic divis tushar
particularli known global market corpor strategi experi
believ greiner like fill void corpor strategi experi
tushar departur may left
possibl question manag
statu backord associ roll-out new
remaind transit complet go
like financi impact
along sale brand name halyard compani also sold system
compani migrat new system proven costlier
anticip well disrupt
avano attribut major sale shortfal backord associ
new system implement complet emea region global
complet plan avano experienc temporari custom suppli
issu implement requir manual workaround result avano
reduc organ sale growth outlook ep throughout manag note
possibl backord could continu
broker confer novemb manag comment work way
backlog quarter date make progress manag
felt issu
possibl question manag
investor view strategi near mid longer term
compani like focu make sure foundat stabl focu
cost optim near-term look meaning
transact continu two-prong approach
one expect smaller deal similar done larger
transact could significantli shift portfolio divestitur option
see compani core compet greatest strength
see greatest weak plan address
formerli halyard health product spin-off
essenti anoth spin-off technic divestitur
june halyard sold slower growth/margin surgic infect prevent ip
segment halyard name owen minor close april
compani rebrand avano focu sole chronic care digest
respiratori health well pain manag post-surg chronic care
avano strategi two-prong approach
focu acceler revenu growth organ opportun
focu cost transform right-siz structur oper
multi-year phase restructur program reduc dis-synergi corpor cost
net proce ip sale approxim million avano use
million proce retir debt intend invest rest back
busi acquisit
time deal close manag estim million
acquisit capac sinc manag acquir number compani
asset see figur includ game readi neom summit medic total cash
outlay acquisit approxim million call novemb
manag estim acquisit capac million reduct
acquisit capac reflect deploy capit sever acquisit also
reduct due cash outflow higher separ cost lower ebitda
outlook transact occur compani felt increas
pressur on-q busi
avano licens activ si sale
juli
game readi provid cold therapi compress therapi system
market primarili orthoped sport injuri relat market
game readi revenu pro forma revenu total
neom manufactur neonat pediatr feed medic dose
avano acquir minor interest april acquir remain
juli
avano note neom sale million grow
asset
summit develop market ambit famili ambulatori electron infus
summit annual sale pump approxim million
design ready-to-us deliveri system infus drug
asset
fv
endoclear develop airway manag devic accessori avano
believ acquisit complementari exist respiratori health portfolio
bring enhanc clinic tube clear close suction cathet custom
si acquisit readi neom summit endoclear chang netcash posit barclay medic suppli devic
possibl question manag
key put take investor consid
system-rel cost flow start
impact backlog implement challeng
risk gpo contract come renew
still feel confid achiev million restructur cost
save clarifi whether save would drop
bottom line whether reinvest back busi
manag comment long-rang plan lrp target outlin
investor day june unlik achiev timelin
specifi achiev target achiev date
target
plan updat long-rang plan
challeng year
avano proven challeng year varieti reason
outsid compani control continu drug shortag
impact on-q franchis manag reduc organ sale ep guidanc
throughout year shown figur notabl loss per share
latest issu
manag commentari
think manag comment novemb earn call
expect backord due system could potenti continu
although on-q drug suppli recov like take time market
improv still disrupt channel drug filler manag
expect on-q sale flat sale growth approach low-singl digit
back half year impli declin first half
consider
system-disrupt depreci
new system roll emea complet august avano encount
challeng led week manufactur downtim caus backord
cost estim million novemb earn call manag
comment implement challeng backord could continu
note could also continu compani expect complet migrat
global
complet system roll-out previous capit cost
system depreci flow sg approxim million
capit cost one assum averag life though could less would result
million annual cost could lower life
approxim avanoss sale contract four major nation group
purchas organ contract expir end
conjunct divestitur ip busi avano develop three-phas
restructur plan gener annual pre-tax cost save million
sinc announc plan cost phase increas shown
avano continu expect save million expect
occur origin anticip
realign organ manag
capit
june avano push million save
million
investor day june seem like manag express save would
drop bottom line howev februari investor
present manag highlight save annual save reinvest
growth
avano laid long-rang plan investor day june
plan illustr figur forecast acceler top-lin growth mid-singl
high-singl digit along improv profit
howev manag express past two earn call august novemb
believ could achiev lrp target time period specifi
avano long rang lrp issu june
compani face challeng first acut pain busi
pressur owe pressur drug suppli well disrupt drug filler
channel outsid compani control second separ si prove
costlier also believ addit invest spend may requir achiev
possibl question manag
view near longer term outlook acut pain busi
cant on-q sale better flat
partnership leiter ramp relationship key
investor view opportun summit medic ambit pump
longer term partnership bio-q
view on-q posit rel drug therapi view
potenti risk may pose on-
 franchis could impact launch similar exparel
avano acut pain franchis includ on-q surgic pain pump game readi cold
compress therapi system acquir juli
novemb earn call manag comment despit return drug
suppli expect on-q sale flat
avano on-q ambulatori pain pump provid pain relief five day
on-q balloon-typ pump fill local anesthet deliv
cathet place near surgic site physician pump program infus
local anesthet steadi rate model allow patient control
dose level roughli on-q sale relat orthoped procedur pump
also use cardiovascular cardiothorac urolog gynecolog obstetr
gener surgic procedur pump predominantli use inpati set
past two year avano on-q franchis face two challengesshortag
drug suppli disrupt drug filler channel improv
outlook on-q remain somewhat challeng
drug shortag one industri largest drug manufactur not-cov
on-going manufactur issu legaci hospira facil backord start
earli complet remedi action plant octob suppli
ropivacain recoveri present bupivacain still
backord ropivacain use estim time bupivacain rest
filler issu on-q fill pump fill hospit albeit long
labori process earli pharmedium pump filler
shut due find fda audit caus disrupt channel
juli avano announc prefer provid relationship leiter fda-
regist outsourc provid fill on-q avano abl move
hospit leiter
view recogn challeng face on-q prefer
hospit august avano acquir asset summit medic product
specif ambit famili ambulatori electron infus pump million
front plu futur conting payment estim futur valu million
summit medic annual sale pump approxim million avano also
enter agreement bioq pharma develop ready-to-us electron deliveri
system infus drug
on-q also face challeng non-opioid product post-op pain relief
today pacira pcrx-cover balaji prasad exparel approv fda use
treat post-surg pain also compani work non-opioid
drug altern could competit on-q heron not-cov
new pdufa date march also work extend version
formul day pain relief taiwan liposom co ltd tlc
cover develop treatment post-surg pain manag
possibl question manag
comfort double-digit sale growth profil coolief
translat entir intervent pain franchis
big opportun believ coolief knee osteoarthr
near longer term
need enabl adopt particularli broader manag
prospect higher reimburs physician
see emerg competit accurian
avano intervent pain franchis includ tradit radiofrequ rf ablat
well coolief rf ablat technolog tradit rf ablat minim invas
procedur use thermal energi heat destroy nerv fiber stop
transmiss pain signal brain coolief differenti standard rf
treatment use water-cool technolog instead heat gener energi
use heat limit amount rf energi deliv given time therebi
limit effect standard rf treatment shape lesion use thermal
energi also ellipt necessit probe place parallel target
nerv order success ablat nerv fiber use cool rf technolog
allow addit rf energi creat lesion volum thermal rf
lesion shape spheric allow physician approach target nerv perpendicularli
well parallel combin allow success rf treatment rf
proven provid pain relief far month
june analyst meet avano note rf almost entir use treat
chronic spine pain knee hip pain compris procedur
volum respect avano estim market share leader rf
market analyst day manag note intervent pain sale grown
period driven growth coolief
coolief receiv fda approv manag chronic osteoarthr oa knee
pain april coolief remain rf ablat treatment approv treatment
chronic moder sever knee pain caus osteoarthr indic expans
knee pain provid increment million patient popul coolief
though evid need support usag reimburs remain challeng
march avano releas top line result trial compar efficaci
coolief vs hyaluron acid ha trial achiev primari endpoint
statist signific improv knee osteoarthr patient experienc least
reduct knee pain month treatment coolief versu
ha arm patient coolief arm also achiev statist
signific improv function outcom month use
trend lower time howev effect categori
question american academi orthoped surgeon aao
coolief procedur done mainli hospit outpati set reimburs
econom today support procedur elsewher kit gener cost around
new code went effect januari genicular nerv rf ablat
hope new code reimburs rate could make procedur
econom feasibl perform set howev reimburs rate
final novemb similar effect
possibl question manag
confid sustain mid-singl digit sale growth
avano chronic busi largest franchis repres sale
digest health busi includ compani legaci mic-key enter feed
tube well corpak patient feed solut latter acquir
avano competit includ boston scientif cook medic appli
respiratori health busi includ product ballard close airway
suction system well oral health kit avano competitor includ becton
dickinson sage smith medic
juli avano acquir remain interest neom manufactur
neonat pediatr feed medic dose product previous acquir
minor interest compani april
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
underweight believ compani
right strategi redeploy ip proce
medic devic growth initi howev
believ risk on-q franchis
coolief reimburs may pressur
earn leav compani short lrp
upsid case could driven greater sale
 lead improv outlook greater
recoveri on-q busi drug shortag eas
downsid could driven deceler sale
growth trend inabl achiev cost save
unsuccess intensifi drug
shortag could pressur on-q sale
axon modul technolog inc quarterli annual ep usd
consensu number bloomberg receiv gmt
price pe perform
novemb axon modul complet initi public offer time compani european approv
ce mark axon r-snm system primarili use treat overact bladder februari axon announc top line data
artisan-snm pivot studi receiv expand ce mark label becom first snm system approv use full
bodi mri scan may artisan-snm result present american urolog associ meet august compani
host call comment expect pma approv occur sometim septemb earli septemb
axon announc fda approv axon r-snm system fecal incontin indic octob medtron
announc file fda approv interstim micro novemb axon announc receiv fda approv urinari
indic send stock closer retrac though decemb stock grind higher
background overact bladder oab
intern contin societi defin overact bladder oab presenc urinari urgenc sudden compel
desir urin usual accompani nocturia wake one time night urin without urgenc
urinari incontin individu higher averag number void act empti one bladder may oab
individu gener void around six time day everi hour oab void frequent
sacral neuromodul snm consid third-lin treatment oab also treat fecal incontin fi urinari
retent ur snm market approxim million valu domin exclus
develop market launch interstim snm devic
overact bladder overview comparison second- third-lin treatment
uroplasti labori
uroplasti
appli gel
perform wherebi
temporari lead wire
place stimul
needl electrod
insert ankl
near tibial nerv
physician inject botox
needl insert
approxim mm
detrusor bladder
extern stimul
muscl inject
extens connect
symptom
least reduct
connect stimul
tibial nerv
travel sacral nerv
minut per week
ml inject
patient retreat
clinic studi
week sooner
he/sh proce
week
week
posit therapi
mani drug gener
efficaci therapi
done offic
done offic
neg therapi
thu less
concern long-term use
anticholinerg drug
risk dementia
surgic implant test
stimul second
perman implant
perman lead
requir weekli visit
physician offic initi
week retreat
effect botox wane
fda websit fda prescript use/ind use compani websit barclay research
background axon r-snm system
courtesi axon
axon r-snm system miniatur recharg sacral neuromodul system axon r-snm system receiv ce
mark european approv receiv fda approv septemb fecal incontin indic fda
approv novemb urinari indic
technic aspect competit advantag devic includ follow
magnet reson imag mri compat axon r-snm system label mr condit system
test compat use head coil system use bodi coil system certain
medtron interstim current design head mri scan
recharg implant puls gener part titanium part ceram smallest charg coil
technolog reduc charg time recharg lithium-ion batteri requir charg hour everi week
estim implant life year result fewer surgeri well econom save healthcar
medtron interstim ii non-recharg need replac everi year
significantli smaller size axon r-snm system volum cc smaller size may comfort
prefer patient
medtron interstim ii
current-control r-snm system current-control mean automat adjust imped
increas provid continu stabl stimul
medtron interstim voltage-control requir manual adjust voltag event
new lead design axon also patent new lead design contact point helic tine prevent issu
intuit patient control physician programm r-snm patient control adjust devic key fob
button patient chang level stimul also separ touch-screen tablet devic
clinician program believ easier-to-us compon advantag
invest case axon turn lie ahead us launch
compani receiv fda approv urinari indic novemb
indic readi execut plan signific take-away
quarterli updat call manag intend target consensu
sale estim estim view unchang
continu rate share overweight
addit detail quarter
manag highlight novemb fda approv overact bladder
urinari retent indic note physician wait
indic order implant manag confid could
proceed broader launch though note upcom holiday potenti
roadblock schedul procedur
manag express could achiev consensu sale estim
though note still quit feat
axon experienc season europ believ coupl
lack us revenu first commerci implant prompt
revenu come consensu revenu slightli estim
incorpor season assum us contribut
oper expens came bit higher quarter reflect axon launch
sale versu consist entir ou revenu
gross profit gross margin y/i
 y/i reflect increas personnel cost contract
consult expens though off-set lower clinic cost
 sequenti y/i reflect mainli public
compani cost personnel cost
 sequenti reflect build
commerci organ ahead launch
oper loss versu reflect increas
axon end quarter cash cash equival short term
invest manag note enough fund compani
launch per suffici least next month
file shelf good housekeep purpos may choos
ask view consensu revenu estim cite ww us cite
manag acknowledg cite intend make note noth easi lay-up
manag note would provid formal guidanc get quarter belt would
r-snm system superior attribut
recharg smaller size mri compat
enabl compani rapidli gain share
medtron establish relationship physician
hospit may result inabl axon penetr
market fulli expect
new technolog like acceler market growth rate
su axon patent infring
increas adopt versu third-lin treatment
pullback share price high result
attract valuat rel smid cap med-tech
risk clinic outcom compar
axon enter million sacral neuromodul snm market
enjoy monopoli year see sale execut stori superior
product believ axon gain share expand market given financi opportun
stock valuat rate compani overweight
jan earli medtron ce mark interstim micro surescan mri lead
spring medtron fda approv interstim micro surescan mri lead interstim ii
possibl question topic manag
roll-out unit state progress initi feedback account
typic market share account establish
pushback account lower market share unabl
competit respons market
featur reson physician patient
introduct new snm technolog snm therapi compar favor
third-lin treatment botox peripher tibial nerv stimul market could
manag strategi increas physician accept adopt snm/ r-
snm system broadli
time second-gener snm devic extend recharg time
what time devic compat exist lead
devic competit disadvantag today
what time non-recharg recharge-fre devic devic
view medtron interstim micro system hear field
thought emerg implant peripher tibial nerv stimul
ptn technolog develop
manag thought patent lawsuit
possibl questions/top manag
roll-out unit state
possibl question manag
roll-out unit state progress initi
feedback account
typic market share account establish
pushback account lower market share
unabl penetr
competit respons market
featur reson physician patient
axon r-snm system receiv ce mark european approv fda approv
septemb fecal incontin indic fda approv novemb urinari
market europ axon estim achiev de novo market share
england share netherland
axon receiv fda approv fecal incontin indic septemb
overact bladder urinari retent indic novemb axon
began ship last week octob first commerci implant perform
octob
novemb earn call manag express comfort consensu
estim million world-wide includ million sale us
million sale forecast present chose bit
conserv lack convict technolog
recogn challeng sometim bring new technolog hospit system
market awar market build activ
possibl question manag
introduct new snm technolog snm therapi compar
favor third-lin treatment botox peripher tibial nerv
stimul market could expand overal
manag strategi increas physician accept
adopt snm/ r-snm system broadli
sacral neuromodul market approxim million size
unit state estim repres approxim new patient implant
patient undergo replac implant owe current non-
recharg batteri estim market growth rate mid-to-high singl digit
one limit today technolog mri compat physician
comment would inclin offer snm therapi patient
mri-compat devic avail
axon manag believ introduct new
technolog market growth could acceler
axon pipelin competit dynam
possibl question manag
time second-gener snm devic extend
what time devic compat exist medtron
lead devic competit disadvantag today
what time non-recharg recharge-fre devic
devic competit disadvantag today
view medtron interstim micro system
hear field
thought emerg implant peripher tibial
nerv stimul ptn technolog develop
axon work enhanc sacral neuromodul offer includ
next-gener devic would reduc recharg session month
expect
next-gener devic would allow patient exist lead
non-recharg devic expect
first launch snm devic origin interstim sinc
launch one iterationth interstim ii plan
microstimul system sinc least highlight desir introduc
product analyst meet
interstim micro surescan mri lead
octob announc file pma supplement interstim
micro neurostimul devic surescan mri lead
interstim micro miniatur sacral nerv stimul system interstim micro
expect volum roughli smaller interstim ii implant
puls gener expect recharg also expect system full
bodi mri compat standard review process
would put approv late spring although extent question
file need data approv could push back
surescan mri lead use interstim ii make system mri elig
nuvectra medic devic compani focus neurostimul product chronic
condit spun-off integ nuvectra leverag algovita spinal
cord stimul devic file product virti brand snm system
treat oab urinari retent fda nuvectra expect fda approv
howev novemb nuvectra announc file chapter bankruptci
possibl question manag
manag thought patent lawsuit
novemb file patent litig suit axon
district court central district california claim axon lead infring four
patent ask court award damag infring
includ award trebl damag wil infring plu reason attorney
fee also ask court perman enjoin axon
axon respond suit novemb argu claim without
merit attempt suppress innov competit compani retain
legal counsel defend alleg axon character lawsuit
attempt use legal tactic engag clear anticompetit behavior note
fail introduc meaning innov long monopoli
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight differenti product
believ axn penetr million sacral
neuromodul market r-snm system
axon readi hit ground run
experienc sale organ physician feedback
posit devic given financi opportun
stock valuat rate compani
upsid driver includ faster adopt r-snm
greater market share gain sacral
would acceler overal market growth
rate introduct new technolog
downsid could stem slower uptak
inabl manufactur suffici quantiti
interstim micro altern treatment oab
price pe perform
quarterli annual ep usd
consensu number bloomberg receiv gmt
share struggl due concern around compani bioscienc busi particular recombin factor viii franchis
march baxter announc would spin-off bioscienc busi spin-off baxalta complet juli
octob baxter announc name almeida posit chairman ceo effect januari share
outperfom period driven earn out-performance stock came pressur
owe concern perform medic deliveri busi novemb baxter announc expans share
repurchas program share appreci although octob stock sharpli declin follow announc
intern investig inter-compani transfer purpos gener fx gain loss stock move higher sinc
investor view start look past investig due non-oper incom matter
intern inc equip pe ntm estim pricepric lh rel pe barclay medic suppli devic
sale product categori
sale geographi
divis includ product patient chronic kidney diseas end-stag renal diseas estim
baxter sale nearli periton dialysi in-hom remaind hemodialysi in-cent product
devic design icu patient need organ support includ prismax continu renal replac
therapi crrt patient acut kidney injuri
estim medic deliveri busi roughli two-third iv therapieslarg volum small
volum solutionsand remain third infus solut includ sale relat infus pump iv set
inhal anesthesia agent supran sevofluran
nutrit divis includ parenter intraven nutrit solut pre-matur babi chemotherapi
patient chronic ill patient patient recov surgeri baxter offer premix nutrit
balanc formula provid manag compound technolog meet uniqu patient need
surgic care product design reduc bleed heal tissu prevent adhes procedur
product includ floseal hemostat matrix product part acquisit
recothrom topic thrombin preveleak surgic sealant
baxter categori includ contract manufactur revenu pharmaceut product baxter
manufactur behalf partner
sale came street/our estim result primarili driven
lower expect medic deliveri sale baxter announc intern probe
intra-compani transact use gener fx gains/loss incom due
investig baxter report anyth oper incom provid full
year guidanc updat baxter expect report sale growth constant
currenc oper growth oper margin net/net
view stock chang continu rate stock equal weight
million except per share data chang sale report basi baxter provid constant currenc result
addit detail quarter
oper margin estim y/i due
top line perform on-going oper effici
renal sale street expect driven
strength pd therapi patient volum increas y/i despit headwind
in-cent hd includ bloodlin busi exit impact revaclear
suppli constraint less impact
sale street report basi
baxter began intern investig intra-compani transact undertaken
order gener fx gains/loss report incom expens
line compani previous report net fx gain
year respect
medic deliveri sale street estim
manag still express confid ramp sale
clari facil re-inspect fda baxter work cmo
back-up think could risk new product outlook margin pharma
nutrit sale report basi street
estim
advanc surgeri sale roughli in-lin street
estim rel forecast baxter less benefit
 surgiflo suppli issu expect
sale constant currenc oper basi report growth
gross margin y/i benefit manufactur varianc
off-set dialyz suppli constraint issu reduc gross profit
sg sale y/i reflect disciplin focu manag
 sale y/i due benefit optim initi
oper margin y/i
given intern investig baxter provid result oper
incom line tax rate given
estim constant currenc result product
baxter expect sale growth report basi street expect top rang growth
constant currenc oper basi baxter also expect adjust oper margin
manag would comment state prepar remark consid capit invest support
advanc american kidney health initi invest make oper improv enhanc qualiti manufactur
capabl final agreement gpo idn hospit product busi
baxter one best manag team healthcar
consensu estim lrp oper margin target
follow recent declin announc
intern investig stock valuat attract
baxter signific financi flexibl abil
acquir compani enhanc overal growth
may high
clari fda warn letter may remain outstand
inhibit new drug approv baxter contract
manufactur organ help new product
margin profil lower
octob baxter announc investig intra-compani transact taken
purpos gener fx gain loss near-term believ creat overhang
stock put asid believ consensu estim may high moreov
believ valuat current give credit qualiti manag balanc sheet
upcom releas find intern investig
feb tent releas result
possibl question topic manag
investig intra-compani transfer relat fx complet
broader implic intern control compani
key put take investor consid pension transfer
headwind incom
investor think long-term growth profil compani
chang sinc last investor updat lrp goal still achiev
potenti implic higher periton dialysi growth margin capit
requir perspect margin hemodialysi busi us versu ou
manag see market opportun theranova unit state could
theranova receiv add-on payment
manag current think opportun adjac offer
greatest opportun would manag will acquisit white
latest updat fda warn letter relat clari baxter ahmedabad
facil expect time resolut current statu risk mitig
contract manufactur organ margin give
give confid grow pharmaceut busi lrp rate
period key new product drive growth
pharmaceut still area interest
level comfort long-rang plan forecast medic deliveri
growth assum contribut cheetah medic much cheetah
key product within portfolio believ drive growth
possibl questions/top manag
intern investig misstat
possibl question manag
investig complet potenti outcom
matter say broader intern control compani
octob along preliminari result baxter announc intern
investig certain intra-compani transact purpos gener fx
gain loss compani previous report net foreign exchang gain
million million million million million million year
first half respect incom
investig limit period
audit committe overse investig independ extern advisor
baxter hire karen leet former googl assist treasur interim treasur
almeida becam ceo baxter cfo jay saccaro join baxter
manag strategi bioscienc busi assum posit increas
respons throughout tenur jay baxter treasur
assum leadership role within medic product commerci organ left
briefli serv hillrom cfo re-join baxter cfo todd young serv
treasur replac scott bohaboy upon split
possibl question manag
key put take investor consid pension
transfer headwind incom
investor think long-term growth profil
chang sinc last investor updat lrp goal still achiev
potenti implic higher periton dialysi growth
margin capit requir perspect
pipelin product manag confid
area carri greatest risk
baxter initi guidanc start constant currenc growth
adjust cyclo competit oper margin expans ep growth
april juli baxter rais expect constant currenc oper
sale guidanc oper margin expans ep growth
announc investig octob baxter suspend
full year guidanc metric guid report constant currenc
growth adjust margin
baxter manag reiter long-rang goal septemb octob
call said prematur comment guidanc beyond
complet annual plan note consid sever factor impact
includ propos advanc american kidney health initi relat capit
invest support along govern renal polici renal initi
capit invest oper improv enhanc manufactur qualiti
capabl final agreement variou gpo idn hospit product
look ahead believ consider well
octob baxter transfer billion pension liabil non-act employe
insur compani manag believ reduc volatil result
incom expens benefit plan invest perform pension
postemploy benefit plan contribut million incom million
incom expens million million
transfer believ may repres headwind earn
may baxter host bi-annu investor meet provid updat long
rang plan lrp outlook period includ specif
target lrp call constant currenc sale growth
period sale growth last guidanc
would impli around would expect baxter expect oper
margin rang would impli fairli signific step
estim level
baxter manag estim weight averag market growth rate wamgr
expect grow market lrp period baxter
expect sale growth slower growth period
faster growth period growth expect come
new product geograph expans new product expect account
growth billion long-rang plan term new product sale
divis expect contribut million follow
renal medic deliveri million new contribut also expect
acut therapi million clinic nutrit million advanc
baxter expect see continu oper margin expans driven cost
reduct importantli product mix specif baxter expect oper
margin expand
possibl question manag
manag current think opportun
area adjac manag believ offer greatest
opportun
would manag will acquisit white space
baxter significantli improv cash flow capit posit june
billion cash/equival billion total debt net debt billion
term capit alloc philosophi manag comment
first prioriti reinvest busi deliv exceed plan extent
increment idea capit equip standpoint help acceler
growth look properli fund
second prioriti fund dividend goal move pay-out ratio
third prioriti balanc versu share buy-back manag
focus market grow baxter growth rate consid return
invest capit import metric want robust return invest
capit year manag believ logic baxter
own asset plug directli sale forc build onto
and/or compet baxter bring tabl allow extract valu
uniqu way versu other compet compani built
cost transform manag note size never import factor
despit capit flexibl baxter bought back share
billion sinc spin-off baxalta spent
baxter acquir clari inject limit million net cash clari
ad capabl product gener inject medicin anesthesia
analges renal anti-infect critic care varieti present
includ bag vial ampoul
march baxter acquir two hemostat sealant product recomthrom
preveleak up-front payment million
subsequ paid million post-clos payment
septemb baxter announc definit agreement acquir cheetah
medic million million up-front million clinic
commerci mileston acquisit close octob cheetah medic develop
non-invas hemodynam monitor system use enhanc baxter
decemb baxter announc enter agreement sanofi
acquir seprafilm adhes barrier relat asset million seprafilm
product expect contribut approxim million sale
month follow close transact includ advanc
surgeri busi baxter expect transact close
past investor present baxter manag team mention interest
gener inject icu/crit care set advanc surgeri baxter manag
also talk chronic diseas manag biosimilar critic care/extracorpor
therapi multi-organ therapi clinic decis support new surgic specialti
baxter ventur arm invest outset medic compani develop tablo
dialysi system oper tap water real-tim water purif system
dialysi fluid product integr board baxter also invest compani
target infect prevent includ prescient surgic surgic site infect
possibl question manag
latest updat fda warn letter relat clari
baxter ahmedabad facil expect time resolut
confid move clari pipelin product
contract manufactur level margin give
quickli revert product clari facil
statu scinopharm partnership product
expect launch begin
octob mention part million pharma pipelin
extern busi develop licenc well alway
case origin lrp
make confid grow pharma busi lrp
rate period key new product drive
growth
pharmaceut still area interest
baxter pharmaceut busi repres approxim total compani sale
busi includ three categori productsgener inject drug inhal
anesthesia drug compound
one product signific within portfolio cyclophosphamid cyclo
immunosuppress chemotherapi agent baxter peak sale product
product reach roughli million sandoz launch first gener
version product novemb sinc baxter seen sale cyclo
declin estim sale around million initi million
guidanc pace eros slower gener slower enter
market harder manufactur drug
specialti gener pharmaceut focu baxter given higher margin
profil rel rest portfolio
februari baxter enter exclus strateg partnership gener
oncolog inject scinopharm taiwan scinopharm activ pharmaceut
ingredi api manufactur term agreement two parti
develop manufactur baxter hold commerci right five inject
drug arrang also provid baxter option partner scinopharm
mani addit inject molecul product expect launch
begin accord baxter time announc brand sale
initi five product total billion
juli baxter broaden gener inject busi acquisit clari
inject limit approxim million revenu
million clari ad capabl product gener inject medicin
anesthesia analges renal anti-infect critic care varieti present
includ bag vial ampoul clari contribut sale million
letter regard violat current good
manufactur practic cgmp regul ahmedabad india facil fda
start inspect day baxter acquir compani violat
correct complianc cgmp confirm fda may withhold approv
new applic supplement
octob baxter note fda yet inspect facil
pursu implement manufactur plan includ contract manufactur
support new product distribut baxter note remain commit
lrp goal million new product revenu inclus facil
intern program extern busi develop licens
altern manufactur locat investor confer decemb baxter
manag note clari contribut approxim million
million new product revenu work contract manufactur
organ secur altern manufactur sale volum
would lower level margin
possibl question manag
statu gpo idn negoti give
price obtain long-term contract iv solut would
will abil sell pump product futur
level comfort long-rang plan forecast medic
deliveri growth
talk acquisit cheetah medic impact
lrp outlook medic deliveri help get
rate allow grow faster much cheetah contribut
confid manag abil gain pump market share
opportun syring pump patient-control analgesia pump
baxter medic deliveri busi account total compani sale roughli
two-third busi intraven iv therapi solut remain
third infus system sigma spectrum infus pump iv set market
product oligopoli grow around year
baxter medic deliveri busi come focu invest commun
baxter manag revis guidanc baxter origin
constant currenc sale growth medic deliveri busi
revis upward manag revis lower baxter end year
sale manag believ busi rebas believ lrp
goal still achiev target constant currenc growth
note easi comp help estim sale constant currenc basi
month end septemb believ baxter fall short goal
year
infus solutionsfrom market shortag oversuppli
three main iv solut compani unit state baxter
braun freseniu kabi sell grifol also sell product
us far smaller player baxter estim infus solut market
grow year
six year iv solut shortag offici per fda drug shortag
websit shortag sodium chlorid inject bag last januari
end novemb
quality/manufactur problem one reason behind capac constraint
hurrican maria impact puerto rico also caus signific disrupt
major manufactur facil baxter baxter work remedi modern
product process facil abl sourc product
manufactur facil past year braun significantli increas
amount manufactur unit state vow remedi solut shortag
icu note suppli market increas pull back product
plant accordingli
increas suppli believ infus solut manufactur like see
less favor price period shortag infus solut price increas
common
baxter infus system busi includ sale drug pump well
unit state three main competitor includ
baxter braun also provid pump signific market share outsid
unit state smith medic smith group also manufactur pump
share outsid unit state three major manufactur fair
share problem drug infus pump year baxter lead
pump manufactur colleagu pump lost share time carefus
part
baxter set sight recaptur infus pump market share us global
acquir spectrum pump launch subsequ gener along
evo iq pump intern baxter also plan launch evo iq syring pump
intern market baxter plan launch next gener global
infus pump platform also includ syring pump
shortli thereaft baxter plan launch patient-control analgesia pump
thereaft ambulatori pump
expand monitor
octob baxter acquir cheetah medic million million up-front
million clinic commerci mileston acquisit expect
immateri earn cheetah medic develop non-invas
hemodynam monitor system use enhanc baxter fluid manag
product cheetah latest system call starl sv system measur fluid
optim show cardiac index cardiac output stroke volum index stroke
volum total peripher resist import paramet
possibl question manag
larg opportun presid advanc american kidney
manag see market opportun theranova
could theranova receiv add-on payment unit state
margin profil renal dialysi busi vari
hemodialysi versu periton dialysi us versu ou well
signific point solut opportun
expect timelin launch
level uptick investor expect kaguya launch japan
baxter renal busi repres total sale two-third renal busi
relat periton dialysi product remain third hemodialysi
kidney renal diseas
kidney simpli remov wast product excess fluid bodi
also regul salt potassium acid content well releas hormon
regul blood pressur produc activ form vitamin kidney also control
product red blood cell
respect job filter accord nation kidney foundat nkf
kidney filter quarter fluid everi hour kidney contain million
nephron contain filter unit tini blood vessel call glomerulu attach
tubul nfk describ blood enter glomerulu filter
remain fluid pass along tubul chemic water either ad
remov final product urin excret
two main caus chronic kidney diseas diabet report caus
high blood pressur accord data us renal data system nkf
creat guidelin help identifi level kidney diseas divid kidney diseas
five level stage stage someon like need dialysi kidney
transplant near futur stage refer end stage renal diseas esrd
someon lost nearli kidney function requir dialysi and/or kidney
transplant live unit state approxim million peopl
classifi stage
three main form dialysi therapi today hemodialysi hd home
hemodialysi hhd periton dialysi pd
hemodialysi hd perform dialysi center hd blood remov
bodi set tube run filter dialyz remov
impur return back bodi individu undergo treatment three time
week session four hour long center patient also receiv
medic necessari
freseniu medic davita healthcar partner largest provid
outpati dialysi serv approxim patient renal care provid
includ us renal american renal associ dialysi clinic inc largest not-for-
profit provid hospital-bas provid
hemodialysi equip suppli dialyz primarili manufactur
freseniu manufactur includ baxter acquir gambro busi nipro
medic asahi kasei nikkiso toray braun
baxter develop theranova dialyz design filter wider rang
molecul blood convent hemodialysi filter target remov
larg middl molecul kda kda requir gener replac
fluid work standard equip baxter submit theranova de
novo process anticip approv bit later initi think
investor day baxter also expect approv dialysi system
support theranova dialyz likewis slightli later investor day
hemodialysi hhd perform patient home essenti
process hd hhd treatment plan vari convent home hd done three time
week three four hour time short daili dialysi done five six time
week session last two hour patient also nocturn treatment
wherebi treatment done night six night week everi night last
six eight hour
freseniu main manufactur home hemodialysi system quanta uk compani
also home hemodialysi system baxter develop system year ago
discontinu develop program
periton dialysi pd differ approach use tube place
abdomin caviti allow dialysi exchang dialysi fluid pd solut
done night use pd cycler machin day manual
exchang typic four last minut patient usual go clinic
baxter lead manufactur periton machin solut freseniu also sell
pd system solut nxstage acquir freseniu develop
next-gener periton dialysi system concentr solut howev
statu program unclear
freseniu medic estim nearli million dialysi patient global
nearli treat in-cent hemodialysi periton dialysi
less home hemodialysi individu countri level rate hd
us use pd vari time accord govern account
offic gao report publish octob esrd see link medicar payment
method concern effect pd may play role declin
use howev chang factor contribut
subsequ rise pd use past decad prior medicar paid separ
inject drug creat anoth sourc revenu financi incent
steer patient in-cent care place inject drug bundl remov
incent moreov payment rate began differenti
payment base dialysi method use base regimen three dialysi
nearli fee-for-servic medicar esrd beneficiari dialysi total
spend dialysi inject drug billion
on-going effort year unit state move patient
home set periton dialysi and/or home hemodialysi potenti
benefit patient well healthcar system overal treatment cost
periton dialysi lower accord usrd total medicar esrd expenditur per
person hemodialysi periton dialysi
previous note pd penetr rate lower unit state rel
countri compar accord challeng
achiev higher pd penetr rate averag patient spend two year
therapi patient start dialysi hospit physician train
periton dialysi view inadequ
juli presid trump sign execut order call advanc american
kidney health three goal
prevent kidney failur whenev possibl better diagnosi treatment
incent prevent care
increas patient choic afford altern treatment esrd
encourag higher valu care educ patient treatment altern
encourag develop artifici kidney
increas access kidney transplant modern organ recoveri
transplant system updat outmod counterproduct regul
 depart human servic hh parallel set three tangibl
goal outlin report advanc american kidney health see link
reduc number american develop esrd
new american esrd patient home receiv transplant
doubl number kidney avail transplant
achiev goal hh highlight sever initi underway
agenc would take includ
advanc public health capabl research
identif
popul risk earli stage kidney diseas hh also aim encourag
adopt intervent seek delay stop progress kidney failur
support program kidneyx kidney innov acceler public-priv
partnership hh american societi nephrolog acceler
innov prevent diagnosi treatment kidney diseas
esrd treatment choic etc model would encourag greater use home
dialysi kidney transplant propos would requir certain esrd
facil manag clinician particip base locat randomli
select geograph area repres half medicar popul would
posit adjust claim home dialysi home dialysi relat servic
initi three year model second adjust would appli
home in-cent dialysi relat claim could posit neg
propos model would begin januari run june
contract ckcc graduat ckcc profess global model model test
new medicar payment option aim improv qualiti care delay need
dialysi encourag transplant help provid reduc cost care
variou timelin particip
expect reset lower
believ appropri level near-
term ep growth significantli aid financi
engin share repurchas believ
warrant lower valuat multipl rel other
sector think risk/reward fairli
upsid case could driven gener
competit less expect greater
success bring new product market
greater-than-expect improv profit
accret
downsid case could driven greater-
pressur renal med deliveri fx rate
inabl drive pharma sale pharma price
inabl expand margin
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
price pe perform
co quarterli annual ep usd
consensu number bloomberg receiv gmt
share outperform market past five year compani success execut integr carefus
acquisit complet march april bd announc intent acquir bard billion bd complet
acquisit decemb stock appreci first half though come pressur owe concern
around outlook fiscal stock preform improv follow releas result issuanc fiscal
guidanc novemb decemb safeti concern emerg regard paclitaxel-co balloon believ impact
perform share also creat slight headwind financi result also believ concern around outlook/guid
limit perform stock
dickinson co equip pe ntm estim pricepric lh rel pe barclay medic suppli devic
sale product categori
sale geographi
insert venou cathet midlin cathet port access central line peripher insert central cathet
iv connector extens set iv fluid closed-system drug transfer devic hazard drug detect
convent safeti hypoderm syring needl anesthesia needl spinal epidur tray enter
busi includ two main franchis includ infus pump dedic dispos
medic suppli manag system
diabet product includ insulin pen needl syring product infus inject insulin
product includ pre-fil syring self-inject system safeti shield system sold
pharmaceut compani use contain inject pharmaceut product
product collect blood specimen analysi bd vacutain blood collect
autom blood cultur tuberculosi cultur system molecular test system infecti diseas
women health microorgan identif drug suscept system liquid-bas cytolog system
cervic cancer screen rapid diagnost assay respiratori infect test microbiolog lab autom
brand name includ bd molecular test system kiestra lab autom system bd surepath cervic
fluorescence-activ cell sorter analyz antibodi kit perform cell analysi reagent system
life scienc research solut high-throughput single-cel gene express analysi clinic oncolog
immunolog hiv transplant diagnostic/monitor reagent analyz
hernia soft tissu repair biolog graft bioresorb graft biosurgeri surgic product
bdchloraprep surgic infect prevent product thorac abdomin drainag product mueller
surgic laparoscop instrument product
vascular stent self-expand balloon-expand stent graft vascular graft port biopsi chronic dialysi
feed filter endovascular fistula creation devic drainag product
urolog drainag product intermitt cathet urinari fecal manag devic kidney stone
manag devic target temperatur manag
result solid sale come street
estim compar constant currenc sale growth ep beat
street expect howev issu somewhat disappoint
sale ep guidanc rel expect said think guidanc
appropri risk adjust thing consid still reflect compani
sale growth underli growth adjust gore
fx tariff view unchang rate overweight
addit detail quarter
million except per share data chang sale constant currenc basi unless otherwis note
sale ep expect
urolog critic constant currenc growth expect
driven acut urolog continu strength temperatur manag sale
bioscienc constant currenc growth driven research clinic
instrument sale along research reagent
ep guidanc street/w expect
pre-releas bloomberg barclay key driver differ
expect fx headwind versu previou manag commentari
sale growth guidanc slightli
street expect guidanc includ price headwind
includ pressur china tender process deliveri md well
dcb sale expect lower y/i anniversari
fda letter march
medic deliveri system md china sale overal weaker
expect price pressur basic medic devic due china tender
sale compar constant currenc basi growth
fairli balanc medic life scienc intervent
gross margin y/i acceler revenu growth continu
improv synergi captur currenc headwind abat off-set
margin pressur lower dcb sale raw materi
sg sale y/i reflect disciplin spend
continu achiev bard cost synergi
 sale y/i
oper margin y/i
adjust tax rate
adjust ep y/i currency-neutr basi
manag expect compar constant currenc revenu growth due softwar upgrad within medic
manag solut like push revenu price headwind china tender dcb declin anniversari
fda letter impact ep expect rang
bd expect report sale growth inclus fx headwind compar constant currenc sale growth
expect reflect growth divis bd medic life scienc intervent
adjust ep expect includ headwind gore royalti fx tariff
becton well-diversifi compani categori
leadership posit price pressur limit
sale ep growth profil compani
bd face pressur china medic deliveri
busi baxter also launch new pump platform
given outlook valuat attract
becton set hit leverag target come year
cash flow devot tuck-in
compani lack notabl product growth driver
bard transact cost synergi third
final year becton margin expans moder
believ bd built diversifi busi base success integr bard achiev
plan synergi believ look supplement exist infrastructur technolog
orient tuck-in deal support continu mid-singl digit growth see bd
least high-singl digit ep growth compani like compani fundament basi
lack catalyst environ altern valu stock catalyst may limit
abil stock pe expand moreov given valuat rel pt rate equal
on-going updat below-the-kne lutonix pma file
possibl question topic manag
might chang leadership tom polen ceo
polen view bd see bd compani potenti acceler
growth compani durabl growth
investor think long-term growth profil compani provid
three-year outlook investor meet may
risk-adjust fiscal forecast investor think potenti
addit headwind china and/or potenti benefit new product
manag think capit deploy
manag still commit smaller tuck-in technology-ori deal
need increas rate spend bd need becom innov
manag see sustain rate medic manag solut
busi go forward past year better-than-market taken share
infus pump medic manag hospit capit equip environ
favor current rate growth sustain busi revert lower
at-market rate growth
latest think lutonix drug-coat balloon below-the-kne btk expand
indic opportun peripher product could drive growth
investor think futur plan market opportun swatch
effort move forward third parti swatch potenti diabet
drug-deliveri applic
make becton right owner lifesci franchis
rational consolid preanalyt system diagnost
new instrument assay sustain growth go forward
possibl questions/top manag
possibl question manag
might chang leadership tom polen ceo
polen view bd see bd compani potenti
acceler growth compani durabl growth
septemb bd announc tom polen compani current presid
would take role presid ceo effect januari
compani current ceo vinc forlenza would remain bd board director
execut chairman announc surpris us polen advanc
varieti leadership role compani includ overse three busi
segment polen led acquisit bard carefus polen bd
year also spent year baxter
possibl question manag
risk-adjust fiscal forecast investor think
potenti addit headwind china and/or potenti
benefit new product approv
investor think long-term growth profil compani
provid three-year outlook investor meet may
prior bard acquisit becton dickinson manag expect deliv
sale ep growth period april
announc bard transact manag updat longer-rang forecast
sale growth mid-teen ep growth period
may becton host analyst day provid updat
busi longer term outlook
fiscal becton compar constant currenc sale growth impact
drug-coat balloon dcb headwind thu adjust
underli sale growth mid-point long-rang target bd
adjust ep grew howev adjust adjust fx ep grew ep growth
impact number factor includ dcb headwind impact
divestitur difficult flu comp tariff higher resin raw
materi cost though partial off-set favor tax rate bd
estim underli ep growth rate in-lin deal model
novemb becton dickinson issu initi fiscal guidanc becton expect
constant currenc revenu growth reflect medic growth
life scienc growth intervent growth medic growth
slower year past year owe pressur china tender
affect medic deliveri solut busi intervent growth reflect
continu pressur dcb anniversari fda notif safeti
concern increas competit pact dcb approv use
treatment fail arterioven av access patient esrd undergo
dialysi assum fda approv lutonix below-the-kne indic
report basi sale expect increas includ
headwind fx becton expect adjust ep reflect
underli growth off-set headwind loss gore royalti
tariff tougher flu comp fx
possibl question manag
optim leverag structur
compani achiev optim leverag ratio manag
think capit deploy
respect manag still commit smaller tuck-in
rate spend need increas bd need becom
transform portfolio past five year becom larger
divers med-tech compani march becton dickinson complet
billion acquisit carefus ad infus pump medic manag
medic suppli portfolio decemb complet
billion acquisit bard ad peripher intervent surgic access
urolog product mix acquisit becton lever complet
transact move rapidli de-lev afterward septemb becton
gross leverag becton goal reduc debt level
end
tuck-in acquisit central bard strategi becton state continu
look supplement legaci bard busi tuck-in deal howev
acquisit becton done juli tva medic acquisit tva develop
endovascular arterioven av fistula creation product everlinq endoavf system
minim invas vascular access product use hemodialysi call system
market wavelinq
possibl question manag
sustain rate medic manag solut busi
past year better-than-market taken share
infus pump medic manag hospit capit
equip environ favor current rate growth
sustain busi revert lower at-market rate growth
would character competit dynam infus pump
market competit disadvantag broad offer infus
current statu complet time updat alari
becton medic manag solut repres sale includ
two key product areasdispens technolog infus system estim
sale roughli split two busi sourc
growth becton past year
dispens technolog busi includ primarili system sold bd
pyxi brand major sale unit state outsid unit
state bd also offer rowa robot medic storag retriev system retail
hospit pharmaci
bd pyxi medstat autom medic dispens system typic
maintain access nurs unit bd also sell system medic suppli
manag call pyxi supplyst pyxi signific market share posit
like greater medic manag unit state main
competitor
infus system includ infus pump sold hospit ambulatori
surgeri center transport servic becton also sell dedic dispos
administr set thu becton benefit sale pump
enjoy long-term revenu stream dispos
unit state becton largest instal base larg volum alari
alari pump smart pump allow simultan iv medic
fluid administr multipl deliveri modul syring pump larg volum
pump patient control analgesia pump
outsid unit state becton market caesarea medic electron pump
infus syring expand bd busi ambulatori home specialti
becton dickinson primari competitor infus pump unit state baxter
baxter plan launch new pump platform unit state
reclaim market share outsid unit state competitor
includ braun freseniu smith medic
earn call manag indic medic manag
sale could push remaind year due time pump softwar
becton signific supplier iv solut suppli iv solut vi -- vi
suppli distribut partnership freseniu januari bd freseniu
announc suppli distribut agreement freseniu kabi would
suppli bd portfolio intraven solut fresensiu kabi also acquir bd
rx/simplist gener inject program believ revenu associ
distribut agreement minim fiscal fiscal us infus
solut market domin three providersbaxt icu medic legaci hospira
 braun
peripher intervent opportun risk
possibl question manag
latest think lutonix drug-coat balloon below-the-kne
peripher product help off-set dcb soft
bd peripher intervent repres compani total sale busi
product endovascular fistula creation devic
one bard key product lutonix dcb help acceler growth
profil bard lutonix sale pressur fiscal owe safeti
concern late mortal event initi gener decemb meta-
analysi publish journal american heart associ see link paclitaxel
drug-coat elut peripher devic along subsequ fda letter healthcar
profession peak estim dcb sale around million
estim sale fell long-term data becom avail physician
start slowli increas usag product becton manag assum
fiscal forecast sale rebound includ benefit
expand indic moreov believ appropri given receiv
expand indic av fistula competit dcb product
becton dickinson seek expand label indic us includ
indic below-the-kne indic europ canada australia lutonix
commerci avail use btk arteri associ critic limb
ischemia sinc bard estim market opportun associ
btk indic around million bard submit pma fda approv
august earn call manag announc fda notifi
pma not-approv current form becton discuss
fda expect file supplement fda includ addit data
earn call manag note peripher intervent sale would
grown low doubl digit dcb impact exclud venovo covera
wavelinq growth driver peripher intervent busi segment
cover vascular stent av graft av fistula wavelinq endovascular av fistula
possibl question manag
futur plan market opportun swatch effort
move forward third parti swatch potenti
diabet drug-deliveri applic
statu dose captur insulin pen
sustain growth rate diabet pharm system
becton diabet busi repres approxim total compani sale
includ syring pen needl use inject insulin drug use
treatment diabet
throughout histori diabet area focu becton dickinson
compani explor way expand busi
earli becton dickinson interest blood glucos monitor
market januari compani announc two new fda-clear blood glucos
monitor product bd logic blood glucos monitor bd latitud diabet
manag bd also announc enter two separ unrel
strateg relationship eli lilli increas diabet care market
presenc respect term agreement
distribut co-brand version bd logic blood glucos monitor bd strip
compani collabor develop integr system respect lilli
term lilli use diabet sale organ provid target support
market introduct new bd latitud diabet manag system lilli
bd would jointli pursu futur opportun diabet diseas manag becton
endeavor blood glucos monitor continu decid septemb halv
effort bd manag conclud futur outlook increasingli
competit market justifi level invest addit resourc
necessari continu right call view bgm market would
subsequ come intens price pressur owe medicar reimburs
becton also sought expand diabet infus set use
conjunct insulin pump deliv insulin becton collabor jdrf
develop bd flowsmart technolog featur side-port cathet design
improv insulin flow reduc number flow interrupt bd flowsmart
technolog approv canada januari april part
agreement bd commerci set infus set
recal due issu compon becton work redesign set howev
becton announc novemb would discontinu product redesign
provid level differenti set hope
becton also made effort partnership jdrf relat continu blood
glucos monitor well combin devic continu blood glucos monitor
infus devic bd perform trial use glucose-bind protein-
becton also work dose captur insulin pen product smart pen becton
product smartsens needl would flow-sens technolog would
abl captur amount insulin dose deliv product design
univers fit dispos insulin pen howev compani februari
announc decid stop program reassess near-term commerci
opportun rather decid deploy resourc smart type patch pump
comment would return back pen program later date
becton effort patch pump type ii patient swatch on-going
number year swatch design three-day pump adjust basil bolu
rate becton state design product low cost near price pariti
current therapi pen august becton announc withdrew
fda applic receiv comprehens feedback fda engag
outsid organ address issu identifi form factor manag
provid updat timelin product launch
compani launch valerita attempt launch subsequ
sold product cequr insulin patch technolog gear type ii patient
popul tradit pump player note pump use type ii
patient well
pharma system repres revenu bd includ prefil drug
deliveri system syring self-inject system provid
pharmaceut compani use contain inject pharmaceut product
becton work host pharmaceut biotech compani
possibl question manag
reason behind join preanalyt system
diagnost system specif manag tri achiev
make becton right owner lifesci franchis would
manag will spin divest diagnost system
key new system new assay launch expect
next year
bd lifesci divis account total compani sale includ three
busi unit howev effect octob bd join preanalyt system
diagnost system busi unit togeth creat new integr diagnost
solut organiz unit done drive focu growth innov
around integr specimen manag diagnost solut
histor known preanalyt system busi includ blood collect
product system product sold hospit laboratori clinic
histor known diagnost system unit includ autom blood cultur
tuberculosi cultur system microbiolog lab autom molecular test
system rapid diagnost assay liquid-bas cytolog system cervic cancer
screen blood cultur busi largest part diagnost includ
compani flagship bd bactec system bd molecular platform includ bd
unit includ fluorescence-activ cell sorter analyz reagent molecular
index next-gener sequenc sampl prepar genom research
clinic oncolog immunolog hiv transplant diagnostic/monitor reagent
analyz bd research cell analyz includ bd accuri bd facscanto bd
facscelestra bd facsymphoni system name bd clinic cell analyz
includ bd facscalibur bd facscanto bd facspresto bd facsvia bd
product typic sold pharmaceut biotechnolog compani well
academ govern institut research clinic tool use
studi cell cell compon aid discoveri develop new drug
and/or improv diagnosi manag diseas
adjac opportun read-thru other
possibl question manag
reason exit bd simplist program gener inject
year ago seem like logic adjac attract market
opportun read-thru baxter expand gener
bd announc program call bd simplist compani effort enter
pharmaceut manufactur take advantag signific opportun
gener inject product becton develop program year prior
announc north carolina plant approv fda
subsequ year becton receiv approv seven drug ready-to-administ
pre-filled glass syring howev becton sold busi freseniu kabi state
believ freseniu kabi logic owner given exist capabl
inject becton acquir carefus thu decis exit may also
relat bandwidth chang strateg direct manag focu
success integr
co
equal weight believ bd continu
success integr bard achiev plan
revenu cost synergi view recent
pullback share drug-coat balloon
concern overreact see upsid
share consid bd sale
ep growth profil compani view
valuat attract
upsid case could driven better-than-
bard acquisit improv overal
growth rate btk indic and/or favor
fda letter updat june panel
downsid case could driven foreign
exchang stronger usd could pressur
expect sale legaci bard busi
slowdown emerg market growth inabl
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
quarterli annual ep usd
consensu number bloomberg receiv gmt
price pe perform
share upward climb past seven year compani improv overal growth profil resolv
major legal liabil stock outperform broader market healthcar period owe
share perform in-lin market stock bit constrain view premium valuat
multipl slower anticip organ growth year concern around impact scope trial ischemia trial
fall
scientif corp equip pe ntm estim pricepric lh rel pe barclay medic suppli devic
sale product categori month
compani report note btg intervent includ peripher
sale region month ex- btg
boston intervent cardiolog busi make product diagnos treat coronari arteri diseas
system structur heart therapi like watchman left atrial appendag closur devic acur aortic
valv sentinel cerebr embol protect lotu edg transcathet aortic valv replac tavr
peripher intervent includ devic diagnos treat peripher arteri diseas like stent balloon
cathet guid wire product also includ eluvia drug elut stent venou stent intervent
oncolog product like embol devic product acquir btg acquisit
rhythm neuro
urolog pelvic health
product includ implant devic monitor heart deliv electr treat heart function disord
among devic segment implant defibril pacemak patient manag system
electrophysiolog product includ minim invas technolog diagnos treat rate rhythm
disord product includ portfolio diagnost cathet along rhythmia cardiac map solut
blazer ablat cathet product line
segment includ devic treat neurolog movement disord chronic pain boston spectra
wavewrit spinal cord stimul use chronic pain vercis deep brain stimul superion spinal
decompress system vertiflex acquisit key product
endoscopi busi make product diagnos treat gastrointestin pulmonari
condit minim invas technolog major product segment includ spyglass flexibl
endoscop exalt model singl use duodenoscop jagwir revolut high perform guidewir epic
includ devic treat urolog pelvic condit men women includ kidney stone benign
abnorm bleed uterin fibroid polyp lithovu single-us digit flexibl uretoscop greenlight laser
rezum treat bph spaceoar hydrogel use prostat radiotherapi key product
segment
product acquir btg acquisit includ acut care antidot treat overexposur
certain medic toxin
report strong quarter sale ep come ahead consensu
organ sale growth guidanc driven
cardiovascular medsurg manag expect organ sale growth remain
strong expect full year mid-point prior
rang net/net view result manag commentari
investor concern ischemia scope btg favor reiter
addit detail quarter
million except per share data chang sale organ basi unless otherwis note
organ sale growth led cardiovascular medsurg
higher manag guidanc
street expect
neuromodul sale despit face tough comp flat
reflect strength deep brain stimul db
busi sale nearli doubl
intervent cardiolog due strength structur heart
watchman lotu edg acur sentinel structur heart
expect deliv sale toward higher end guidanc
emerg market sale oper basi
manag quantifi potenti impact ischemia trial
present american heart associ neg
slight positiveoveral see manag
cardiac rhythm manag grew quarter defibril sale outpac
market grow low single-digit driven reson platform
replac s-icd also continu grow pacemak declin low singl digit
ep sale overal market
oper margin lower end guidanc rang due btg
acquisit neg impact includ guidanc
gross margin near midpoint guidanc flat y/i
favor fx impact manufactur improv off-set price eros
de pacer mix shift de complex pci product
sg sale y/i due oper expens control
optim initi guidanc due inclus btg
 sale y/i high end guidanc rang also
due guidanc reflect btg acquisit
oper margin y/i lower end guidanc
lower due btg
adjust tax rate guidanc result
benefit stock-bas compens
adjust ep
expect report revenu growth includ fx headwind net
acquisition/divestitur contribut organ revenu expect ep expect street
boston expect report revenu growth includ fx headwind net
acquisition/divestitur contribut organ sale growth expect midpoint prior rang adjust
ep expect prior guidanc fx expect neutral year
actual mix product categoryyoy chang barclay medic suppli devic
boston scientif launch new product across
busi unit allow compani sustain high-
singl digit sale growth drive leverag deliv
key risk trajectori stock new product
approv time market uptak on-going competit
pressur price pressur success integr
execut well strateg acquisit
stock trade premium good news seem
continu drive
alreadi reflect price
believ one highest sustain growth profil larg cap med-tech
warrant premium valuat compani pipelin broad deep includ new
product across busi segment manag also continu make strateg
acquisit like btg allow continu shift mix busi higher growth
end market keep deliv above-averag growth rate share overweight
feb ambu report competitor dispos scope
feb result guidanc
american colleg cardiolog
possibl question topic manag
put take investor consid
follow acquisit btg number smaller acquisit
investor expect boston scientif term capit alloc
btg integr track rel expect still double-digit growth
outlook eko view competit landscap pulmonari embol
specialti pharma busi core monet
initi feedback sinc fda clearanc exalt still confid
billion-plu opportun broader billion single-us opportun
view structur heart growth outlook given move part tavr launch
abbott launch laa amulet us sentinel
time milliped iri transcathet annuloplasti system system
outlook urolog franchis acceler rezum prostat treatment
sale interest broaden women health would enter sacral neuromodul
ramp potenti spaceoar hydrogel
view neuromodul growth rate chang investor day
note expect franchis grow period
current statu polarx lumin single-shot balloon launch europ
time market entri unit state what outlook ep growth
outlook cardiac rhythm manag sale growth next year
lux-dx track launch plan differenti
latest think timelin leadless pacemak modular system
see impact de franchis ischemia trial
current think opportun eluvia ranger
possibl questions/top manag
possibl question manag
put take investor consid
investor think long-term growth profil compani
acquisit btg includ
boston scientif dramat improv perform sinc begin
decad owe acquir product improv intern focu execut
organ revenu growth adjust major acquisit
boston scientif organ revenu growth end
manag target full year manag expect deliv adjust
ep y/i exclud ir settlement btg
acquisit expect neutral adjust ep compani gener billion
adjust free cash flow million report basi expect
gener adjust free cash flow billion full year
june investor day boston scientif laid long-rang plan lrp
compani broad prioriti time-frame includ
continu shift mix high growth market invest pipelin
deliv consist revenu growth margin expans cash flow
revenu growth manag expect annual organ growth
period growth expect fuell revenu mix continu shift
higher growth market new product
margin ep expect annual oper margin expans
annual period larg driven on-going cost reduct
effort turn help facilit double-digit adjust ep growth
free manag believ increas larg part stori
underappreci legal liabil primarili rear-view mirror
manag expect increas adjust free cash flow billion
ep includ full year btg acquisit time
btg acquisit close august boston scientif expect btg
accret adjust ep increasingli accret thereaft
novemb announc acquir billion outstand
debt matur averag coupon issu million
note provid compani interest expens save
possibl question manag
follow acquisit btg number smaller acquisit
investor expect boston scientif
go forward term capit alloc
acquisit number year compani
shape portfolio toward higher growth market outcom
acceler top line compani past nine year
boston scientif resolv fund product legal
liabil cash flow go toward valu creation opportun go forward
ablat gi cancer
diagnosi ovarian
balloon cathet pvi
oncolog
spacer lumbar
cosman
possibl question manag
btg integr track rel expect
confid acquir btg busi grow double-digit
outlook eko view competit landscap
outlook btg intervent vascular product
expect btg intervent oncolog franchis
talk opportun radiat bead tumor ablat
confid abil achiev million cost
view specialti pharma busi core potenti
monet franchis would dilut
august boston scientif complet acquisit btg billion
btg gener million revenu fiscal year end march btg
busi segment includ intervent medicin includ intervent oncolog
intervent vascular licens product though note
novemb ontario municip employe retir system
enter royalti purchas agreement wherebi bought
zytiga royalti payabl million cash
btg intervent vascular busi complementari boston scientif peripher
intervent busi intervent oncolog busi build onto boston
scientif effort categori btg headquart unit kingdom
compani gener revenu unit state provid
opportun boston scientif leverag global infrastructur togeth legaci
intervent medicin sale expect grow double-digit provid boston
scientif growth corpor averag initi margin profil
intervent medicin busi compar boston scientif today expect
accret compani year three achiev revenu cost
synergi expect total million
million revenu
flagship product within vascular franchis ekoson endovascular system
eko eko first fda approv product may minim invas
endovascular therapi pulmonari embol devic consist control unit
connect cathet provid ultrasound deliv thrombolyt agent
help break blood clot dissolv pulmonari embol btg believ eko treat
pulmonari embol estim annual procedur us market
grow deep vein thrombosi estimate procedur grow
peripher arteri occlus estimate procedur grow btg estim
rel high penetr at/abov share pulmonari embol market
lower penetr rate estim deep vein thrombosi
compani look expand product offer treat pulmonari embol
novemb extract-p prospect single-arm
multicent us trial result show indigo aspir aspir
mechan thrombectomi use patient acut pulmonari embol pe met
primari endpoint studi
sentri first bioconvert inferior vena cava filter use protect
pulmonari embol devic self-expand bioabsorb filament
hold arm togeth day dissolv allow arm open
restor normal vessel function btg estim annual us filter insert procedur
total decreas previou market size due
fda mandat requir retriev filter compani believ sentri
uniqu design allow gain share hope increas market size back
million includ drug-elut chemotherapi agent microscop bead use
transarteri chemoembolis tace bead stop flow blood target
tissu deliv local sustain dose drug direct tumor
theraspher glass bead contain radioact isotop use
radiat primari mode action select intern radiat therapi sirt
transarteri radioembol tare theraspher receiv fda approv
humanitarian devic exempt hde limit use radiat treatment
neoadjuv surgeri transplant
patient unresect
hepatocellular carcinoma placement appropri posit
hepat arteri cathet hde number patient per year also limit
current two key on-going clinic trial product epoch phase iii-
patient metastat colorect carcinoma refractori first line chemotherapi
stop- phase iii-pati unresect expect time trial
read-out first half new/expand indic boston scientif
estim market opportun theraspher could billion
icefx argon-bas cryoablat therapi design use treat kidney
cancer tumor/tissu destruct applic btg also microwav ablat
platform develop anticip tumor ablat could
million market opportun
btg fiscal end march gener million
revenu compani pharmaceut divis consist three productscrofab
snake anti-venin digifab anti-toxin overdos digoxin heart failur drug
voraxaz reduc methotrex blood crofab declin due
launch competit product
segment high profit cash flow view like consid core
asset manag given outsid med-tech
possibl question manag
initi feedback sinc fda clearanc exalt
confid billion-plu market opportun size
exalt billion-plu market estim single-us
boston scientif single-us endoscopi develop effort mid-
endov termin make time around differ
address competit
decemb receiv fda clearanc exalt single-us
duodenoscop grant break-through design fda boston
scientif plan limit market releas see longer term billion-
plu market opportun product
exalt single-us scope product line eventu includ bronchoscop
model tg therapeut gastroscop boston scientif single-us digit
cholangioscop spyglass market expect continu expand offer
includ choledochoscop boston scientif see single-us therapeut
imag market billion-plu market
boston scientif evalu opportun dispos endoscop
extens period time boston scientif program call
endov integr system includ scope consol flat
screen monitor use endoscop procedur colonoscopi boston scientif
hope commerci launch product mid-to-l howev
boston scientif determin would commerci viabl product
termin product
duodenoscop fda highlight risk infect reprocess
duodenoscop flexibl light tube thread mouth throat
stomach top small intestin duodenum duodenoscop use
endoscop retrograd cholangiopancreatographi ercp procedur year
diagnos treat problem
pancrea bile duct duodenoscop
manufactur today includ fujifilm olympu pentax devic difficult
clean reprocess concern rais infect risk upon reus
recent studi found high risk-organ duodenoscop test
august fda issu press releas titl fda recommend health care
facil manufactur begin transit duodenoscop dispos
compon reduc risk patient infect press releas state specif
challeng clean devic reus reprocess persist
high level contamin agenc recommend move away use
duodenoscop fix endcap dispos compon includ
dispos endcapsor fulli dispos duodenoscop becom avail
time fda announc fujifilm pentax duodenoscop
dispos endcap olympu issu letter custom octob indic
work fda bring newest-gener duodenoscop
dispos endcap market soon possibl olympu also note
offer buy-back program duodenoscop amount
cash credit model fda encourag healthcar profession
transit away
novemb pentax receiv fda clearanc first duodenoscop steril
dispos elev compon duodenoscop reduc number part
need clean disinfect fda put press releas novemb
highlight clearanc note part tradit difficult clean
reprocess
addit compani plan sell single-
ambu danish compani seek becom single-us compani ambu today
commerci avail bronchoscop ent scope isiri cystoscop ureter
stent remov ambu expect full rang single-us flexibl endoscop
advanc monitor address million annual procedur market may ambu
cook medic announc partnership wherebi cook would distribut
single-us duodenoscop unit state follow fda clearanc expect
end septemb
karl storz mtp single-us product includ c-mac video laryngoscop
olympu also plan complement portfolio single-us scope
structur heart franchis opportun growth
possibl question manag
view long-term growth rate structur heart
see sustain growth rate watchman view
competit landscap risk abbott amulet enter us
market
expect transcathet aortic valv portfolio lotu
acur grow next year timelin acur
us see us market play two valv
approach longer term time intermedi low risk
signific driver could sentinel next year
time milliped iri transcathet annuloplasti system
transcathet mitral program develop
boston scientif structur heart busi within intervent cardiolog divis
includ sale watchman left atrial appendag devic acur lotu
transcathet aortic valv replac tavr system sentinel cerebr embol
protect devic manag expect structur heart busi gener sale
higher end million guidanc
courtesi boston scientif
courtesi boston scientif
courtesi boston scientif
watchman boston scientif left atrial appendag closur laac devic devic
deliv via femor arteri prevent migrat blood clot form
left atrial appendag migrat brain caus stroke form system embol
watchman flx second-gener devic design simplifi implant
fit wider rang anatomi allow implant fulli enclos
round frame physician fulli recaptur reposit devic
procedur devic also design enhanc seal receiv ce
mark watchman flx march launch japan receiv
reimburs septemb boston scientif target launch
boston scientif estim global laac market approxim
million would includ global watchman sale well abbott amulet devic
sold intern boston expect market increas billion
billion
abbott plan launch amplatz amulet devic unit state late
approv support result amulet studi compar
outcom amulet watchman amulet receiv ce mark januari
boston scientif acquir lotu valv acquisit sadra medic
lotu valv receiv ce mark european approv octob octob
suspend launch initi voluntari remov field inventori
due report devic could fulli lock procedur due
prematur releas pin connect lotu valv deliveri system februari
initi remov lotu valv devic global commerci
clinic site due aforement issu
address technic issu product relaunch lotu
april lotu edg aortic valv system receiv fda approv patient
consid high surgic risk recent call present manag
comment launch go plan product track reach
account first year boston scientif enrol intermedi risk studi
anticip fda approv
next-gener lotu valv call lotu mantra valv
shorter frame height improv coronari access also open cell design top
valv reduc risk intra-annular valv thrombosi gener
optim radial forc insid left ventricular outflow tract reduc pacemak rate
boston scientif initi focu valv expect enter trial mid-
expand size
acquir acur valv platform symeti acquisit
may acur neo transfemor system commerci launch europ
boston scientif develop next-gener acur system
extend skirt minim paravalvular leak boston scientif expect european
approv approv time acur becom increas focu
invest commun sinc releas scope data tct show
edward valv perform better acur neo particularli area
paravalvular leak
boston scientif also develop acur neo prime enhanc radial
strength includ extra-smal extra-larg size rang boston scientif
expect introduc acur prime us studi launch us
sentinel cerebr embol protect devic use reduc stroke
transcathet aortic valv replac tavr boston scientif acquir sentinel
devic claret acquisit august million million cash
up-front million reimbursement-bas mileston
courtesi boston scientif
june investor day well tct investor brief septemb
manag estim sentinel use procedur adopt account
 tavr procedur
courtesi boston scientif
expand structur heart portfolio made invest milliped
januari along option acquir remain option acquir remain
share compani million boston scientif exercis option acquir
milliped decemb million million payabl upon
achiev commerci mileston payment
milliped iri system replic surgic repair annuloplasti ring deliv
transept deliveri system reduc size dilat mitral annulu tee
navig ice-guid anchor boston scientif optim system
technolog enhanc current timelin call return human
earli feasibl trial think late
urolog pelvic health
possibl question manag
acceler perform rezum prostat treatment given
reimburs competit urolift
one think revenu ramp potenti expand
indic spaceoar hydrogel
view women busi opportun
expand franchis meaning
boston scientif urolog pelvic health busi repres total sale
busi sell product treat condit male femal anatomi includ
male incontin pelvic floor disord abnorm uterin bleed uterin fibroid
polyp major product includ lithovu single-us digit flexibl ureteroscop
greenlight xp laser system rezm system spaceoar hydrogel system
benign prostat hyperplasia bph enlarg prostat tissu
effect urinari function portfolio includ greenlight xp laser
moxi fiber rezm
greenlight xp laser typic perform outpati basi
gener anesthesia laser use heat vapor excess prostat tissu
creat larger channel urin pass greenlight system also
use treat bladder tumor urethr strictur
rezum system acquir purchas nxthera april rezum
use water vapor target prostat adenoma cell lead cell remnant
absorb bodi procedur perform office-bas set
januari four-year data publish journal urolog show surgic
retreat rate
rezum compet teleflex urolift view sale uptak rezum
disappoint owe part reimburs profil product urolift
favor reimburs work improv reimburs profil
product moreov surgic retreat rate rezum better
four-year data publish rezum versu lift studi rezum
requir post procedur catheter
associ sexual
dysfunct retrograd ejacul urolift
octob boston scientif acquir augmenix million million up-
front million mileston payment augmenix spaceoar hydrogel spacer
current use protect rectum healthi tissu exposur unwant
radiat treatment prostat cancer expect augmenix
gener million revenu plan expand new market includ
treatment pancreat breast gynecolog thyroid cancer
boston scientif women health busi includ product treat condit
uterin fibroid polyp
april purchas nvision million up-front cash payment
million mileston payment nvision develop mako hysteroscop
accessori intend collect cell sampl fallopian tube offer potenti
platform earlier diagnosi ovarian cancer accord american cancer societi
ovarian cancer case late stage due lack reliabl diagnost boston
believ ovarian cancer diagnost market million near term could
grow billion
possibl question manag
view neuromodul growth rate chang investor
day note expect franchis grow
product sub-seg see drive growth
expect enter sacral neuromodul market
strategi
boston scientif neuromodul segment repres sale includ product
manag neurolog movement disord chronic pain neuromodul
product revenu grew organ howev sale slow
single-digit reflect slowdown overal market june investor day
boston scientif manag note expect segment grow
like spectra
wavewrit system treat chronic pain
deep brain stimul db system includ product vercis system
superion spinal decompress system treat patient moder lumbar spinal
stenosi boston scientif obtain system vertiflex acquisit june
million boston scientif expect gener million sale
possibl question manag
current statu polarx lumin single-shot balloon
launch europ time market entri unit state
growth rate expect ep busi grow next
boston scientif electrophysiolog busi repres approxim total sale
sale grow double-digit slightli
boston scientif estim mix busi mainli bit core ep
product market grow low-singl digit remaind advanc
map navig market grow mid-to-high teen manag
see opportun acceler growth enter higher growth market name
single-shot atrial fibril cathet market estim million market
today increas presenc advanc map navig
boston scientif polarx cryoablat cathet pulmonari vein isol
treatment patient paroxysm atrial fibril paf boston scientif
target year-end launch polarx europ though expect slip
septemb receiv approv begin us approv
studi target us launch
boston scientif obtain technolog buy remain stake
cryterion juli million
lumin singl shot multi-electrod irrig radiofrequ rf balloon cathet
system allow physician configur control ablat electrod boston
scientif obtain technolog octob acquisit apama medic
million cash up-front million mileston payment
expect receiv ce mark begin us
possibl question manag
outlook cardiac rhythm manag sale growth
lux-dx track launch plan
differenti latest gener icm
latest think around timelin leadless pacemak
boston scientif cardiac rhythm manag busi repres approxim
total sale matur market busi sale grow low singl digit
past sever year product includ cardiac pacemak implant cardiovert
defibril icd cardiac resynchron therapi crt devic subcutan
icd s-icd product use treat patient irregular heart rhythm
implant cardiac monitor market million-plu market grow
mid-singl digit market domin although abbott
enter space well
boston scientif develop insert cardiac monitor icm lux-dx
work tandem mylux patient app latitud clariti data
manag system identifi arrhythmia provid predict alert plan
launch around time hr confer may
look farther boston scientif develop lux-dx beyond
plan new sensor capabl address addit diseas state includ
leadless pacemak system market sever year
leader field st jude abbott receiv ce mark nanostim devic
stop sell product due issu product focus
boston scientif plan start us evalu modular system
incorpor emblem s-icd empow leadless pacemak
drug-elut stents/balloon coronari peripher
possibl question manag
see impact de franchis ischemia trial
current think opportun eluvia ranger
believ market start move beyond fear associ
boston scientif drug-elut coronari stent busi approxim billion size
concern regard ischemia trial result releas
american heart associ meet novemb whether trial could
prompt pullback sale stent relat product doctor chose delay
intervent patient consid stabl asymptomat prior releas
ischemia trial manag estim worst case impact
million headwind best case slight posit
boston scientif also sell within peripher intervent franchis drug-elut
peripher stentsund eluvia brandand expect receiv fda approv
ranger drug-coat balloon use peripher indic novemb
result ranger ii sfa studi present show ranger superior
primari patenc month compar plain pta balloon product
incorpor drug paclitaxel come scrutini safeti
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight one
highest sustain sale growth profil larg cap
med-tech compani number new
product across busi segment
provid above-averag growth expect
double-digit ep growth continu believ
premium valuat warrant given
expect growth
upsid case could driven new product
regulatori approv time greater traction new
product improv profit success
integr leverag acquisit
downsid case could driven delay
inabl receiv regulatori approv slower
uptak new product greater competit
pressur key area stent structur
heart greater-than-expect price pressur
price pe perform
conm corp quarterli annual ep usd
consensu number bloomberg receiv gmt
share struggl compani went proxi battl novemb curt hartman name presid
ceo initi enthusiasm around prospect turnaround drove share higher though perform
consist led stock trade lower sideway howev begin manag team
start make progress turnaround stock start move higher surgiquest acquisit anniversari earli
sale growth rate start inflect growth rate compani acquir buffalo filter earli
view buffalo filter provid anoth platform growth given market product line gain addit comfort sustain
growth
corp indexrussel equip lh highlight small barclay ical suppli devic
sale product categori mo
sale geographi mo
sale product categori mo
market size main competitor
devic repair soft tissu injuri joint particularli
knee shoulder
exclus commerci right mtf allograft tissu use
surgic drill saw relat singl use cut
high-definit surgic visual system enabl
platform devic accessori creat enter
surgic work space minim invas procedur
rf energi affect tissu cut seal caus
hemostasi open minim invas procedur smoke
evacu filtrat support surgic environ
instrument accessori minim invas
laparoscop open robot approach
therapeut diagnost endoscop product use
mainli also depuy synth
single-us devic monitor cardiac activ
bloomberg barclay sale street estim
deliv impress quarter report growth constant
currenc growth buffalo filter acquisit contribut growth
translat organ growth ep street
estim rais buffalo filter guidanc maintain full year
organ growth rang larg due tough comp also rais
ep guidanc rang due on-going margin improv lower tax rate net/net
view impress quarter mix guidanc reiter overweight rate
million except per share data chang sale constant currenc basi unless otherwis note
addit detail quarter
sale growth expect driven strong organ sale growth
well signific contribut buffalo filter ad
buffalo filter full year sale guidanc increas prior
rang origin guidanc rang acquisit
oper margin y/i
ep guidanc rais previou rang
organ sale growth guidanc maintain manag
continu expect tough comp well incorpor potenti
impact plan sale forc expansion/channel chang
fx headwind expect versu previou expect
sale y/i constant currenc basi
acquisit contribut sale growth extra day ad
gross margin y/i
sg sale y/i manag note better-than-expect
buffalo filter integr leverag broader busi
 sale y/i
op margin y/i adj ebitda margin y/i
adjust tax rate y/i help stock compens expens
adjust ep street estim estim
manag expect organ growth full year guidanc rang due tough comparison potenti
salesforc disrupt due expans channel chang gross margin expect around trend
sale maintain full year organ sale growth rate guidanc rang manag also increas
expect buffalo filter expect contribut sale fx headwind
expect previou headwind revenu expect versu prior rang
repres report growth expect
 manag anticip sg margin improv interest expens expect tax rate
year prior rang rais adjust ep guidanc
bloomberg estim
turn around well-posit
deliv sale growth least mid-singl digit double-
sale growth comparison becom challeng ahead
could find difficult grow
acquisit buffalo filter add potenti long-term driver
compet much larger compani
growth leader grow smoke evacu
market legisl guidelin updat could drive increas
adopt smoke evacu product
smaller compani given financi outlook
could find possibl target med-tech
market consolid
compani may success integr effort
buffalo filter and/or smoke evacu opportun
may less expect
success execut turnaround posit deliv least mid-single-digit
sale double-digit ep growth view acquisit buffalo filter posit enhanc
underli growth rate also confid manag abil integr
buffalo filter given success integr surgiquest acquisit outperform investor
expect extent sustain least mid-singl digit growth compani could
acquisit candid med-tech remain consolid market rate
jan result guidanc
american academi orthoped surgeon aao orlando fl
associ periop regist nurs anaheim ca
apr societi american gastrointestin endoscop surgeon sage cleveland oh
possibl question topic manag
investor think long-term growth profil compani consid
addit buffalo filter
put take investor consid
manag view long-term margin potenti
sustain growth outlook buffalo filter
manag view total address market opportun
manag view competit landscap smoke evacu
potenti legisl and/or guidelin changes/recommend could drive
adopt smoke evacu product
manag strateg vision compani go forward
manag view compani current busi mix
given current leverag compani thought capit deploy
manag believ larg enough resourc well enough compet
larger medic devic compani end market
key new product improv compani perform
greatest opportun spend area like alloc
dollar area might requir extern invest acquisit
new product beyond could significantli acceler growth
possibl questions/top manag
possibl question manag
investor think long-term growth profil compani
consid addit buffalo filter
put take investor consid
manag view long-term margin potenti
last four year execut turnaround plan led curt
hartman appoint presid ceo acceler growth
function improv sale execut focus innovation/new product
addit airseal go forward believ buffalo filter acquisit also
accret growth profil grow double-digit
januari manag provid initi constant currenc revenu
growth guidanc year progress manag rais organ
growth guidanc first result
result manag expect organ growth full year rang due
tough comp potenti sale forc disrupt due expans channel chang
expect buffalo filter also increas throughout time close
februari manag expect buffalo filter sale month
million manag rais expect juli million octob
million buffalo filter sale sold
full year manag expect bp fx headwind bring report revenu
million y/i growth adjust ep expect
reflect y/i growth buffalo filter expect neutral ep
provid guidanc result manag provid
commentari put take result manag note longer
term goal least mid-single-digit revenu growth double-digit earn growth
organ sustain basi comment posit deliv least
level growth beyond manag note greater fx headwind
versu well potenti higher tax rate due number discret tax item
lower effect tax rate maintain double-digit ep growth
outlook despit continu expect buffalo filter accret
possibl question manag
sustain growth outlook buffalo filter
manag view total address market opportun
manag view competit landscap smoke evacu
potenti legisl and/or guidelin changes/recommend
could drive adopt smoke evacu product
februari acquir buffalo filter million busi
outperform sinc close deal origin expect sale contribut
million sinc rais expect twice expect
sale million repres pro forma growth growth y/i
surgic smoke gener surgic procedur use energy-bas
devic cauter vessel vapor human tissu bodili fluid caus surgic
smoke contain toxic chemic benzen toluen carbon monoxid etc
along aerosol pathogen small particl absorb patient
bodi laparoscop endoscop procedur
surgic smoke signific hazard patient surgic staff unit state
healthcar worker expos surgic smoke everi year accord
despit hazard surgic smoke use surgic smoke evacu equip
univers standard fact use smoke evacu estim
approxim penetr us intern
around world howev govern regulatori bodi profession organ
implement law guidanc relat surgic smoke denmark surgic smoke
remov mandat law canada smoke remov becom requir standard
care australia new zealand uk establish regul legal
enforc protect hospit employe smoke
unit state nationwid regul current exist although state
start adopt legisl exampl rhode island colorado pass law requir
use surgic smoke evacu technolog legisl also introduc
oregon california massachusett addit nation institut occup
safeti niosh part cdc establish practic surgic
joint commiss accredit certifi healthcar
organ written standard smoke laser/electrosurg procedur
associ periop regist nurs establish guidelin
surgic smoke safeti anticip continu momentum surgic smoke
restrict guidelin global tailwind surgic smoke remov devic sale
possibl question manag
manag strateg vision compani go forward
manag view compani current busi mix
given current leverag compani thought capit
past four year execut turnaround plan led curt
hartman appoint presid ceo hartman first prioriti
invest human capit end appoint sever new season execut
strategi also includ make customer-centr innovative-driven
hartman restructur market leadership align market product strategi road
map re-invigor product pipelin enhanc sale manag hire in-countri
leadership critic export market focus oper model
hartman strategi also includ restor busi develop function conm
complet number transact product line addit
januari acquir surgiquest airseal system airseal system
consist valve-fre trocar continu pressur sens integr
insuffl smoke evacu use laparoscop robot procedur conm
success integr surgiquest airseal contributor compani
improv growth februari complet acquisit buffalo filter
lead manufactur surgic smoke evacu system like surgiquest believ
buffalo filter enhanc growth outlook year come acquisit
surgiquest buffalo filter shift compani mix busi toward
possibl question manag
manag believ larg enough resourc well enough
compet larger medic devic compani end market
compet end market includ larger medic devic compani includ
 zimmer biomet smith nephew
possibl question manag
key new product improv compani
greatest opportun spend area like
alloc dollar area might requir extern invest
new product expect beyond could significantli
acceler growth profil
past sever year manag refocus effort new
product contribut acceler overal sale growth
new product within orthoped surgeri busi includ crystalview
fluid manag system orthopaed procedur visual new
punch sutur anchor new line acetabular rim arthroscop repair product
within orthoped segment
gener surgeri compani roll pediatr indic airseal system
juli compani also custom new valueblu line electrosurg pencil
within gastroenterolog pulmonari busi within surgeri new
trupass sw short-wir tripl lumen papillotom help simplifi ercp procedur
also new self-expand gore viabil short biliari endoprosthesi
fully-cov metal stent anti-migr technolog reduc risk re-
intervent data show reduc migrat rate compar boston
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight success
execut turnaround posit deliv
mid-single-digit sale double-digit ep growth
view acquisit buffalo filter posit
enhanc underli growth rate
upsid case could driven continu
success drive mid singl digit sale growth
continu strengthen us orthoped
improv new product contribut
greater expect
downsid case could driven slowdown
organ growth comp becom difficult
slowdown hospit capit equip market
invest spend drive futur growth
foreign exchang rate strengthen us dollar
higher tax
price pe perform
edward lifesci corp ew quarterli annual ep usd
consensu number bloomberg receiv gmt
perform ew share historiclli turn mileston relat transcathet heart valv program earli
approv sapien xt success patent litig trial result show superior corevalv
versu surgeri approv better expect tavr sale result drove stock higher share sold octob
compani releas result street expect stock recov tavr util trend continu increas recent
share appreci anticip posit result compani trial evalu sapien valv patient
determin low risk open heart surgeri outlook compani mitral valv replac repair pipelin
lifesci corp equip pe ntm estim pricepric lh rel pe barclay medic suppli devic
sale product categori month
sale geographi month
transcathet aortic valv replac system sapien brand
transcathet valv treatment design use mitral tricuspid valv product includ mainli
pascal valv clasp lesser extent cardioband annuloplasti devic
segment includ surgic mitral aortic valv replac repair technolog
critic care product includ hemodynam monitor system measur heart function fluid
surgeri
risk result present risk result present barclay medic suppli devic
sale ep came well street/our estim driven
underli growth tavr sale structur heart sale critic
sale rel line street/our estim tmtt sale
expect overal sale reflect
underli growth edward expect full year sale top end previou
rang ep guidanc rais
net/net view quarter impress howev given valuat view
growth outlook coupl
linger concern sub-clin
thrombosis/valv durabl maintain underweight rate
addit detail quarter
million except per share data chang sale constant currenc underli basi unless otherwis note
tavr sale well street estim
estim edward abl overcom tradit
season strength low-risk indic sapien sapien ultra
surgic structur heart underli sale surpris given
strength tavr manag highlight growth due premium product
adjust ep street estim driven
notabl tavr sale perform ew rais full-year ep guidanc
manag comment earli forecast process
model return low-double-digit tavr procedur growth next year
tmtt sale street estim
manag expect full year tmtt sale versu
cite disciplin introduct premium price strategi ytd sale
sale billion underli basi underli growth
divis tavr structur heart critic tmtt
sale
gross margin y/i driven favor fx impact product
mix partial off-set spend eu mdr manufactur varianc
sg sale y/i decreas larg function
higher sale despit invest european mitral field personnel relat expens
 sale bp y/i due invest transcathet
oper margin y/i
adjust tax rate y/i includ benefit
stock-bas compens well benefit tax reform switzerland
adjust ep street estim
edward expect sale versu street pre-releas ep versu street pre-
edward expect total sale around top end previou rang edward expect tavr sale
around top end previou rang underli sale growth nearli prior compani expect tmtt
sale prior structur heart sale chang critic sale around top end
previou rang chang gross margin expect in-lin ytd rate versu prior guidanc
sg still expect around year still expect tax rate expect
bottom end rang reflect increas benefit stock base compens net/net edward rais full year
ep guidanc rang
actual million salesrptdunderlyingtranscathet aortic mitral tricuspid heart street divis estim streetaccount els refinitivyoy barclay medic suppli devic
transcathet aortic valv
replac tavr market best technolog
view tavr market expect doubl next
sever year technolog move lower risk patient
greater adopt overal treatment
stock trade premium valuat reflect
transcathet mitral valv market may take longer develop
numer compani develop tmtt devic
edward number shot goal mitral
tricuspid repair replac system transcathet
mitral tricuspid market could larger tavr
believ sale growth like slow experienc bolu patient recent quarter due
data low risk approv edward face competit transcathet aortic valv
tavr expect limit leverag edward invest transcathet mitral valv tmvr/r
opportun sale ep estim street tmvr/r repres potenti second
act still risk like crowd space rate edward underweight
jan/feb quarterli full year result
american colleg cardiolog
possibl question topic manag
prompt chang tavr guidanc result investor day
trend see quarter gave greater confid
investor think long-term growth profil compani opportun
drive signific leverag
see step tavr growth pull-forward procedur new trend line
forecast tavr market doubl much growth come increas
awar new patient versu convert patient surgic
underachiev tmtt goal two year confid achiev
million revenu guidanc rang roll-out pascal europ
proceed success biggest challeng
assumpt billion tmtt market expect sale ramp
mitral repair replac well tricuspid repair play
sapien clinic trial design long expect enrol take
expect us approv line sapien europ
pascal expect complet enrol clasp iid trial end us
approv would surgic inelig patient correct big market
see us timelin enrol pascal clasp iif
studi expect gain fda approv broader indic use
clarifi plan re-work design cardioband evoqu begin
us random studi might timelin
concern regard pascal patent litig level royalti would
will pay would consid reason
view cerebr protect devic chang market share
account use cerebr embol protect
think capit alloc investor expect edward continu share
repurchas activ primari use free cash flow look
past add technolog portfolio
possibl questions/top manag
possibl question manag
prompt chang tavr guidanc result
investor day trend see quarter gave
extent sale upsid would manag inclin reinvest
back busi let flow bottom line
level conservat built relat potenti litig
mitral
investor think long-term growth profil compani
opportun drive signific leverag
investor day decemb manag note expect total edward sale
assumpt divis
transcathet aortic valv replac tavr sale billion repres
underli growth faster growth slower growth
potenti around initi octob commentari tavr
growth would low doubl digit
transcathet mitral tricuspid therapi tmtt sale million
approxim level expect underli basi
surgic structur heart sale million underli growth
critic sale million underli growth
manag expect adjust ep rang reflect gross
margin rang sg remain
sale respect result oper margin rang
edward assum tax rate rang incorpor benefit
employe stock benefit
also investor day decemb edward provid updat long-term
broad stroke guidanc continu expect drive organ sale growth exce
med-tech sector expect minor oper margin expans time gross
margin improv driven mix effici somewhat off-set continu
invest invest sale market support growth initi
manag also note could upward pressur tax rate also less
predict due stock option account howev would look opportunist
reduc share count share repurchas
possibl question manag
experi sinc fda approv low-risk follow
initi bolu observ long expect bolu last
forecast tavr market doubl much growth
come increas awar new patient versu convert patient
surgic penetr rate forecast tavr versu surgeri
view competit landscap boston scientif
edward tavr busi repres approxim total sale
engin behind edward growth almost decad
courtesi
estim tavr market approxim billion estim
edward approxim share market edward expect tavr
market billion-plu market impli least compound-annual-growth-rate driven
indic expans increas awar improv technolog
indic expans expect fuel growth
august fda approv edward sapien valv use low surgic risk
patient symptomat sever calcifi aortic stenosi base trial
result present american colleg cardiolog confer
march show sapien superior surgeri
follow trial result fda indic expans tavr growth outpac
expect grow y/i due bolu patient seek procedur
manag expect increas demand began last
afterward expect growth moder toward long-term expect
current aortic valv replac indic patient symptomat howev
view earli replac could improv longer term surviv
american heart associ meet novemb korean studi
recoveri present evalu asymptomat patient sever aortic stenosi
receiv either earli surgeri conserv care studi show
underw earli valv replac significantli lower rate oper mortal
death cardiovascular caus said limit studi
includ patient studi age absenc congenit bicuspid valv
arguabl patient may met criteria intervent exercis test
may tri asymptomat
edward enrol earli tavr trial enrol patient
sever aortic stenosi asymptomat patient random tf-tavr
arm clinic surveil primari endpoint superior composit all-
caus death stroke unplan cardiovascular hospit studi
half enrol earn call expect complet enrol
edward see two new valv market boston scientif acur neo
europ abbott portico unit state
boston scientif expect receiv ce mark acur neo includ
advanc pvl seal technolog target
launch acur /acur prime
abbott portico us trial present tct meet septemb abbott
plan launch portico flexnav deliveri system unit state
addit next gener evolut pro receiv fda approv
septemb treatment patient symptomat sever aortic
stenosi patient level risk surgeri extrem high intermedi low
possibl question manag
underachiev tmtt goal two year confid
achiev million revenu guidanc rang
roll-out pascal europ proceed
success biggest challeng
assumpt billion tmtt market expect
sale ramp mitral repair replac well tricuspid repair
play expect mitral market split term repair versu
sapien clinic trial design long expect enrol
take expect us approv line sapien
pascal expect complet enrol clasp iid trial end
us approv would surgic inelig
patient correct big market see us
timelin enrol pascal clasp iif studi
expect gain fda approv broader indic use
clarifi plan re-work design cardioband evoqu
begin us random studi might timelin
concern regard pascal patent litig
demograph suggest transcathet mitral tricuspid therapi tmtt market could
larger tavr market edward estim million patient
us alon moder sever mitral regurgit mr tricuspid regurgit
tr moreov estim today less patient signific mr tr
treat us
mitral complex valv diseas state compani develop repair
replac system two decad mani failur success
edward activ research transcathet mitral valv therapi date back
least earli edward acquir percutan mitral valv repair program
jome februari even acquisit pvt complement
exist program edward also acquir asset percutan mitral valv
program sinc edward acquir cardiaq valv technolog
valtech cardio harpoon medic acquisit valtech
one approv deviceth cardioband system receiv ce
mark european approv septemb
figur illustr global transcathet valv market sale corevalv sapien
receiv ce mark european approv mitraclip receiv ce mark
howev seen market growth tavr tmvr
differ despit posit patient demograph opportun
transcathet aortic mitral market sale billion
look ahead edward estim tmtt global market opportun could
billion size reach billion
edward current four technolog platform current appli
tricuspid repair
pascal system transcathet mitral valv leaflet repair system includ
spacer paddl clasp mitral valv leaflet edward also
system use tricuspid indic well
courtesi
februari pascal system receiv ce mark treatment patient
mitral regurgit major edward tmtt sale sale
pascal
pursuit fda approv edward enrol clasp iid symptomat primari
degen /clasp iif symptomat secondari function mitral regurgit
enrol total patient edward also clasp iitr studi includ
patient symptomat sever tricuspid regurgit
clasp iid arm expect fulli enrol end includ
patient degen mitral regurgit deem candid
mitral valv surgeri patient random pascal mitraclip
narrow indic use repres indic abbott prior coapt
clasp iif arm evalu patient function mitral regurgit pascal
guidelin direct medic therapi gdmt mitraclip gdmt studi estim
primari complet date decemb would impli broader indic
use would like
clasp iitr studi plan enrol patient random either tricuspid valv
repair pascal optim medic therapi omt omt tricuspid studi
estim primari complet date august would impli approv sometim
abbott current su edward alleg patent infring pascal sever
jurisdict repres risk edward go forward
uk trial took place decemb judgement expect
end januari though offici deadlin
unit state trial schedul may abbott deni
preliminari injunct temporari restrain order previous
germani district court trial schedul juli
abbott grant preliminari injunct switzerland edward appeal
cardioband annular reduct system edward acquir januari
acquisit valtech approxim million potenti
million mileston cardioband receiv ce mark mitral repair
tricuspid repair
edward expect cardioband sale reach million sale fell significantli
short million owe manufactur suppli constraint decis shift
product anoth edward facil believ demand associ product
procedur took extend period time
decemb edward announc paus enrol cardioband
activ mr us pivot trial evalu trial design light abbott mitraclip
result trial origin design includ patient clinic signific
function mitral regurgit random cardioband system plu guidelin
direct medic therapi gdmt gdmt alon
decemb investor day edward manag note satisfi
procedur time implant devic decid invest redesign
develop next gener cardioband initi random studi
howev would continu forward tricuspid earli feasibl studi
edward two program develop area transcathet mitral valv
replacementth sapien evoquehowev choos move forward
sapien platform first leverag experi
regulatori file sapien tavr system
sapien system transept mitral valv replac system leverag
edward sapien aortic valv platform incorpor dock station edward note
pivot trial approv fda investor day decemb
would provid commentari trial design present tct
present mention could random versu
mitraclip though would anticip arm studi would non-random
possibl random versu surgeri well edward expect begin enrol
studi
way comparison medtron apollo studi evalu
transcathet mitral valv includ patient includ random arm versu
surgeri well single-arm cohort howev investig also
consid chang studi light coapt result tct present
mitral tricuspid repair
courtesi
courtesi
tricuspid replac
courtesi
septemb physician debat whether surgically-elig low-risk patient met
coapt criteria control arm receiv surgeri mitraclip
evoqu transcathet mitral replac system base edward legaci
intern develop forti platform acquir cardiaq platform edward
acquir cardiaq valv technolog million plu mileston payment
evoqu also transept approach
edward plan continu enrol earli feasibl studi initi earli
feasibl studi tricuspid replac edward note investor day decemb
continu develop next-gener innov mitral
tricuspid replac thu believ valv quit readi enter pivot trial
may away prime time
heart failur invest corvia medic
march edward announc million strateg invest corvia medic
exclus right acquir compani later date corvia main product
interatri shunt devic iasd transcathet devic treat heart failur
preserv hfpef mid-rang eject fraction hfmref fund provid
edward use complet corvia reduc lap-hf ii clinic trial octob
fda grant iasd breakthrough devic design heart failur
iasd receiv ce mark
reduc lap-hf ii clinic trial includ patient primari outcom measur
composit incid time-to-cardiovascular mortal first non-fat
ischem stroke month total rate first plu recurr per patient year
heart failur hf admiss healthcar facil visit iv diuresi hf
month time-to-first hf event chang baselin kccq total summari score
month estim primari complet date per clinicaltri gov decemb
thu result like present
possibl question manag
view cerebr protect chang
market share account use cerebr embol protect
past concern regard incid stroke associ tavr
procedur sever compani develop cerebr embol protect system
design filter captur remov and/or deflect embol debri tavr
procedur edward acquir system embrella devicewhich receiv
ce mark european approv may edward commerci devic
unit state edward posit tavr deliveri system technolog
improv stroke rate reduc compani sure whether cerebr
protect devic materi reduc alreadi stroke rate ad increment
overal risk profil procedur
contrari believ role cerebr protect devic
boston scientif estim sentinel cerebr embol protect devic use
 tavr procedur see signific opportun ahead sentinel
receiv ce mark fda clearanc
possibl question manag
investor think capit alloc
investor expect continu share repurchas activ primari use
free cash flow
area look focu futur deal
regard capit alloc edward first prioriti invest intern
innov program second supplement intern invest
minor invest novel technolog excess cash typic use
past year edward made follow invest
march edward announc million strateg invest corvia
medic exclus right acquir compani later date acquir
certain asset includ intellectu properti associ clinic regulatori
experi mitralign transcathet mitral/tricuspid repair undisclos
april edward close acquisit ca medic system casm medic
technolog compani focus monitor tissu brain oxygen non-
invas edward paid million casm plan pair fore-sight
cerebr oxygen technolog hemospher hemodynam monitor
septemb edward million cash cash equival well
short term invest edward anoth million long-term invest
total debt total million edward repurchas nearli million share
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
underweight believ sale growth like
slow edward face competit transcathet
aortic valv tavr expect limit leverag
edward invest transcathet mitral valv
tmvr/r opportun sale ep estim
street tmvr/r repres potenti
second act still risk like
upsid case may driven better-than-
expect tavr sale greater leverag
stronger uptak tmvr europ faster-
than-expect time tmvr/r product
downsid case may driven delay
inabl commerci tmvr/r technolog
slowdown tavr sale due market slowdown
and/or competit pressur fx rate
greater expens support tmvr/r
price pe perform
hill-rom hold inc quarterli annual ep usd
consensu number bloomberg receiv gmt
share appreci past five year compani evolv busi mix aquisitoin sever compani
notabl welch allyn recent increas stock attribut view instal john groetelaar ceo
may mr groetelaar previous bard enthusa view around experi would bring
compani abil acceler growth
hold inc equip pe ntm estim pricepric lh rel pe barclay medic suppli devic
sale product categori
sale geographi
patient support system includ varieti specialti frame surfac med-surg intens care bed
patient mobil devic lift non-invas therapeut product surfac
segment also includ care commun softwar solut
hillrom flc segment includ patient monitor diagnost product primarili acquir welch allyn
lesser extent mortara includ patient exam diagnost patient monitor diagnost
cardiolog vision screen diagnost flc also includ respiratori health product includ
product sold multipl healthcar set includ primari care acut care extend care home care
product includ oper room capit equip like surgic tabl light pendant hillrom also sell
varieti posit equip use surgeri
integr tabl motion surgic tabl pair intuit surgic da vinci xi robot
patient support line barclay medic suppli devic
result street/our estim sale grow report
basi constant currenc basi core basi ex-acquisit
ahead compani guidanc report constant currenc
core growth driven patient support system surgic
solut partial off-set front line ep ahead
street/our estim compani guidanc compani
also issu guidanc new lrp larg in-lin market
expect net/net maintain equal weight rate
addit detail quarter
million except per share data chang sale constant currenc basi unless otherwis note
growth came guidanc reflect growth
patient support system surgic solut partial off-set
declin front exclud acquisit core growth
hillrom finish year new product revenu
manag expect annual new product introduct
gross oper margin increas y/i
expect howev manag note one-tim item effect
front line declin due difficult comp last year launch
monarch airway clearanc system said strong growth respiratori
health product thermometri vision portfolio help off-set declin
quick recap adopt basi current year ago
total revenu report basi constant currenc
core includ revenu voalt breath contribut littl
revenu growth divis patient support system
front line surgic solut
gross margin y/i reflect favor product mix
oper improv partial off-set tariff raw materi inflat
includ discret item relat discontinu product inventori
sg sale y/i dollar basi due
strateg invest primarili em well impact recent acquisit
 sale y/i
oper margin y/i due gross margin expans
adjust tax rate y/i reflect headwind stock
compens benefit year ago quarter expect
adjust ep y/i street/our estim
manag guidanc
hillrom expect core revenu increas exclud impact acquisit report constant
currenc basi revenu growth expect flat y/i compani expect adj ep consensu
manag note guidanc absorb relat surgic consum divestitur
compani expect core revenu growth exclud impact acquisit report constant
currenc basi revenu growth expect increas compani expect adj ep consensu
reflect ep growth exclud divestitur
lrp hillrom expect core revenu growth lrp compani expect ep compound-annual-growth-rate
exclud surgic consum divestitur
john groetelaar current ceo come hillrom
histori success bard help compani expand
intern sale base leadership posit
recent portfolio manag acquisit new product
introduct may enough materi acceler
hillrom increas contribut new product
recent year continu contribut acceler
opportun margin expans roughli
million addit cost flexibl reinvest busi
valuat reason extent compani
hillrom portfolio may translat well bard
effort expand geograph
addit invest may need acceler top
line growth rate compani invest could
either form higher spend sale market
spend extern sourc
acceler top line there room multipl expans
hospit capital-expenditure market trend favor
could soften
believ manag right strategi chang portfolio mix creat durabl mid-singl
digit sale doubl digit ep growth profil compani worri street consensu may bit
high near-term and/or addit invest may need drive top line rate
possibl question topic manag
john groetelaar feel strategi unfold sinc take ceo
greatest lesson learn sinc take ceo
strateg priority-intern innov expans intern a-do greatest
potenti drive valu creation near medium longer term
confid manag guidanc area feel most/least confid
regard lrp think like drive core revenu growth
target new product recent international/emerg market expans
much acquisit voalt breath contribut lrp outlook level
revenu transact contribut
consid divestitur surgic consum slower growth busi addit
voalt breath double-digit growth busi revenu growth
revenu growth come plan would compani inclin reinvest upsid let
flow bottom line
within long rang plan degre incorpor flexibl absorb potenti
dilut smaller transact
integr voalt breath proceed rel plan outlook
busi chang
key mileston breath could help drive signific adopt
manag still focus smaller tuck-in deal will consid larger transact
seven area strateg interest identifi particular area manag view
greater interest present convers area least interest present
product expect contribut increment million
revenu breath voalt includ new product revenu
manag observ past year half respect
intern opportun anyth chang approach intern
possibl questions/top manag
possibl question manag
john groetelaar feel strategi unfold sinc take
greatest lesson learn sinc take ceo
strateg priorityintern innov expans intern
 ado see greatest potenti drive valu
creation near medium longer term
divestitur like non-cor busi
hillrom board director appoint john groetelaar next presid
ceo groetelaar took ceo may previou evp presid
becton dickinson intervent segment join compani becton
acquisit bard groetelaar join bard held varieti role
compani includ presid davol divis surgical/hernia group vice-president overse
busi china asia australia group presid ad bard access system
piccs/port prior bard groetelaar held posit boston scientif guidant
corpor
decemb hillrom appoint barb bodem next cfo bodem join hillrom
svp financ also work hospira vice-president global
commerci financ varieti role lilli
leadership groetelaar bodem hillrom four strateg prioriti includ
advanc categori leadership differenti solut innov
expand intern penetr emerg market
transform portfolio select optim initi
drive oper execut strong financi perform
address four strateg prioriti greater detail subsequ section
possibl question manag
confid guidanc area feel least
confid deliv
regard lrp think like drive core revenu
growth target new product recent
much acquisit voalt breath contribut lrp
outlook level revenu transact contribut
consid divestitur surgic consum slower growth busi
addit voalt breath double-digit growth busi
cant revenu growth
revenu growth come plan would compani inclin
reinvest upsid let flow bottom line
within long rang plan degre incorpor flexibl
absorb potenti dilut smaller transact
previous mention sinc acquisit welch allyn hillrom
manag team strive achiev sustain rate growth
recent compani abl achiev rate
fiscal hillrom expect core revenu growth growth
exclud impact acquisit report constant currenc basi
manag expect grow revenu compani expect adjust ep
reflect growth y/i exclud divestitur
hillrom expect core revenu increas y/i exclud
impact acquisit report constant currenc basi revenu growth
expect flat y/i due divestitur surgic consum busi
compani expect adjust ep
novemb hillrom manag issu fiscal guidanc updat
long rang plan next three year outlin figur
compani expect core revenu growth lrp includ
new product contribut emerg market contribut revenu
exclud foreign currenc divestitur non-strateg asset compani may exit
core revenu growth includ acquir revenu contribut
voalt breath acquisit exclud revenu growth would
core constant currenc growth rate converg
adjust ep expect grow report basi exclud
divestitur manag expect cumul oper cash flow billion
cumul
revenu growth exclud fx divestitur non-strateg asset compani may exit includ surgic
recent transact strategi
possibl question manag
integr voalt breath proceed rel plan
outlook busi chang
key mileston breath could help significantli drive
adopt non-invas ventil
manag still focus smaller tuck-in deal would will
seven area strateg interest identifi see list background
inform particular area manag view greater
interest present convers area least interest present
 play believ continu play import role hillrom
follow financi crisi hillrom prior manag purpos diversifi
portfolio away hospit capit equip med-surg bed recur
dispos revenu acquisit improv overal weight market growth rate
divestitur asset sale note earlier acquisit
later unwound sold
sinc john groetelaar took ceo may hillrom continu acquir
compani howev compani growth asset groetelaar divest
previous acquir aspen surgic busi
softwar compani approxim million addit million
mileston payment voalt annual revenu approach million grow
main competitor vocera gener revenu million per
bloomberg consensu expect gener revenu flat level
breath septemb hillrom acquir
million breath gener million annual revenu breath
develop wearabl non-invas ventil technolog peopl
suffer respiratori failur due copd disord manag
believ leverag respiratori channel particularli dme busi
drive growth hillrom manag comment consid decid
acquir new aera also sell non-invas ventil product
sidekick tidal assist ventil new aera subsequ acquir
million cash front million potenti earn-out payment
follow acquisit voalt breath divestitur surgic
consum busi manag comment comfort
portfolio see larger busi like sell divest
hillrom manag howev continu look bolt-on tuck-in acquisit
respect area interest manag note seven categori consid
attract one would like transact in/around
seven categori repres billion total avail market mani
growth rate overal wamgr compani
acquisit divestitur complet prior manag team
except divestitur aspen
volker purchas sold hillrom acquir volker long-
term care acut care bed frame surfac furnitur manufactur europ
elsewher million time compani gener annual revenu
approxim million hillrom sold volker term disclos
judg cash cash flow hillrom receiv million cash
sale annual revenu million
aspen purchas sold hillrom acquir aspen surgic
bring surgic consum specialti medic product approxim
million time aspen annual revenu approxim million
hillrom divest busi approxim million busi
gener annual revenu approxim million
trumpf medic hillrom acquir trumpf integr oper room
solut portfolio approxim million cash time trumpf
medic revenu past month approxim million
revenu outsid north america
welch allyn largest transform acquisit welch
allyn close septemb welch allyn cash stock
transact valu billion time welch allyn gener annual
revenu million gross margin welch allyn
establish hillrom front line busi unit manufactur medic
diagnost equip key product area physic assess vital sign
monitor blood pressur thermometri diagnost cardiopulmonari product
mainli sold hospit remain sale sold primari
care/ambulatori set approxim sale north america
mortara hillrom acquir mortara instrument million
net present valv tax benefit mortara product includ diagnost
cardiolog patient monitor solut technolog devic time
mortara annual revenu approxim million grow
architectur product watchchild busi sold hillrom receiv
million cash proce sale architectur product busi
togeth busi gener annual revenu approxim million
possibl question manag
key new product drove new product sale million
fiscal ahead compani million guidanc much
pipelin addit vs cannibalist
new product hold greatest growth potenti
product expect contribut increment
million revenu breath voalt
includ new product revenu
hillrom spend approxim revenu long-term manag
view revenu appropri new lrp
hillrom defin new product launch sinc note new product
revenu increment cannib exist product manag estim
roughli new product cannib exist product
hillrom gener million new product new product
revenu total million origin lrp plan million
compani forecast year million
new lrp period extend hillrom expect new product revenu
reach million hillrom plan launch new product year overal net
product expect contribut approxim growth annual
new product launch includ connex monitor vision screener retinavu
tru surgic tabl linq mobil watchcar
incontin signific product
centrella smart medsurg bed system within pss centrella launch fall
manag believ product acceler replac cycl
us bed design new technolog enabl nurses/physician
better prevent patient fall enhanc surfac help reduc pressur
ulcer skin deterior issu centrella gener million
revenu launch end fiscal product
experienc continu strength us fiscal grow double-digit
contribut pss core growth howev manag expect growth
deceler low-single-digit mid-single-digit fiscal given difficult
comparison expect launch new medsurg bed sometim
retinavu retinavu network welch allyn acquir hubbl telemed januari
hubbl telemed call retinavu network combin
softwar specialist network allow point-of-car retin scan detect
diabet retinopathi encrypt scan sent state-licens board-certifi
ophthalmologist turn send physician diagnost report fundu imag
code recommend referr care plan scan complet
process typic complet minut retinavu imag launch
march hand held fundu camera low power microscop camera
use photograph retina cost approxim less tradit
fundu camera manag size us diabet popul
approxim million believ retinavu could becom million-plu per
year product may hillrom announc new partnership siemen
healthin market leader test us retinavu imag
includ suit diabet instrument provid proactiv test treatment
singl visit product gener revenu sale devic
well fee per screen fiscal hillrom invest person dedic sale
team retinavu note devic placement increas doubl digit
year fiscal compani launch retinavu imag first
handheld camera capabl captur high-qual retin imag fulli
autom fashion pupil small millimet
integr tabl motion hillrom intuit surgic receiv clearanc
offer integr tabl motion itm da vinci xi surgic system us
januari trusystem design connect da vinci xi
surgic system order allow dynam patient posit surgeri
part agreement intuit surgic intuit offer itm softwar
part da vinci xi sale process softwar sale success hillrom
sale rep respons close final sale itm tabl
watchcar watchcar incontin manag system design detect
incontin event alert caregiv goal reduc prolong
exposur moistur skin prevent patient bedsor watchcar
full launch began thu didnt contribut significantli
revenu product expect contribut much meaning fiscal
help drive new product revenu
earlysens earlysens privat compani manufactur earlysens vital
surveil system contact-fre continu heart rate respiratori rate monitor
alert clinician patient deterior earlier tradit monitor
method earlysens partner welch allyn distribut
earlysens system hillrom gain access partnership
acquisit welch allyn decemb hillrom announc equiti invest
partnership earlysens earlysens technolog
integr hillrom centrella platform product didnt contribut meaning
fiscal expect help drive new product revenu fiscal
product expect approv next two year includ next-gener
sign patch next-gener respiratori therapi
possibl question manag
manag observ past year half
respect intern opportun
anyth chang way
manag
approach intern develop emerg market
market view easier market drive growth
market believ take longer see improv
hillrom revenu current heavili skew market
revenu emerg market
bard ceo john groetelaar oversaw signific expans emerg
market success growth ventur bard groetelaar join
hillrom identifi under-index natur hillrom revenu intern
market compani made organiz chang invest improv
perform lrp period hillrom expect intern
develop market perform improv grow low-singl digit
expect emerg market revenu growth grow double-digit though start
high single-digit contribut approxim growth
overal corpor growth rate manag particularli focus
invest china believ materi opportun within emerg
market manag expect benefit recent china invest materi
late fiscal beyond
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight believ manag
right strategi chang portfolio mix creat
durabl mid singl digit sale doubl digit ep
growth profil compani howev stock re-
rate believ take time market get
comfort transform sustain
especi hospit capital-expenditure profil
rate driven new product introduct better-
than-expect margin improv
downsid case driver includ challeng
hospit capital-expenditure environ inabl drive
acceler top-lin growth increas
competit pressur dilut
johnson johnson quarterli annual ep usd
consensu number bloomberg receiv gmt
price pe perform
share typic macro stock view stock often trade gener line market period
period stock much volatil owe news flow relat talc lesser extent opiod litig
share significantli under-perform index
 johnson n/a unclassifi unexpect error encount process unclassifi unexpect error encount process equip pe ntm estim pricepric lh rel pe barclay medic suppli devic
sale product categori month
sale geographi month
babi includ johnson brand line product
major brand beauti includ aveeno clean dabao le petit marseillai neutrogena ogx product line
oral care includ listerin reach product line
over-the-count medicin includ broad famili tylenol acetaminophen product sudaf cold flu allergi
product benadryl zyrtec allergi product motrin ib ibuprofen product pepcid line acid reflux product
product includ major brand outsid stayfre carefre sanitari pad tampon brand
wound care/oth product includ band-aid brand adhes bandag neosporin first aid product line
immunolog includ brand drug remicad simponi simponi aria stelara tremfya treatment
rheumatoid arthriti inflammatori bowel diseas psoriasi
infecti diseas brand drug treatment hiv/aid includ edur intel prezista prezcobix/rezolsta symtuza
brand drug concerta invega sustenna/xeplion invega trinza/trevicta risperd consta treatment
mood disord neurodegen disord schizophrenia
oncolog includ treatment zytiga imbruvica darzalex velcad procrit/eprex prostat cancer
 acquir therapeut categori actellion acquisit brand drug opsumit uptravi
treatment pulmonari arteri hypertens
brand drug treatment thrombosi diabet includ xarelto invokana invokamet/vokanamet
intervent solut includ mostli biosens webster electrophysiolog busi also includ cerenovu
busi sell neurovascular product treat stroke
depuy synth orthoped busi compos joint reconstruct trauma spine sport medicin extrem
power tool cmf
 js surgeri busi brand ethicon includ advanc surgeri minim invas energi base product
stapler gener surgeri sutur commod product specialti area breast aesthet mentor nose
vision includ two busi line contact lens acuvu famili surgic busi
acquir abbott legaci amo busi focus cataract laser refract surgeri
sale street estim driven strength pharmaceut
medic devic ep street estim
estim rais full-year organ sale guidanc
adjust ep guidanc
net/net despit impress beat rais maintain equal weight rate
litig may remain overhang stock
addit detail quarter
million except per share data chang sale constant currenc underli basi unless otherwis note
 rais full-year organ sale guidanc adjust ep
guidanc
sever js drug continu report robust sale growth includ stelara
darzalex imbruvica tremfya invega/sustenna
simponi/simponi aria erleada uptravi
opsumit also expect continu grow pharma franchis
market
medic devic organ growth continu improv exclud
impact benefit buy-in ahead japanes consumpt tax hike
strongest year
 provid earli commentari note expect grow ep
least line revenu growth
 continu face pressur gener biosimilar remicad
 zytiga velcad
 continu lose share knee albeit less
knee growth help off-set declin
minim increment updat given regard litig remain
overhang stock make addit litig accrual
gross margin sale y/i
sg sale y/i reflect js cost contain
measur priorit spend
 sale y/i primarili driven invest medic
devic particularli robotics/digit surgeri program key growth platform
oper margin y/i
adjust tax rate y/i driven adjust exist tax
adjust ep street estim estim
 rais full-year organ sale growth guidanc constant currenc sale growth guidanc
full-year rais report sale growth guidanc rais
manag also rais low-end full-year tax rate guidanc full-year adjust ep
expect rais
manag plan releas formal guidanc along result januari howev manag provid
commentari around segment note expect pharma deliv above-market growth continu sale
momentum medic devic improv profit portfolio optim consum expect incom
approxim half level record effect tax rate rang net/net ep growth
litig concern around talc opioid
price current level stock attract valu
reflect underli fundament
litig like remain news headlin
could continu keep multipl depress
new product may deliv level growth market
substanti new product within medic devic could
increas growth busi pipelin
continu deliv growth market
pharma patent begin expir timelin
unless pipelin deliv growth could challeng
think check lot box head leav risk/reward skew upsid
think consensu outlook achiev there extra week help top-lin growth
rate bottom-lin less market extend upsw investor look
defens name find valu past sever week share resili
advers opioid/talc headlin anyth there favor news
fundament posit pharma continu growth opportun exist portfolio
formid pipelin manag medium-term patent expir devic consum
day bring confid improv outlook
jan result guidanc
possibl question topic manag
expect hear daubert rule could time bellweth
case talc mdl
think time could appeal process could ingham case
compani anticip financi impact talcum powder
latest think opioid settlement feel billion still
reason settlement figur opioid could figur increas
outstand litig prevent compani pursu limit compani
repurchas share chang strateg agenda
particular segment look bolster via acquisit
convers identifi divis product line consid candid
divestitur
invest commun expect tuck-in acquisit would manag
will larger transact
break-up compani spin-off still tabl
put take fiscal
confid manag abil drive leverag bottom line
main driver behind faster ep growth allow overcom lower gain incom
impact extra sell week top bottom line
investor think long-term next year growth profil compani
possibl question topic manag
pharma key data releas potenti product approv
confid pharma grow overal expect pharmaceut market
growth rate forese futur
strategi defend immunolog franchis longer term biosimilar
come market beyond
stelara tremfya darlazex imbruvica deliv signific growth anyth
concern competit otherwis outlook expect four drug
continu main driver behind pharma busi next mileston
drive growth
investor day may highlight nme potenti file
time-frame program confid could deliv
potenti upsid may greatest risk failur next major mileston
project would encourag investor focu
rational buy-in verb joint ventur transact
structur econom verili go forward anticip
 impact transact beyond
upcom mileston verb project
commerci mileston major region
plan differenti verb surgic platform
view emerg competit landscap other tri enter
field
integr auri health proceed upcom clinic
commerci mileston monarch
upcom clinic commerci mileston orthotaxi knee robot
confid improv growth rate knee spine well
action take improv growth rate knee spine
manag view consum mix busi today
product line busi could prune seem like focu
skin/beauti otc/self-car busi less specialti busi prune
product line
view overal competit dynam consum space might
portfolio manag strategi evolv given chang competit dynam
see js advantag consum
acquisit zarbe over-the-counter dr ci labo beauti perform
balanc strategi compet two world new digital/e-commerc
world influenc old brick mortar provid updat e-
possibl questions/top manag
eleph room opioid talc litig
possibl question manag
expect hear daubert rule could time
bellweth case talc mdl
think time could appeal process could ingham
compani anticip financi impact talcum powder
latest think opioid settlement feel billion
still reason settlement figur opioid could figur increas
outstand litig prevent compani pursu
limit compani repurchas share chang strateg agenda
 websit dedic inform talcum powder safeti legal updat
talc link asbesto
talc miner compos magnesium silicon oxygen hydrogen mine
earth chemic talc hydrou magnesium silic talc use cosmet
person care product includ js babi powder
talc safeti concern asbesto cancer new rather
concern nearli half centuri
asbesto also silic miner occur natur bundl fiber mainli
made silicon oxygen well element two main kind
asbesto link cancer accord american cancer
chrysotil asbesto also known white asbesto serpentin curli asbesto
common type industri applic fiber spiral
amphibol asbesto fiber straight needl like sever variou
form amphibol asbesto includ amosit brown crocidolit blue tremolit
actinolit anthophyillit
tremolit miner natur occur talc deposit talc
contain amphibol inosil miner name tremolit asbestiform
fibrou non-asbestiform cleavag fragment
fda conduct four-year intens investig issu
whether cosmet talc product includ js contamin asbesto
result investig fda conclud none talc use product
contain asbesto contamin
concern continu fda state reason put
warn label cosmet talc cite result studi on-going surveil
fda test raw talc four talc supplier includ js supplier
babi powder shower-to-show divest fda confirm
none contain asbesto
fda review relev bodi scientif literatur conclud
find data submit present conclus evid causal associ
talc use perin area ovarian cancer
cancer societi also opin topic physician data queri pdq
nation cancer institut comprehens sourc inform nci ovarian
fallopian tube primari periton cancer prevent pdq conclud weight
evid support associ perin talc exposur
increas risk ovarian cancer remain sceptic scienc studi
claim associ talc ovarian cancer
 note legal brief observ studi
numer meta-analys sever experiment studi publish issu
none studi purport establish causal link talc ovarian cancer
scientif commun taken posit
octob fda found asbesto disput find
octob announc receiv test report fda
show sub-trac amount chrysotil asbesto greater singl
bottl johnson babi powder purchas on-line retail voluntarili recal
lot bottl test sampl taken initi
investig identifi possibl sourc contamin believ
matter contamin given asbesto chrysotil form
octob subsequ announc new test bottl
previous test fda found asbesto addit bottl
lot also found asbesto test conduct behalf two third-parti lab
 also note expedit test third-parti deviat normal protocol
sampl contamin asbesto highlight import investig
posit result safeguard follow protocol
decemb issu final updat note test conduct two third-
parti lab show asbesto present singl bottl fda
contract lab ama analyt servic test present retain sampl
finish lot bottl produc moreov js investig reveal
test protocol fda contract lab ama deviat standard practic
ama execut full asbesto confirm requir lab test
method js press releas note js investig conclud probabl caus
fda result either sampl contamin and/or analyst error ama lab
 test test use four differ test method sampl
bottl test ama recal lot well three lot three lot
recal lot note result confirm asbesto also note rule
mine manufactur suppli chain root caus ama sub-trac find
 face numer lawsuit claim bodi powder contain talc primarili
johnson babi powder caus cancer ovarian cancer mesothelioma
 js recent period end septemb disclos
plaintiff direct claim file lawsuit relat talc note
lawsuit relat talc primarili file state court missouri new jersey
california well outsid unit state case file us feder court
organ multi-district litig mdl unit state district court
district new jersey
figur list talc case date note success number
case includ last sever case also note success defend case
upon appeal fact everi case gone appeal process
await appeal believ strong ground overturn initi
verdict establish accrual defens cost connect
product liabil litig associ bodi powder contain talc
notabl case lost far missourith ingham case includ
plaintiff out-of-st juri award plaintiff total million
compensatori damag billion punit damag total billion
accord juror punit damag calcul take roughli
million earn sell babi powder recent year multipli year
sinc compani claim babi powder contain asbesto see talc cancer
verdict billion st loui juri send power messag st loui post-
dispatch appeal case could heard appel level later
year like could fall
talc-rel lawsuit organ multi-district litig mdl
new jersey parti move exclud certain expert known daubert
motion court held daubert hear mid-juli attend hear
view js expert credibl plaintiff less plaintiff
 submit final round brief court next mileston
judg rule expert present bellweth case expect
day though could also week
next mileston mdl
judg rule
expert present
bellweth case
expect day though
could also week
 talc tracker
jjcc plaintiff damag
citi
revers appeal
citi
revers appeal
citi
revers appeal
citi
citi
revers appeal
citi
appeal jnov affirm jj jnov
affirm punit jnov
revers jjci liabil juli
new trial jjci
appeal file
citi
plaintiff file appeal
compensatori
punit j/jjci resp
mcneil
jj/jjci
respons total
appeal file
appeal file
wait see plaintiff appeal mesothelioma
plaintiff seek new trial base
product liabil generaland accrual
uncommon healthcar product compani subject product liabil
claim lawsuit multipl potenti legal liabil relat drug
devic pharma compani devic compani form legal liabil
relat product point time cost busi view
 establish accrual product liabil claim lawsuit complianc
 book accrual loss probabl amount
reason estim exampl accru estim legal defens cost
need defend matter cost probabl reason estim
may also accru addit amount settlement damag loss howev
advers verdict necessarili mean accrual
loss must probabl reason estim
sinc compani name lawsuit relat market
opioid lawsuit alleg varieti claim relat opioid market practic includ
act practic fals claim unjust enrich
august state oklahoma vs johnson johnson judg balkman rule
engag fals mislead market caus public nuisanc order pay
million abat octob judg balkman acknowledg miscalcul
 js total liabil judgement revis figur million appeal
rule believ appeal process like take two year
octob announc settlement agreement cuyahoga summit
counti ohio ahead feder multi-district litig mdl resolv claim
admiss liabil agre pay two counti combin million
settlement payment plu million reimburs counti legal expens
prepar trial addit agre direct million charit
contribut non-profit organ opioid-rel program two counti
also octob johnson johnson announc agre principl settl
opioid litig publicli announc outlin committe state attorney
gener octob wherebi js settlement amount would billion
agreement principl would resolv opioid lawsuit file well futur claim state
citi counti howev unknown agreement would final
book accrual billion settlement figur
besid talc opioid signific product liabil case includ
depuy asr xl acetabular depuy asr hip resurfac
pinnacl acetabular on-going cash drain
compani set settlement program sinc specifi billion
pre-tax charg relat asr matter
women pelvic mesh case relat women pelvic mesh like sever
medic devic compani settl otherwis resolv major us
case estim cost associ reflect accrual case
outsid unit state
hernia mesh withdrew ethicon physiomesh market june
numer product liabil case relat physiomesh well proceed mesh
ventral patch product establish accrual associ litig
risperd face lawsuit primarili file pa ca mo well
jurisdict octob billion verdict punit damag
 believ strong ground overturn
xarelto case file well partner bayer may
announc agreement principl settl xarelto case us
agreement final execut may establish on-going us
settlement program compani establish accrual associ program
relat product liabil litig
invokana lawsuit file feder court well variou state court
settl otherwis resolv mani case claim us cost
associ reflect compani accrual
end septemb nearli billion cash equival
market secur nearli billion long-term debt among two
compani aaa-credit rate gener roughli
billion free cash flow per year thu believ cash posit
adequ cover litig matter
possibl question manag
given buy-in verb consid pipelin pharma level
 spend need increas significantli absolut dollar
percentag revenu appropri level spend
prevent manag team aggress
share repurchas
manag look opportun today rel
past what chang anyth
particular segment look bolster via
acquisit convers identifi divis product
line consid candid divestitur
invest commun expect tuck-in acquisit would
manag will larger transact
break-up compani spin-off still tabl
 js capit alloc strategi four tenet first foremost reinvest
organ growth need busi vi -- vi capit expenditur secondli
free cash flow use fund dividend share repurchas
illustr capit alloc strategi follow figur
compani report earn present octob
 on-track spend estim billion estim
billion last year pharma divis account js spend
 js pharma spend ratio pharma sale fairli similar peer medic
devic account js spend devic ratio devic
revenu howev exclud divest diabet franchis ratio would
like higher consum repres remaind spend consum sale
 made number acquisit divestitur shape busi mix
compani sale profit compani remain weight toward
pharmaceut notabl transact past sever year includ
announc would buy remain stake verb surgic strateg collabor
verili alphabet compani verb work soft-tissu surgic
robot transact expect close financi term disclos
devic tachosil acquir tachosil fibrin sealant patch
takeda million tachosil annual revenu million
pharma bermekimab acquir xbiotech inc decemb
million bermekimab monoclon antibodi mab phase
develop treatment atop dermat hidraden suppurativa
devic auri health acquir billion cash front plu
billion conting mileston payment auri health privately-held
develop robot technolog initi focus lung cancer monarch
platform fda-clear current use diagnost therapeut procedur
consum ci hold japanes compani focus dermocosmet
cosmet skincar product brand includ dr ci labo labo labo genom
line skincar product enter long-term strateg collabor
compani acquir share acquir remain interest
compani approxim billion
devic advanc steril product sold april
billion asp sold capit consum softwar use low-temperatur termin
steril high-level disinfect reusabl surgic instrument
consum zarbe naturally-bas consum healthcar product
acquir term disclos
devic lifescan diabet tradit blood glucos monitor
busi sold platinum equiti privat equiti firm approxim
billion busi gener net revenu billion also shut
anima insulin pump busi
devic orthotaxi orthoped robot knee system acquir
transact term disclos
devic abbott ical optic acquir approxim
billion expand js vision busi surgic
pharma actelion approxim billion cash actelion
expand therapeut focu pulmonari arteri hypertens also obtain
share actelion drug discoveri oper early-stag clinic develop
asset spun-off newli creat swiss biopharma compani idorsia
devic codman neurosurgeri sold integra lifesci billion
consum vogu acquir approxim billion
vogu acquisit acquir ogx collect shampoo condition
treatment style product bodi care bath product fx line hair style
product proganix maui moistur hair care line
decemb announc billion share repurchas program media
report js talc prompt signific volatil share see announc billion
share buy-back program report wipe billion market valu cnbc
 complet billion buy back
last share buy-back program announc octob billion
prior last program juli billion
 member dividend aristocrat select member stock
consecut year dividend increas fact increas dividend
last year increas annual dividend annual
dividend pay-out ratio estim non-
indic dividend yield current attract rate view
possibl question manag
put take fiscal
confid manag abil drive leverag bottom line
main driver behind faster ep growth allow
compani overcom lower gain incom
investor think impact extra sell week
top bottom line
investor think long-term next year growth profil
compani
divis greatest potenti margin expans
opportun drive financi leverag
opportun refin debt euro-denomin debt drive
tax rate lower aggress share repurchas
 js financi focu grow sale organ rate faster market
grow earn faster sale part fairli success
face period work fix area
troubl portfolio optim recent histori medic devic
busi abl deliv growth line overal market
 sale ep growth y/i chang
 js pharma divis primari driver behind compani sale growth
illustr figur given higher profit margin also primari driver
behind compani earn growth well
sale divis month
sale geographi month
note adjust exclud gain asset sale
previous held ci hold co invest
note adjust exclud gain asset sale
previous held ci hold co invest
compani report barclay research adjust currenc major acquisit identifi
 js initi sale guidanc call report declin roughli
billion midpoint reflect assumpt
billion loss exclus generics/biosimilar pharma
impact remicad procrit velcad tracleer us zytiga sale
net/net manag expect organ growth
billion acquisition/divestitur impact
billion fx headwind
manag expect adjust ep rang inclus
fx headwind growth report basi constant
year progress impact gener biosimilar less expect
 note underli busi outperform better well led increas
sale ep expect
 js guidanc octob call report sale increas
rang billion reflect assumpt
organ growth versu origin
billion fx headwind
 expect also reflect adjust ep rang includ
manag plan releas formal guidanc along result
januari provid color earn call octob specif
respect sale growth manag note
pharma expect deliv above-market growth estim overal pharma
market grow around
medic devic expect continu sale momentum estim medic
devic market grow around note pronounc
presenc higher growth segment
consum remain focus optim portfolio competit growth
improv profit comment estim market grow around
expect incom approxim half level record
expect rang billion effect tax rate rang
compar level manag expect currenc fluctuat
headwind less year impact manag comment ep growth
could moder back toward level sale growth
possibl question manag
key data releas potenti product approv
confid pharma grow overal expect
pharmaceut market growth rate forese futur
strategi defend immunolog franchis longer term
biosimilar come market beyond
feel launch erleada spravato meet
expect believ still potenti becom
billion-plu brand
stelara tremfya darlazex imbruvica deliv signific growth
anyth concern competit otherwis outlook
expect four drug continu main driver behind
pharma busi next mileston drive growth
investor day may highlight nme potenti file
time-frame program confid
could deliv potenti upsid may greatest
risk failur next major mileston project
would encourag investor focu
janssen compani six therapeut area focu
illustr figur js busi repres total sale
nine month end septemb estim profit
exclud gain asset sale js pharmaceut sale compound-annual-growth-rate
nearli doubl global brand market growth rate
janssen approach area focu
acquir
pathogen
may host busi review day discuss outlook
busi believ continu outpac pharmaceut market growth
compound annual growth rate period believ achiev
given current portfolio product patent competit landscap
pipelin moreov expect launch product line extens
million-plu market potenti
see four drugs/biolog drive disproportion amount growth
stelara biolog first approv treat psoriasi
biolog subsequ approv treat psoriat arthriti moderately-
to-severely-act crohn adolesc moderate-to-sever plaqu
psoriasi adult moderately-to-severely-act ulcer coliti
stelara sale constant currenc basi estim
reach billion make js top-sel pharma product use
mani indic still under-penetr evalu indic
lupu thu still room continu growth
tremfya biolog first approv juli moderate-to-
sever plaqu psoriasi tremfya first show superior versu humira
show superior versu therapi cosentyx biolog use
dermatolog indic under-penetr believ room growth
current indic said number addit indic seek
tremfya tremfya sale doubl year-over-year
estim surpass billion mark becom multi-billion-
dollar revenu biolog next coupl year addit indic gain
darzalex first approv multipl myeloma fda
approv singl agent well combin drug also receiv
approv front-lin indic seek number differ
indic well subcutan formul use darzalex sale
constant currenc basi estim could reach nearli billion
believ peak sale darzalex could billion genmab receiv
royalti sale darzalex
imbruvica btk inhibitor approv across indic evalu
number addit indic imbruvica sale constant
currenc basi estim could reach approxim billion
sale therapeut area
pharma analyst day may note least nme file
and/launch billion-plu potenti
 select nme file expect time-frame
spravato esketamin
treatment-resist depress
adult balversa erdaftinib
treatment adult bladder
cancer spread
surgic remov
filings/approv us eu unless otherwis note
compani report may investor day
investig cell matur antigen bcma car-t patient
refractori multipl myeloma car-t cell therapi structur differenti
two approv car-t therapi kymriah yescarta use two molecul target
differ epitop bcma protein highli express myeloma cell
 origin licens legend biotech emerg chines biotech
compani decemb up-front payment million well undisclos
mileston agreement compani split cost profit equal except
greater china janssen legend percent cost-sharing/profit-split
decemb janssen announc fda grant breakthrough
therapi design base phase studi result present
american societi hematolog annual meet fda previous
grant orphan drug design februari
europ janssen announc april european medicin agenc ema
grant prime prioriti medicin design base result
phase phase studi
time agreement product phase trial china
clinic develop sinc expand japan franc
januari janssen initi enrol phase trial
china primari endpoint overal respons rate orr defin
percentag particip achiev partial respons pr better accord
date septemb estim studi complet date june
janssen initi enrol studi june
patient relaps refractori r/r multipl myeloma decemb
janssen present annual meet initi result trial show
orr earli deep respons patient orr compris
stringent complet respons cr rate cr rate good partial respons pr
rate pr rate
madduri et al result phase studi car-t cell therapi direct
b-cell matur antigen bcma patient relaps and/or refractori multipl myeloma r/r mm
american societi hematolog annual meet exposit orlando fl us dec oral abstract
novemb janssen initi trial enrol phase
trial primari endpoint percentag
patient neg minim residu diseas mrd open-label trial intend
enrol approxim patient us may expand belgium franc germani
israel netherland spain estim primari complet date april
estim studi complet date septemb
phase trial underway compar
standard combin therapi primari endpoint progress free surviv
defin time date random date first document diseas
progress defin imwg criteria death due caus whichev occur
first estim primari complet studi complet date april
 js vision digit surgeri includ robot
possibl question manag
rational buy-in verb joint ventur
transact structur econom verili go
forward anticip impact transact
upcom mileston verb project launch
 commerci mileston major region
plan differenti verb surgic platform intuit
surgic view emerg competit landscap
other tri enter field
integr auri health proceed upcom
clinic commerci mileston monarch
upcom clinic commerci mileston orthotaxi
robot effort orthoped applic spine
area beyond relationship tinavi brainlab
 js vision medic devic busi includ advanc digit surgeri
describ futur medic intervent smarter less invas
person digit ecosystem combin ground-break robot
imag data analyt power end-to-end
instrument
year end messag js head medic devic ashley mcevoy note acquisit
auri health acceler compani entri robot platform
commerci avail kick strong cadenc digit
surgeri launch specialti surgeri orthopaed gener surgeri moreov
note bring verb famili confid deliv truli
disrupt digit surgeri solut holist ever mcevoy believ
collect strength verb auri health c-sat ethicon
orthoped launch veli digit surgeri platform decemb initi
veli focu includ joint reconstruct technolog like kincis system
jointpoint kincis surgic autom system design improv precis
jointpoint system design analysi implant select posit
non-invas comput navig pre-surg digit templat case plan
howev overtim includ new technolog orthotaxi robot solut
patient select tool advanc visual sensor app
decemb announc would acquir remain stake verb surgic
verili alphabet compani term transact disclos
transact expect close
 verili form verb surgic joint ventur intent develop
next-gener surgic robot advanc toward digit surgeri detail
system limit date target launch howev
said earn call juli focus come market
quickli focus make sure robot differenti earn
call octob note progress updat would like provid
suspect detail may withheld close verb transact like
to-be-determin medic devic consum day spring
kurt azarbarzin appoint verb surgic ceo juli expect join
 post deal close previous serv chief technolog offic
join vi -- vi surgiquest acquisit found
surgiquest previous experi covidien tyco healthcar
april close acquisit auri health billion cash plu
billion mileston relat conting payment auri work
togeth pursu develop robot assist bronchoscop ablat
lesion lung compani enter cooper develop
commerci agreement may goal integr ethicon
neuwav flex microwav ablat technolog system
auri monarch platform receiv fda clearanc march diagnost
per robot pipelin monarch lung biopsi well lung treatment via
ablat oncolyt virus addit compani look applic
endourolog treatment kidney stone well potenti applic
octob announc enter co-market distribut
agreement well agreement tinavi orthoped robot compani
china agreement js depuy synth unit abl bring tinavi
robot solut spine trauma surgeri china
brainlab spinal navig system cirq robot surgic assist
on-going collabor brainlab js depuy synth busi featur
north american spine societi nass meet septemb brainlab cirq robot
surgic assist clear part brainlab spinal navig system
includ compat js expedium viper minim invas system
navig us also highlight sentio mmg neuromonitor
acquir sentio june transact term disclos
februari acquir orthotaxi develop robot platform orthoped
manag expect file approv launch orthotaxi end
american academi orthoped surgeon annual meet march
think march like competit standpoint robot
design minim footprint requir pre-op imag comment
price order magnitud cheaper competitor orthoped robot space
 stryker mako zimmer biomet rosa time tell still plan
possibl question manag
confid improv growth rate knee spine
well orthoped segment
action take improv growth rate knee
spine franchis
estim js depuy synth orthoped busi gener billion sale
repres third medic devic sale maintain top market share
posit major orthoped segment howev perform knee
spine gener lag market
 launch attun cementless knee rotat platform option septemb
plan launch cementless fix bear knee fiscal compani view
new platform pivot return knee market perform expect file
fda clearanc orthotaxi robot system around expect receiv
fda clearanc around end and/or launch product earli
 believ stabil declin market share spine identifi three mean
return growth focus top countri shore commerci
execut concentr degen disk diseas deform complex cervic
septemb launch conduit interbodi cage degen disc diseas
januari launch new symphoni occipito-cervico-thorac oct system
design stabil spine patient undergo posterior cervic fusion
possibl question manag
manag view consum mix busi today
product line busi could prune seem like
focu skin/beauti otc/self-car busi less
specialti busi prune product line
view overal competit dynam consum
space might portfolio manag strategi evolv given
see js advantag consum
acquisit zarbe over-the-counter dr ci labo beauti
balanc strategi compet two world
new digital/e-commerc world influenc old brick mortar
provid updat e-commerc effort
 js consum divis account total sale estim total
pre-tax profit consum divis offer icon brand babi care
skin care oral care wound care over-the-count women health product
septemb host thibaut mongon js world-wide chairman consum
barclay global consum stapl confer mr mongon assum
role effect march mr mongon year experi
work three busi unit
takeaway present convers mr mongon well
paul ruh cfo consum health attend break-out session includ
algorithm success like come credo-bas cultur talent
leadership qualiti complianc agil innov model focu brand
root scienc endors profession focu drive profit
 well-posit see sale growth acceler across three broad segment
self-car over-the-count skin health beauti skin health specialti babi
mr mongon discuss period consum market
 compet expect grow compound-annual-growth-rate
e-commerc rel small consum global region weight
higher fast grow part believ macro trend support
individu focus health digit creat new
opportun demand person
exampl js innov categori mr mongon point icon brand
tylenol develop dissolv pack also develop johnson cotton touch
formul babi categori
term acquisit mr mongon note ogx acquisit continu perform well
continu grow double-digit also leverag knowledg
gain deal implement throughout part consum health
franchis latest acquisit zarbe dr ci labo also track well mr
mongon note intend global zarbe brand
said believ cfo comment earn call point
consum divis focu priorit skin health self-car improv
profit profil end would surpris see select prune
within specialti businesseswhich would includ busi line oral care
wound care women health babi care though case latter dont see
johnson babi care line divest
overweight believ share like
trade fundament next
month trade closer peers/market
believ fundament solid pharma growth
strong driven darzalex imbruvica
stelara tremfya portfolio move posit
medtech/consum allow least
market growth
upsid driver includ capit deploy drive
faster growth greater success new drug
outcom greater margin expans
downsid risk includ drug price
pharmaceut pipelin lower expect
clinic commerci success medic devic
action drug/devic recal margin eros
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
medtron plc quarterli annual ep usd
consensu number bloomberg receiv gmt
price pe perform
last seven year share gener trend higher though price perform chart show far
linear reflect two step forward one step back path announc acquisit covidien june complet januari
past five year fx major headwind compani impact oper margin ep perform
progress made pipelin period overal growth outperform long-rang target although oper margin
ep perform mix pipelin start emerg clearli lead stock
plc equip pe ntm estim pricepric lh rel pe barclay medic suppli devic
sale product categori
sale geographi
product includ devic design diagnos treat manag heart rhythm disord heart failur
implant cardiac monitor left ventricular assist devic lvad
coronari structur heart product treat coronari arteri diseas heart valv disord includ coronari stent cathet transcathet
aortic valv replac surgic ablat product brand includ corevalv line transcathet
aortic valv resolut drug-elut stent
aortic peripher vascular aortic peripher vascular product treat aortic diseas peripher vascular diseas venou diseas via
graft stent system drug coat balloon carotid arteri embol protect
product includ surgic product stapl devic vessel wound closur electro surgeri
product divis also includ hernia gynecolog product
respiratori monitor airway manag product devic minim invas gastrointestin
procedur treatment renal diseas
spinal implant treat degen disc diseas spinal deform spinal tumor fractur spine
stenosi spine also includ product facilit less invas thoracolumbar surgeri treat condit
cervic region spine biolog solut infus deminer bone matrix product
neurovascular product coil stent devic treat brain aneurysm stroke brain
modul product use treat parkinson epilepsi ocd neurosurgeri product includ
product treat ent diseas control pelvic gastric condit interstim system specialti
surgic product surgeri system aquamanti system
spinal cord stimul implant drug infus system chronic pain intervent product
diabet product design type type ii diabet patient includ insulin pump continu glucos
monitor system diabet manag softwar minim line insulin pump major brand
busi segment
sale street expect constant currenc
organ ep streets/our estim rel
estim function higher sales/slightli better op margin
lower-than-expect interest expens tax rate rais
full year ep guidanc rang beat maintain organ growth
guidanc increas cvg mitg ritg growth off-set reduct
diabet growth expect maintain overweight rate view base
long-term outlook turn pipelin stock valuat
opportun improv cash flow deploy valu enhanc
addit detail quarter
million except per share data chang sale constant currenc basi unless otherwis note
restor therapi group rtg deliv expect constant
currenc growth organ growth strong sale growth spine
organ includ enabl tech like mazor robot brain therapi
off-set slower growth pain therapi
pipelin continu look solid view key program track
emerg market continu grow doubl digit
free cash flow continu strong quarter ytd
cr hf expect factor drive weak
eas quarter ahead tyrx suppli challeng manufactur
move facil resolv mid-singl digit pace growth micra
us growth off-set low doubl digit declin icd due
cobalt icd/crt famili plan launch plu micra av track launch
last tough quarter lvad share loss anniversari
diabet grew reflect declin us increas ou
full year diabet sale outlook lower low-single-digit growth low end
higher growth busi unit cvg mitg rtg
expect off-set full year organ sale growth maintain
gross margin y/i impact relat fx
sale organ constant currenc report basi
adj gross margin y/i manag highlight fx
china tariff drive major impact
sg sale y/i reflect effici improv
result enterpris excel initi
 sale y/i line expect
oper margin y/i larg in-lin expect
adjust tax rate higher year ago y/i
though much expect contribut ep beat
adjust ep y/i ex-fx
expect overal organ growth divis organ basi expect mitg rtg
growth cvg growth diabet expect flat slightli fx expect
headwind manag expect slight improv oper margin off-set currenc headwind ep expect
rang includ estim neg impact fx slightli street pre-releas
maintain organ sale growth guidanc though divis chang cvg
previou mitg previou rtg growth previou diabet grow low
singl digit previou lower end rang fx still expect headwind continu expect
oper margin expand fx neutral ep guidanc rais beat prior ep
includ fx headwind previou
trade discount med-tech
histori misstep commun around
compani offer attract valuat rel other
results/expect mix
robust product pipelin allow
compani big constrain overal growth
compani sustain grow long rang plan
rate broader med-tech market
compani well posit market share gain key
area cardiovascular structur heart surgic
neurostimul
stock reflect conglomer discount
pipelin like acceler growth
believ number new product across busi allow
sustain mid-single-digit growth expect leverag provid high-single-digit
ep growth believ stock valuat attract expect stock pe appreci sale
feb advanc treatment diabet attd
american colleg cardiolog
possibl question topic manag
would consid chang fiscal year end
novemb earn call geoff martha comment plan put emphasi
innov laser-focus get organ revenu growth rate aggress
 decis capit alloc goal increas wamgr
barrier past what differ allow achiev goal
geoff martha right team today accomplish goal
confid martha sean salmon fix diabet biggest challeng
fix long take see near-term outlook what
end game diabet look like realli fix
put take fiscal investor think extra sell
week term bottom line impact invest spend fx tax
investor expect analyst day june
robot initi feedback unveil hugo robot clinician
view js buy-in verb joint-ventur surgic robot system what
broader view js effort digit surgeri seem buy lot technolog
auri medtron go get robot arm race view cmr
versiu surgic robot system seem similar modular design hugo offer
investor get excit renal denerv anoth case dj vu
would take make real market opportun given manag care patient
popul need build market data need
expect near- long-term growth rate cdhf given micra av cobalt/crom
linq ii replac cycl headwind eas
impact see launch axon r-snm system level share
axon abl obtain account gain traction current
approv timelin interstim micro devic ce mark fda approv
outlook transcathet mitral valv program replac repair
updat timelin market
street underappreci pipelin
possibl questions/top manag
leadership chang implic strategi
possibl question manag
would consid chang fiscal year end
novemb earn call presid geoff martha spoke
put emphasi innov laser-focus
get organ revenu growth rate aggress
decis capit alloc goal increas wamgr
sound great prevent
past what differ allow achiev goal
state target return least free cash flow sharehold
via share repurchas dividend chang geoff martha leadership
allow aggress
divestitur opportun could allow increas
wamgr willing consid strateg option
play hockey colleg geoff martha know import team
right team assembl today win accomplish goal
defens offens player miss
confid martha sean salmon strengthen diabet group
leadership issu need fix
august announc plan ceo leadership transit current
ceo omar ishrak approach mandatori retir age
effect novemb geoff martha age becam presid member
board director effect april martha succeed omar ishrak ceo omar
ishrak assum newli creat posit execut chairman provid counsel
oversight leadership team ensur smooth ceo success drive execut
long-term strateg plan
martha join head corpor strategi busi develop
work ishrak ge healthcar ge capit martha name
chief integr offic lead covidien integr martha becam head
medtron restor therapi group martha graduat state degre
financ captain hockey team induct hockey fame
novemb earn call martha made remark regard
initi impress thought ahead appoint ceo comment
one thing chang focu mission use
technolog allevi pain restor health extend life
look place even emphasi innovation-driven growth
would laser-focus get organ revenu growth rate get
aggress tuck-in decis capit alloc highest-
growth segment moreov note action would increas weight
martha highlight reinvigor diabet busi prioriti rapidli
grow market huge long-term potenti comment
confid sean salmon rest diabet busi get right
octob announc effect immedi sean salmon svp
presid coronari structur heart promot evp group presid
diabet group salmon replac hooman hakami lead diabet
last five year announc hakami leav would stay
advisor need basi februari
diabet busi strateg execut misstep mani year
past includ time hakami tenur surpris see
organiz chang subsequ leadership chang reduc guidanc
divis novemb earn call
martha note novemb earn call reinvigor diabet prioriti
sean salmon well-regard leader within think sean improv
effect diabet organ time
capit alloc strategi
manag state target return least free cash flow
sharehold via share repurchas dividend fiscal paid
billion dividend billion net share repurchas total sharehold
pay-out ratio non-gaap net incom
sinc covidien acquisit acquisit mainli tuck-in
surpris given magnitud covidien deal
acquisit activ deal valu greater million
front
diamondtemp cathet temperature-control cardiac ablat system
mazor co-develop mazor stealth robot system use
spine surgeri made equiti invest mazor
smith nephew busi gener million revenu key
technolog truclear system hysteroscop morcel remov
abnorm uterin tissu less invas treatment surgic procedur
hysterectomi
nitinol mesh cover technolog fold stent retriev treat clot
self-expand mesh embol coil treat brain aneurysm medtron
previous stake compani
front
ce mark
twelv develop would known intrepid transcathet
radiofrequ track prevent surgic item spong gauz
towel left behind patient
anchor system help attach endograft nativ vessel wall use
endovascular thorac endovascular aneurysm repair
compani develop new approach improv map electr
disord heart ecvu system
possibl question manag
manag level confid achiev guidanc outlin
balanc given revis diabet
put take fiscal investor think
extra sell week term bottom line impact
invest spend support pipelin fx tax rate
investor expect analyst day june manag
provid updat long-term plan anyth like chang
confid manag margin expans annual
target op margin expans ep growth
extent upsid organ growth rate would manag
inclin let flow bottom line would look reinvest
quintessenti start-up compani found medic equip
repair compani garag founder earl bakken along brother-in-law
palmer hermundsli compani first major product wearabl cardiac
pacemak rapidli grew diversifi ultim becom med-tech
conglomer today compani investor believ could deliv
sale growth indefinit drawn sceptic deliv sale growth
almost periodalthough fact averag sale growth rate sinc
view investor overlook growth given hiccup along way
adjust major acquisit sell week
fiscal end april sale grew constant currenc basi
report basi growth driven diabet rtg
mitg cvg grew
provid initi ep guidanc along result may
substanti chang sale guidanc under-perform
diabet busi off-set better perform across three busi unit
adjust ep outlook rais reflect lower interest expens lower
may
expect overal organ growth divis
expect organ growth cvg mitg rtg
diabet expect flat slightli fx expect headwind
manag expect slight improv oper margin off-set currenc
headwind ep expect
fiscal outlook extra sell week
provid guidanc may use fiscal
year end last friday april thu everi year there extra sell week
year extra sell week fall past quarterli
benefit full year
manag offer commentari earn howev note expect
top line momentum acceler given increas benefit
product launch across divis see sever mileston valid
view lead expand pe multipl next sever year
long-rang tune updat june analyst day
analyst day june manag provid updat longer-
term expect manag expect drive least organ revenu growth
incorpor view develop market grow emerg market grow
low doubl digit busi group expect cardiac vascular group cvg
minim invas therapi group mitg restor therapi group rtg grow
line corpor averag diabet expect grow faster manag
expect sustain annual underli oper margin expans rang
manag expect adjust ep growth
host analyst meet june expect manag
team provid updat thought longer term outlook
diabet challeng opportun
possibl question manag
biggest challeng medtron diabet program
past led point
confid diabet program becom
competit leadership chang
confid manag minim close gap eas
recent market share loss meaning innov requir
sensor side share loss abat
long term growth outlook diabet busi
time achiev factori calibr elimin finger stick
confirm togeth cgm ultim go pharmaci
develop patch pump pump could compet sport
effort underway expand type patient popul
one could go pharmaci channel
diabet busi repres total sale acquir
franchis acquisit minim time premier
compani diabet space domin leader insulin pump us market
year number diabet pump compani attempt break
us market displac leadership posit though struggl
tandem two enter us market remain
cover found receiv first fda clearanc
omnipod system though commerci version
clear ship patient entir differ approach
tandem cover found launch first slim devic model
iphon ease-of-us touchscreen along continu
glucos monitor cgm system consid superior medtron
cgm help tandem gain share
struggl advanc technolog succeed date launch
patch pump slow iter beeper-lik interfac legaci minim
pump launch pump go smoothli also
behind develop competit person cgm system result
diabet franchis live street revenu expect
one lag peer medtron diabet revenu growth see figur
also volatil owe time product cycl account revenu recognit
technolog upgrad program revenu recognit rule requir defer
new product receiv
medtron world-wide diabet constant currenc y/i chang revenu
previous note start fiscal guid diabet revenu growth
rang subsequ revis rang twice cite competit
pressur tandem unit state also decis offer technolog
upgrad program offer us custom promot insulin
pump cgm system
pump offer technolog upgrad custom meet certain
criteria new pump therapi upgrad out-of-
warranti pump final day enrol program us signal
us roll-out new pump like beyond date
guardian connect offer trial offer
upgrad program pump prompt defer revenu
new pump deliv custom current diabet
guidanc low singl digit increas includ assumpt
like flat mainli reflect declin unit state intern
grow double-digit
review near-term pipelin june investor brief held
conjunct american diabet associ ada meet see figur
unclear whether timelin still intact
average time auto mode
time rang
average time auto mode
goal time rang tir
person control real-
time therapi meal handl
goal time rang tir
part submit await
day calibr
allow medicar expans
need mealtim finger stick
day calibr
dispos smaller
barclay medic suppli devic
octob announc effect immedi sean salmon svp
presid coronari structur heart promot evp group presid
diabet group salmon replac hooman hakami lead diabet
last year announc hakami leav would stay
advisor need basi februari
geoff martha take ceo begin highlight reinvigor
diabet busi prioriti rapidli grow market huge long-
term potenti comment confid sean salmon rest
diabet busi get right think sean improv effect
diabet organ time herein lie opportun
medtron busi face competit headwind compani await upcom
product approv minim advanc hybrid close loop system
bluetooth technolog state expect receiv regulatori
approv pump around end manag specifi
geograph region ce mark fda approv note final
date enrol technolog upgrad program signal us fda
approv like medtron end april
initi pivot trial enrol june comment
expect data present februari advanc technolog
treatment diabet confer madrid spain howev manag note
may us pivot data may european data due cut-off data
submiss look program januari see
present agenda howev could last minut addit schedul
june investor brief held conjunct american diabet
associ ada meet review expect data
expect system time rang greater said believ
invest commun somewhat skeptic achiev goal
definit time-in-rang whether time-in-rang time-in-rang
way comparison nih-fund diabet close loop trial particip use
tandem diabet slim insulin pump control-iq six month averag
time-in-rang per day time-in-rang overnight
also work person close loop pcl system time-in-
rang goal greater devic receiv breakthrough design
fda februari june investor brief note anticip
fda submiss date senior leadership chang unclear whether
timelin still intact would expect hear updat compani investor day
pcl devic would incorpor medtron latest-gener continu
glucos sensor technolog like synergi sensori also incorpor medtron
extens capabl built acquir nutrit databas data scienc
nutrit scienc expertis artifici intellig driven compani develop
algorithm predict glycem respons food relationship
compani two year prior recent decemb acquir
klue softwar compani focus food behaviour track
courtesi
return patch patch-lik product
year ago work patch-lik insulin pump compet
insulet omnipod appeal user wish tube product medtron
discontinu effort execut cite patent present challeng
develop product tandem develop sport expect
likewis look altern deliveri vehicl beyond excit durabl pump design
possibl compet omnipod sport longer term moreov given
sizabl patient popul type also wonder whether would consid
evalu opportun tap marketalthough date effort develop
type patch commerci success
continu glucos sensor medtron play catch-up
play catch continu glucos monitor cgm side current
system guardian sensor still requir finger stick calibr well finger stick
confirm wherea compet cgm system abbott freestyl libr
longer requir finger stick juli howev compani submit non-
adjunct label guardian sensor part minim system
expect approv non-adjunct label allow reimburs
medicar open market opportun though note would
use cgm along pump stand-alone system
number cgm technolog advanc pipelin next
gener sensor dub expect file approv
compani first sensor icgm design still calibr requir
limit beyond develop synergi sensor
smaller shape like squar flat also dispos product
calibr requir day expect submit fda
approv chang diabet leadership unclear whether
timelin still intact and/or whether may move back possibl forward
resourcing/effect
possibl question manag
initi feedback unveil hugo clinician
view js buy-in verb joint-ventur surgic
view cmr surgic versiu surgic robot system
seem similar modular design hugo offer similar econom
proposit cmr offer managed-serv model reduc capit outlay
compar cost hospit pay manual laparoscopi
thought emerg soft tissu robot system
thought mazor rel spine robot platform
today develop
thought robot system market
endolumin system j/auri monarch system intuit ion
area interest well
consid corindu vascular robot endovascular coronari
peripher intervent siemen acquir
area robot interest
robot surgeri market pioneer intuit surgic today remain
lead robot surgic compani sale approach billion accord
bloomberg consensu estim model proven success
influx compani started-up surgic robot space
compani larger organ defens posit
covidien/medtron other opportunist cmr surgic
legaci covidien manag team publicli skeptic applic
surgic robot invest aggress program
abl surmis legaci covidien robot surgic platform date back januari
two year deal close past sever year
devot signific amount resourc bring hugo robotic-assist surgeri
ra program market
unveil hugo ra analyst meet septemb
meet highlight key attribut system see figur
provid think around timelin mileston potenti financi impact
attribut medtron plan modular solut address
see barrier adopt robot surgeri todaycost util
specif tower univers use robot surgeri well
laparoscop procedur end effector bring trust expertis legaci
covidien/u surgic also aim bring technolog market
scale cost laparoscop
regulatori mileston expect initi launch product
intern market begin gather data end end april
plan ce mark submiss expect file
us studi would allow place initi system train
gather clinic data receiv ce mark european
approv current anticip receiv us clearanc fall
calendar would
financi impact comment expect hugo ra provid
increment growth less minim invas therapi group mitg
growth rate given limit approv time-frame note would
rel guidanc medtron expect
increment contribut base
base word expect prove
correct number could get big fast even assum contribut
low end rang would impli rate growth rate
meaning busi group
may mazor announc two strateg agreement commerci
agreement promot develop mazor product well equiti
invest mazor mazor start integr mazor robot guidanc
system spine implant navig intraop imag technolog
invest agreement includ three-step equiti invest mazor
paid million mazor outstand share follow juli
approv mazor system subsequ invest million bring
total invest mazor outstand share august compani
announc third tranch invest million bring total invest
mazor outstand share agreement assum
exclus global spine market commerci respons mazor platform
decemb close acquisit remain stake mazor
billion total gross deal valu billion
courtesi
januari launch next gener mazor stealth robot
allow real-tim imag guidanc visual navig inform
interact plan inform system mazor outperform
competit drive capit equip sale within neurosurgeri
expand mazor area
manag also comment leverag mazor expand
area mazor renaiss current indic cranial procedur
recent receiv fda clearanc stealth auto-guid system smaller cranial robot
robot use lead placement db procedur electroencephalographi
eeg placement epilepsi tumor resect
possibl question manag
expect near- long-term growth rate cdhf
expect market share gain approv micra av
outlook icd/crt-d busi given eas
replac cycl well launch new platform could
busi return growth suffer declin time impact
would overal crhf growth cvg
despit launch linq concern boston launch
market icm
big opportun see diamondtemp rf cathet
see opportun expand af busi
near- long-term outlook heart failur left ventricular
assist devic lvad busi like drag overal crhf
cardiac rhythm heart failur divis sale account total compani sale
repres largest sub-seg within cardiac vascular group cvg sale includ
implant devic pacemak defibril icd resynchron therapi
devic mechan support left ventricl assist devic lvad insert
cardiac monitor atrial fibril cathet tyrx anti-bacteri envelop remot
monitor servic softwar
overal crhf market matur categori grow low singl digit
howev believ well posit grow mid-singl digit given
product pipelin replac cycl headwind eas
number expect product launch within divis next
month includ micra av pacemak reveal linq icm next-gen
icds/crt-d unclear whether host investor brief heart
courtesi
rhythm societi hr scientif session may meet coincid
compani expect time product launch whether hold updat
investor confer expect june
micra av expand leadless pacemak address patient popul
receiv fda approv micra leadless pacemak april though
first full fiscal year reimburs exit year sale
annual well million revenu product today individu
need single-chamb pacemak estim pacemak popul
micra one-tenth size tradit pacemak implant via minim
invas approach estim overal pace market billion
compani develop next-gener version micra expand
address market entir pacemak commun one product micra av
expand indic popul estim pacemak
popul novemb submit micra av expand indic
popul av block normal sinu rhythm target releas micra
av end fiscal
third version devic develop micra ar expand applic
pacemak popul micra ar sinu node diseas allow
exist micra place atrium allow sens pace atrium
approv expect sometim around fiscal
dual chamber pace
medtron reveal linq implant cardiac monitor icm first launch
product quit success build market busi face
headwind abbott late launch confirm rx icm first smartphone-
develop second-gener reveal linq ii icm linq ii expand
product indic current cryptogen stroke syncop atrial fibril
heart failur renal
arrhythmia moreov linq ii offer batteri life compar current linq
courtesi
life bluetooth connect abil monitor addit physiolog
paramet devic expect launch late fiscal allow
protect share icm busi compani anticip product contribut
significantli cvg growth fiscal boston scientif also plan launch
icm well
next-gen icd crt-d
medtron busi pressur due replac cycl
batteri life extend replac less often begin replac
headwind eas becom net posit moreov plan launch
next-gener cobalt chrome famili icd/crt-d earli product
improv batteri life bluesync technolog enabl triage-hf
compet boston scientif heartlog
develop extravascular ev- would compet
boston scientif emblem subcutaneous-icd believ s-icd adopt
limit larg size premium price lack capabl endovascular
devic offer includ painless post-shock pace anti-tachycardia pace atp
medtron ev-icd place sternum thu allow atp well post-
shock pace size similar convent system requir half energi
boston scientif emblem s-icd smaller size devic believ
market could potenti tripl size roughli million today
top rib
initi pivot studi evalu investig ev octob
studi includ patient site primari endpoint defibril
test success rate implant primari safeti object freedom major system
and/or procedur complic six month implant patient assess
two week three month six month everi six month thereaft compani
target approv commerci launch fiscal
expand af diamondtemp
medtron atrial fibril busi growth driver within crfh busi
main product arctic front cardiac cryoablat cathet design
pulmonari vein isol treatment patient drug refractori paroxysm af
acquir cryoablat technolog cryocath acquisit
million ablat frontier acquisit million
march close million acquisit epix epix
manufactur diamondtemp cathet temperature-control radiofrequ
ablat system cardiac arrhythmia ablat system closed-loop mean
provid physician improv feedback control ablat procedur
epix diamondtemp cathet expand exist cryoballoon offer
radiofrequ rf ablat larger billion-plu rf focal cathet segment
ablat market diamondtemp system receiv ce mark plan
europ launch two on-going trial diamond-
af diamond-af ii
diamond-af trial complet enrol octob evalu
safeti efficaci diamondtemp system patient symptomat
paroxysm atrial fibril paf pivot data expect
diamond-af ii trial current enrol evalu diamondtemp
system patient persist af estim primari outcom complet date
januari estim studi complet date april
medtron lvad busi recent face signific pressur owe competit
headwind abbott approv destin therapi well impact guidelin
chang organ transplant headwind annual expect
octob receiv breakthrough devic design fulli
implant lvad system compani think implant system could meaning
expand market lvad technolog though doesnt anticip commerci launch
within plan period fiscal
renal denerv hope case deja vu
possibl question manag
manag view renal denerv market opportun
unit state intern
requir data-wis support build market
reimburs standpoint given patient popul unit state
potenti timelin data releas fda approv
reimburs mileston renal denerv system
given know symplic trial outcom would
make renal denerv success time around on/off med trial
renal denerv potenti back view renal denerv higher risk
long-term potenti opportun even initi short term clinic data good
signific market build opportun need happen along gather
around seven year ago signific enthusiasm around multi-billion market
prospect renal denerv ablat renal arteri reduc blood pressur
patient resist hypertens time expect market opportun
treatment resist hypertens billion three major cardiac
compani boston scientif st jude renal denerv program
place mani compani jump bandwagon covidien
mani start-up
acquir program million ardian deal boston
scientif acquir program million plu mileston
million vessix deal covidien acquir program maya medic
million cash million mileston
market enthusiasm significantli cool announc januari
medtron symplic trial fail meet primari endpoint chang
offic systol blood pressur osbp month initi trial shown promis result
trial first blind studi compar renal denerv sham
procedur result show renal denerv fail demonstr statist
signific blood-pressure-low effect compar sham treatment
went back draw board attempt anoth shot
redesign symplic spyral system multi-electrod cathet allow convent
distal renal arteri ablat
multi-electrod cathet simultan
ablat electrod
multi-sensor feedback control energi deliveri
on-going random sham-control spyral htn global clinic program design
measur safeti efficaci symplic spyral renal denerv system
absenc spyral htn-off presenc spyral htn-on anti-
may affect result includ studi popul look
moder hypertens patient instead sever procedur method medic
chang adher patient known non-adher
jung gechter jl wunder et al resist hypertens assess adher toxicolog urin analysi
osbp hg hg odbp hg
abpm average sbp hg hg
osbp month
hour abpm month
hour abpm month
major advers event month
major advers event month new
main arteri
spyral htn-off april announc fda approv begin
pivot trial evalu symplic spyral renal denerv system patient
high blood pressur absenc anti-hypertens medic trial
random sham-control studi patient site
europ australia japan primari efficaci endpoint blood pressur
three month primari safeti endpoint incid major advers event
one-month post random manag expect present data
compon march
spyral htn-on novemb began fda-approv trial
evalu symplic spyral renal denerv system patient high blood
pressur alreadi prescrib anti-hypertens medic trial
random sham-control studi random patient center
 japan europ australia canada patient follow three
year primari safeti endpoint includ major advers event one month new
renal arteri stenosi six month primari efficaci endpoint ambulatori
blood pressur abpm six month subject prescrib stabl regimen
three anti-hypertens medic includ diuret calcium channel blocker
ace/arb inhibitor beta blocker compani expect complet enrol
first half approv
possibl question manag
impact see launch axon r-snm system
level share axon abl obtain account
current timelin ce mark fda approv interstim
percent market expect select recharg devic
intend make smaller recharge-fre interstim devic
take drive increas adopt snm therapi broadli
thought implant percutan tibial nerv stimul
ptn devic see devic potenti threat snm
strateg view broadli pelvic health
thought expand men health/urolog genecolog broadli
within restor therapi group specialti therapi group includ
pelvic health busi flagship product includ medtron interstim franchis
overact bladder found sacral neuromodul market launch
interstim devic sinc launch one iter interstim
ii estim sale interstim ii approxim million
control market two decad axon first compani
enter market competit devic axon receiv ce mark european
approv axon r-snm system market europ axon estim
achiev de novo market share england share
netherland unit state axon receiv fda approv septemb
fecal incontin indic fda approv novemb urinari indic
rel devic axon devic significantli smaller mri compat
recharg view axon devic highli competit capabl take
signific amount share
plan microstimul system sinc least highlight
desir introduc product analyst meet octob
announc file pma supplement interstim micro neurostimul
devic surescan mri lead
interstim micro miniatur sacral nerv stimul system interstim micro
expect volum roughli smaller interstim ii axon r-snm
system approxim implant puls gener expect
recharg also expect system full bodi mri compat
standard review process would put approv late
spring although extent question file need data
approv could push back
surescan mri lead use interstim ii make system mri elig
within pelvic health busi also sell nuro system deliv
percutan tibial neuromodul therapi express interest
implant ptn devic sever privat compani product
possibl question manag
transcathet aortic replac valv tavr franchis level
market share eros expect addit player boston scientif
abbott lab enter/ramp-up market
differenti horizon program platform evolut platform
latest updat apollo intrepid transcathet mitral valv
replac trial expect chang design trial includ
mitraclip studi expect complet enrol
anticip eu fda approv intrepid tmvr
statu transcathet mitral valv repair program
program structur heart interest
left atrial appendag closur intervent heart failur product
structur heart area plan technolog tuck-in
fda approv low risk indic august medtron corevalv evolut
tavr platform indic symptomat sever aortic stenosi across risk
categori extrem high intermedi low indic expans came
heel strong interim data american colleg cardiolog
meet march highlight corevalv evolut use low surgic risk
continu invest next-gener tavr technolog well septemb
compani announc fda approv launch next gener evolut pro tavr
system evolut pro includ four new valv size well
extern pericardi tissu wrap help reduc incid paravalvular leak
also work new platform current name horizon product
expand indic ensur continu double-digit growth tavr busi
forese futur
also develop transcathet system treat mitral valv
manag convey believ tool box approach mitral valv diseas
need see import role mitral repair mitral replac technolog
compani index initi mitral replac believ replac
provid reliabl complet control mitral regurgit better durabl
paid million plu million mileston payment twelv
develop transcathet mitral valv replac tmvr platform
sinc renam intrepid
octob receiv fda approv start apollo transcathet mitral
valv replac trial evalu intrepid valv studi aim enrol patient
accord present updat tct confer septemb
site activ patient enrol clinicaltri gov
list primari outcom complet date octob mind seem
unrealist comment go discuss fda
possibl evalu studi design light coapt result possibl includ
mitraclip system studi random control arm also
plan integr transept deliveri system trial well current
system transap design despit transap design investig tct note
present role-in patient mortal tmvr
interest transcathet mitral valv repair preced purchas corevalv
transcathet mitral valv repair someth compani
follow long time decad follow posit readout abbott
coapt trial manag note invest mitral repair technolog
moreov said effort mitral would includ intern develop effort
well potenti activ intern program would discuss approach
due differenti approach want share detail
possibl question manag
outlook brain therapi busi
signific could cranial mount db system
key new product manag feel could signific
contributor growth
medtron brain therapi divis grew constant currenc basi fiscal
growth driven larg success
sell capit equip strong portfolio neurovascular devic also
record revenu mazor robot guidanc system within brain therapi
mazor stealth edit help drive growth sinc approv demand
stealthstat navig o-arm imag also driven
medtron neurovascular portfolio driven mid-teen high twenti growth
sever year strength attribut solitair platinum stent retriev
acut ischem stroke neuro access product coil intra-saccular therapi well
flow divers product compani launch react cathet riptid
aspir system solitair revascular devic
upcom product launch iter
deep brain stimul medtron activa deep brain stimul db system first
approv treatment essenti tremor tremor associ
parkinson diseas pd fda subsequ approv db gener case
pd dystonia within year db approv patient
treat pd essenti tremor db becam standard treatment pd
sole manufactur db neurostimul
abbott st jude medic infin db approv pd boston scientif vercis db
also approv pd
activa db neurostimul current approv pd essenti tremor epilepsi
well hde dystonia ocd
despit medtron head start db competit pressur abbott boston
scientif led recent declin busi increment innov includ new
clinician patient programm well new indic epilepsi help
slow headwind meaning innov take place near end fiscal
beyond
first percept db primari cell system expect launch near end fiscal
begin fiscal devic sens enabl mean sens
record patient brain activ work toward eventu launch
closed-loop system abl automat adjust stimul respons patient
brain activ also plan launch direct lead allow
omnidirect target stimul medtron hope launch lead fiscal
longer term compani anticip launch cranial-mount db system
devic much smaller recharg devic elimin lead tunnel
chest neck stimul
omnidirect
complex tunnel
possibl question manag
growth rate feel sustain pain busi long-
key differenti next-gener system
launch nan
on-going launch accurian rf ablat system progress
growth outlook broader intervent busi
drug infus system chronic pain well intervent product divis grew
constant currenc basi fiscal despit market slowdown spinal
cord stimul devic howev busi declin due inventori
destock broader market slowdown saw slight return growth
low-double-digit growth help off-set continu declin pain stimul
upcom product launch iter
plan unveil next-gener spinal cord stimul system nan
confer januari
manag also note expect releas new version snapshot
report softwar everi month increment featur cohort report
extern sensor pain monitor time
addit work close loop spinal cord stimul use
evok compound action potenti ecap maintain therapeut activ though
formal timelin given
also continu roll accurian radiofrequ ablat platform
nerv tissu announc last year nan confer accurian featur
radiofrequ probe intern cool creat larger spheric lesion
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight believ
number new product across busi
allow sustain mid-single-digit growth
expect leverag provid high-
single-digit ep growth believ stock
valuat attract expect stock pe
appreci sale growth improv
upsid case driver includ success
deploy market share gain key area
cardiovascular structur heart surgic
neurostimul greater margin expans
expect
inabl receiv product approv market
share loss key categori dilut deal
price pe perform
stryker corp quarterli annual ep usd
consensu number bloomberg receiv gmt
stock outperform broader market past seven year compani acceler organ sale growth rate
period stryker strategi period mainli tuck-in acquisit focus help expand agenc
lift underli growth rate compani
corp equip pe ntm estim pricepric lh rel pe barclay medic suppli devic
sale product categori mo
sale geographi
product includ partial total knee implant primari revis procedur cement
cementless product total knee arthroplasti
offer primari revis total hip replac product offer direct superior approach
instrument help spare muscl damag surgeri
trauma extrem product portfolio includ implant bone fractur bone plate bone nail
extrem arthroplasti product biomateri
includ imag system fluid manag product capit sale mako robot surgeri system
product includ power tool accessori surgic navig system wast manag product
endoscopi product includ laparoscop minim invas surgeri imag system along surgic tool
design procedur
includ emerg medic equip hospit patient transport equip intens care
stryker sustain categori includ reprocess remanufactur medic devic
segment includ neurovascular product focus treat stroke patient surgic tool neurosurg spine
ent procedur craniomaxillofaci product
spine product includ spinal implant instrument biomateri navig diagnost tool
sale ep growth strong street estim
stryker organ sale growth benefit extra sell day
sale driven orthoped medsurg
neurotechnolog spine ep y/i
street within guidanc expect
organ sale growth toward upper end rang tighten
ep rang despit addit fx headwind net/net
view strong quarter favor guidanc
million except per share data chang sale constant currenc basi unless otherwis note
addit detail quarter
sale grew expect y/i organ expect
organ growth toward upper end guidanc rang
tighten ep rang versu prior rang
mako adopt continu us total knee procedur y/i
total mako procedur mako hip grew manag note
order book strong
within medsurg medic sale came street vs street
us sale solid growth acut care
beds/stretch well physio
organ growth led emerg market europ
japan canada
spine sale expect vs street
experienc headwind sale soft price eros
salesforc integr inventori ramp take longer expect
cost synergi ahead plan
instrument expect sale vs street
manag cite sale forc split tough comp
fx expect neg impact full year ep vs prior
sale organ basi organ growth divis
orthoped medsurg neurotechnolog spine
gross margin y/i reflect price mix
sg margin y/i reflect continu benefit
ctg program offset neg impact acquisit bp
 margin y/i
oper margin y/i
adjust tax rate flat y/i benefit treatment
adjust ep street estim estim
upper end guidanc rang
expect ep bracket street estim fx expect neg impact ep
reflect guidanc
stryker expect organ sale growth toward higher end prior rang fx expect impact
sale manag continu expect oper margin expans expect adjust ep versu
prior guidanc fx expect approxim neg impact ep previous
actual million salesrptdex barclay medic suppli devic
well-diversifi compani expect
deliv sale growth overal med-tech market
peer group
abil drive leverag bottom line
stryker underli sale growth could plateau
compani see greater competit orthoped extent
zimmer biomet and/or depuy turn around
becom competit
hospit capital-expenditure market trend favor
like continu success execut
trend could soften
could encount challeng integr
wright medic
remain solid compani fundament believ perform share
like restrain outstand acquisit wright medic on-going integr
pend robot competit knee zimmer biomet rate equal weight
jan result guidanc
american academi orthoped surgeon aao orlando fl
apr societi american gastrointestin endoscop surgeon sage cleveland oh
possibl question topic manag
make wright medic right acquisit right time right valu
potenti synergi and/or dis-synergi wright manag anticip
outlook oper margin expans given impact
manag think follow wright medic acquisit
put take investor consid
investor think long-term growth profil compani wright
view competit environ orthoped emerg
compet robot system zimmer biomet rosa depuy orthotaxi
addit area within orthoped believ robot success
would interest expand soft tissu robot
sustain rate growth medsurg franchis
recent futur product launch import drive futur
sustain rate growth neurotech spine franchis
integr proceed
possibl questions/top manag
possibl question manag
make wright medic right acquisit right time valu
manag current think around potenti divestitur
potenti dis-synergi opportun drive greater
confid manag abil integr sustain wright
manag view extrem biolog market
novemb announc enter definit deal acquir wright
medic orthoped compani focus extrem market per share
equiti valu billion enterpris valu billion
view deal expens deal ev/sal multipl
ev/ebitda basi give full credit cost synergi ev/ebitda use
bloomberg estim wright estim manag expect
year
wright medic focus extrem market includ faster grow sub-
categori within orthoped market wright medic sale total
million project grow million per bloomberg consensu wright
compet within upper extrem shoulder elbow wrist hand market
grow per year well lower extrem market foot ankl
grow per year also biolog franchis market estim grow
transact boost scale lower extrem much double-
digit growth trauma extrem busi come last five year
compani use acquisit memomet catalyst set dedic
foot ankl sale forc continu build product portfolio intern
develop small bone innov estim wright
medic two largest player lower extrem combin repres
 market
transact also give greater scale upper extrem began build
upper extrem busi shoulder market share remain rel low
estim wright shoulder franchis well
posit growth
expect anti-trust review progress take second half
view assum like second review ftc given market share
concentr lower extrem busi
expect wright continu strong revenu growth profil project
growth period wright adjust gross margin
accret corpor averag howev exist oper margin profil
mid-singl digit well corpor averag due size compani well
special sale forc
expect achiev cost synergi million achiev
first three year follow close help move wright busi
closer think still corpor averag
manag note inclus wright would like deliv
target bp annual oper margin expans note
assum one quarter impact well assumpt deal close
earn perspect manag expect deal neutral
adjust earn per share dilut accret thereaft said
manag note would continu target minimum adjust ep growth
beyond
possibl question manag
manag current think follow wright medic
area within medic devic attract least
commerci organ structur realign mean
strateg oper perspect
 core growth strategi compani complet
acquisit sinc compani gener look tuck-in style deal addit
product technolog near adjac specif manag note
sever year view neuromodul area interest analyst day
novemb also note interest gener surgeri
announc wright medic acquisit novemb manag note still
capac pursu tuck-in deal even compani de-lev follow
 focus continu increas dividend view share
repurchas larg tool off-set dilut
august announc realign commerci organ spencer
stile serv group presid orthoped spine overse
replac trauma extrem spine divis andrew pierc serv group
ascent healthcar solut reprocess gaymar industri sonopet asset synerget asset porex neuro-vascular busi memomet concentr medic orthovita mako patient safeti technolog hold pivot medic small bone innov coalign chghospit bed muka product physio-control synerget neuroportfolio stanmor implant world-wide vcf asset bd safewir ivi sport medicin restor surgic novadaq safeair ag mobiu imagingand cardan robot pend wrightmed barclay medic suppli devic
presid medsurg neurotechnolog overse instrument medic
endoscopi sustain neurotechnolog busi
possibl question manag
outsid wright medic transact put take
investor consid
investor think margin expans goal compani
like move top bottom line framework away
oper margin target
think cash flow profil compani go forward
organ sale growth rate impress
januari provid initi guidanc target organ sale growth
throughout manag rais organ sale growth expect
along result manag increas low-end forecast guid
organ sale growth
result rais organ sale guidanc
octob result comment expect organ sale growth
higher end rang
also rais ep guidanc throughout cours year origin
manag guid current guidanc
includ headwind fx
confer call ceo kevin lobo comment expect compani
strong third-quart momentum continu fourth thu
organ sale growth manag comment come
higher end rang mention ytd organ sale
growth think street expect manag initi guidanc
higher last year like encompass
bottom line manag comment even wright
transact would continu target minimum adjust ep growth
beyond expect wright deal neutral adjust ep manag
note would deliv oper margin target though
first introduc cost transform program goal achiev
oper margin improv annual period stryker
also introduc concept floor ep target ep growth
program first year product recal hurrican damag puerto rico
dilut acquisit novadaq neg impact compani abil
achiev margin expans target oper margin declin
adjust impact headwind achiev oper
margin expans
success expand oper margin despit neg
impact oper margin expand though
oper save continu pressur integr
due wright medic acquisit expect close howev manag
note like wont deliv target oper margin
expans
possibl question manag
extent street overli focus mako vs zimmer biomet rosa
scale much
view zimmer biomet rosa depuy orthotaxi
robot system think system may start impact
inning regard mako penetr
thought wright medic blueprint technolog
thought mako extrem
describ strategi robot spine acquisit mobiu
imag cardan robot timelin project relat
acquisit
believ place soft tissu surgic robot platform within
acquir mako surgic corp decemb billion time
lot skeptic around opportun robot orthoped
time acquisit mako rio robot arm system stryker mako
approv partial knee arthroplasti pka total hip arthroplasti tha
receiv clearanc total knee tka applic initi
limit launch march full roll-out occur march
sold mako robot
end global mako instal base near robot
highlight japan china untap market long-term opportun
gain approv tha countri also gain tka approv
japan compani expect tka approv china near-term
manag anticip signific mako uptak china japan start
compet smith nephew navio system featur
competit environ becom challeng zimmer biomet
launch rosa robot platform approv tka depuy also plan launch
orthotaxi platform late believ like earli
robot spine
manag expect bring robot spine use exist technolog
octob acquir mobiu imag sister compani cardan robot
million up-front cash plu million mileston payment mobiu
found focus integr advanc imag technolog medic
found develop innov robot navig technolog system
surgic intervent radiolog procedur specif cardan robot
develop orion spinal robot system integr airo truct scanner
full imag navig robot solut spine procedur acquisit close
octob expect materi impact bottom line year
stryker success mako platform tka provid compani
market growth knee replac strong foundat build broader
orthoped robot platform next sever year expect continu
build robot focu hard tissu arena compani novemb
investor meet manag note initi project focus improv
shoulder arthroplasti spine surgeri mako technolog focu
reiter wright medic acquisit announc also complet
initi homework appli robot total ankl arthroplasti
regard entri gener surgeri robot manag note
hard tissu near-term focu view gener surgeri logic adjac
possibl question manag
view competit environ hip knee
outsid robot system
much compani above-market growth knee attribut
trend toward cementless tka
product pipelin
outlook hip knee procedur move
outpati set ambulatori surgeri center
time develop psi use knee
implant offer would allow streamlin number instrument
tray one case use
thought overal patient-specif technolog
concern long-term viabil
abil fulfil agreement given liquidity/cash posit
stryker orthoped segment revenu current repres total sale sale
organ basi ytd
maintain steadi mid-single-digit high-single-digit growth larg due
market lead growth knee busi well consist growth trauma
 extrem unit hip knee market typic refer larg joint market
tend grow low-singl digit trauma extrem market grow
decis use cement cementless fixat tka debat sever
decad cement fixat associ high qualiti outcom long-term
follow-up studi osteolysi relat bone stock alter mechan stress due
implant/kne malalign bone/c interfac led surgeon find new
design flaw plagu earli cementless tka implant nearli tka return
cement fixat osteoconduct surfac fixat technolog improv
howev cementless tka implant survivorship grown increasingli compar
cement tka launch tritanium cementless tibial basepl
grown cementless knee total knee volum cementless tka implant
carri higher higher margin benefit major
manufactur cementless tka market sever year howev zimmer
biomet launch persona cementless tibia knee implant depuy johnson
johnson launch attun cementless knee septemb
octob announc licens agreement patient-
specif instrument psi use connect knee implant offer
includ triathlon total knee system
possibl question manag
sustain growth rate medsurg busi
trend hospit capital-expenditure market see sign slow
product categori
aim camera roll-out go continu see up-
near- long-term market opportun novadaq
outlook product
launch new medsurg bed come year
area success hillrom past year
key product launch sustain acceler current rate growth
improv growth rate
sustain solut
medsurg busi current repres total sale view
stryker medsurg busi underappreci busi past six year
divis averag organ sale growth nearli reflect purpos
chang composit mix year away faster grow product line
year-to-d basi septemb medsurg sale
organ basi reflect higher sale across four busi unit
instrument sub-seg includ surgic equip navig system
manag expect sale growth moder due tougher comparison
endoscopi sub-seg includ endoscop commun system
ad categori acquisit novadaq septemb sale
constant currenc basi launch new aim
surgic video platform march help acceler sale growth go
sub-seg includ patient handl emerg medic equip intens
care dispos product well infect prevent product busi
acquir sale constant currenc
neurotech spine
possibl question manag
describ commerci organ structur realign may
mean strateg oper perspect neurotech spine
sustain growth rate neurotech
key new product launch neurotech franchis
latest updat spine integr outlook spine
sale busi spine busi acceler growth corpor averag
view neuromodul market logic
adjac expans strateg align move spine
orthoped neurotech medsurg make like
consid enter peripher vascular space
stryker neurotech spine divis current repres total compani sale
past six year divis averag organ sale growth larg
driven neurotechnolog franchis recent deceler organ growth
mainli reflect spine franchis
august announc realign commerci organ
manag neurotech spine busi split spencer
stile andrew pierc
spencer stile serv group presid orthoped spine overse
joint replac trauma extrem spine divis andrew pierc serv
group presid medsurg neurotechnolog overse instrument medic
endoscopi sustain neurotechnolog busi
neurotechnolog busi includ neurosurg neurovascular product treat
acut ischem hemorrhag stroke busi also includ acquir entellu
medic ent franchis sale constant currenc basi
stryker spine busi includ basic spinal implant devic well complex
devic acquir acquisit enterpris valu
began anticip mid-single-digit growth spine pro forma basi
earn call manag note integr on-going cost
synergi realiz progress ahead expect howev manag also note
sale forc integr issu cross-sel scale rep hire full inventori
avail take longer expect result manag lower full year
expect spine low-single-digit pro forma basi
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
compani fundament believ share-pric
perform like restrain
outstand acquisit wright medic
on-going integr pend robot
competit knee zimmer biomet
growth greater success new product
greater success drive oper margin
downsid case driver includ slowdown
orthoped hospit capital-expenditure market increas
competit knee foreign exchang stronger
us dollar inabl drive margin expans
price pe perform
quarterli annual ep usd
consensu number bloomberg receiv gmt
share risen sinc result improv sale trend margin success execut number transact
restructur initi soft earn report downward earn revis guidanc caus sell end
though compani decemb announc vascular solut acquisit expect sale cost synerig improv
organ trend drove share higher stock trade higher prospect acceler top-line growth septemb
announc neotract acquisit share remain rel rang bound earli sever distributor hiccup question
around growth base busi off-set upsid potenti neotract howev share appreci urolift perform
inc equip pe ntm estim pricepric lh rel pe barclay medic suppli devic
sale product categori mo
sale geographi mo
product includ cathet relat devic posit use intraven medic administr
blood pressur measur draw blood sampl product primarili market arrow brand
teleflex anesthesia segment includ pain airway manag product pain product includ epidur kit
peripher nerv block kit dispos pain pump airway manag product includ mask atom
devic endotrach tube laryngoscop
divis includ product use intervent cardiologist intervent radiologist vascular surgeon
cathet devic treat coronari peripher vascular diseas bone marrow access system
hemodialysi cathet cardiac diagnost cathet includ busi segment
product includ singl use reusabl product ligat wound closur system
laparoscop surgic instrument port
sale entir urolift franchis
categori includ single-us respiratori urolog
teleflex sale ep ahead street/our expect constant currenc
sale growth driven intervent urolog
though perform broad-bas includ intervent access vascular
access surgic rel estim ep beat function higher
sale gross oper margin improv significantli lower expect
tax rate given strength ytd manag rais constant currenc sale
expect well rais low end ep guidanc net/net remain
equal weight believ valuat continu captur posit outlook
addit detail quarter
million except per share data chang sale constant currenc basi unless otherwis note
intervent urolog urolift sale street
estim y/i full-year guidanc urolift rais
unsurprisingli manag highlight roll-out
urolift margin upgrad roll-out japan wasnt includ lrp
adjust ep reflect growth y/i despit fx headwind
quarter given ytd perform manag rais constant currenc
revenu guidanc vs prior despit worsen fx
increment impact steril shut-down invest
spend manag rais low end ep guidanc
manag re-affirmed lrp target note feel confid ever
achiev goal laid may
third-parti sterigen privat steril facil georgia shut
manag expect disrupt top line impact
full year ep impact
fx headwind greater vs prior contribut lower
report revenu growth guidanc vs prior
sale report constant currenc basi
gross margin y/i reflect increas sale volum
favor product mix benefit cost improv program partial
off-set impact tariff
sg sale y/i reflect invest spend
 sale y/i
oper margin y/i driven gross margin expans
time invest spend volum leverag
adjust tax rate y/i
adjust ep y/i y/i exclud effect fx
sale rais constant currenc growth expect vs prior cite ytd perform higher
urolift sale vs prior vascular intervent access product line off-set third-parti steril issu
impact fx headwind expect vs prior net/net report sale growth expect
margins/ep manag reiter gross margin oper margin guidanc
compani expect interest expens vs prior benefit redempt note manag
lower tax rate expect lower end previou net/net manag rais low
end ep guidanc vs prior includ fx headwind vs prior headwind
associ closur third parti steril facil
urolift home run product continu
stock current trade hefti premium
growth given signific total address market
med-tech name reflect high expect growth
achiev beat long-rang plan goal
revenu growth achiev oper margin
rang driven perform continu strength
urolift
improv legaci core busi sale growth along
slowdown urolift sale rel expect could
prevent achiev long-rang plan goal
revenu growth hurt stock trade urolift
believ neotract vsi acquisit help sale growth prospect stock trade
signific premium rest med-tech space believ reflect growth
feb estimate result guidanc
apr societi american gastrointestin endoscop surgeon sage
possibl question topic manag
put take investor consid potenti
impact recent steril issu
urolift continu signific growth trajectori confid
continu drive adopt urolift urologist commun unit state
anticip chang competit reimburs environ truli smooth
sail still forese futur
describ intern opportun factor limit adopt
expect adopt rate japan could similar differ japan
market rel us
latest think around urolift margin impact
urolift sale seemingli track intern expect profit
relat deal deal accret hope
manag confid long rang plan outlin may abil
meet sale object seem easi achiev view also margin target
seem perhap track bit behind perhap
essenti sustain growth
investor confer decemb comment would like tuck-in
acquisit oem segment view attract market opportun
market categori view attract unattract current agnost
current valuat tuck-in scale transact
opportun intern
outsid urolift product could help deliv top-lin growth
expect manta beyond latest updat ez-
plaz view market opportun ez-plaz re-launch strategi
percuv still believ million opportun
possibl questions/top manag
possibl question manag
put take investor consid fx
urolift maintain signific growth trajectori also see urolift section
signific could new product manta percuv
manag confid long rang plan outlin may
abil meet sale object seem easi achiev
view also margin target seem challeng achiev
latest restructur program time save
long quest achiev sustain sale growth rate
primarili pursu end compani achiev goal recent
addit neotract ad urolift portfolio lesser extent
teleflex estim organ growth adjust sell day
initi constant currenc sale growth guidanc in-lin long-
rang plan growth investor felt easi bar consid
adjust ep incorpor fx/tax headwind invest spend
throughout urolift outperform busi lead manag
rais sale guidanc despit expect steril headwind expect
sale growth inclus urolift growth adjust ep
expect high end origin rang despit greater fx
steril headwind invest support futur urolift growth
may investor day outlin long-rang plan lrp
period expect averag organ constant currenc revenu growth rate
assum base busi grow rate vascular
solut acquisit add growth neotract add manag
provid color product assumpt period lrp assum
contribut urolift japan manta sale yet acquir
asset assum million ez-pla million percuv sale
expect adjust gross margin reach oper
margin reach margin improv weight back
end lrp
barclay
barclay
barclay
actual
barclay
expect like guid constant currenc sale growth somewher
lrp guidanc current guidanc
model constant currenc growth larg driven continu
success urolift franchis repres roughli half compani overal
growth model ep predic achiev
oper margin improvementsometh feel less confid given
compani desir invest behind futur urolift growth growth initi well
like pressur fx over-deliv top line recent
year mostli due urolift under-deliv oper margin side
chosen invest well impact fairli significantli fx
possibl question manag
confid continu drive adopt urolift
urologist commun unit state
talk intern opportun factor limit
adopt expect adopt rate japan could
similar differ japan market rel us
latest think around urolift margin impact
urolift sale seemingli track intern expect
profit relat deal deal accret hope
return profil track would like
anticip chang competit reimburs
environ truli smooth sail forese futur
urolift minim invas technolog treat lower urinari tract symptom due
benign prostat hyperplasia bph urolift procedur perman implant place
hold prostat tissu away obstruct urin flow minim invas
acquir urolift acquisit neotract octob
million up-front track pay million conting sales-bas
mileston payment view urolift tremend acquisit
insofar boost compani top-lin growth though yet gener
signific increment cash flow return full invest ad
mileston payment made said sale growth continu sale market
spend moder gener handsom return time
address patient popul urolift extrem larg incid bph
men men men age
project urolift sale nearli million constant
currenc basi view urolift problem surpass million
market continu march toward billion-plu product line
teleflex/neotract view urolift market opportun
compani report per teleflex denot neotract intern market estim
unit state american urolog associ aua clinic guidelin
includ urolift standard care option treatment bph view
help drive adopt technolog reimburs rate also favor
physician well provid perspect lastli importantli clinic
data also posit urolift peer-review
public urolift system lowest cathet rate new sustain
erectil ejaculatori dysfunct
though initi focu us opportun estim billion
market intern opportun equal larg sale primarili
uk though work reimburs countri
receiv shonin japanes approv wait receiv reimburs
occur latter end expect gener revenu
japan manag note includ japanes urolift revenu
lrp plan thu revenu repres upsid plan see japanes
market billion market opportun longer term
urolift design urolift expect reduc wast
dispos single-deliveri cartridg instead entir devic improv margin
estim urolift gross margin current mid-to-upp
urolift margin could
next gener urolift urolift origin plan begin roll
full physician base convert howev compani
decid delay limit launch around decid expand
urolift sale forc want allow time clinician train avoid
overburden sale forc also want make improv devic
visual roll next gener
competit limit thu far
time acquir neotract invest commun
skeptic whether asset right asset bph
boston scientif subsequ acquir nxthera rezum system
treat bph rezum also minim approach fundament differ urolift
rezum use water vapor remov excess prostat tissu allevi obstruct flow
rezum clear fda though uptak rezum thu far
limit reimburs well rel concern around side-effect
possibl question manag
essenti sustain growth
investor confer decemb comment would like
tuck-in acquisit oem segment view
market categori view attract unattract current
agnost current valuat tuck-in scale transact
opportun intern
recent year gener reli acquisit drive top-lin growth may
investor day note intend remain serial acquir focu
invest key diseas state market
figur highlight acquisit histori deal greater million
valu year done varieti deal two recent
platform acquisit includ vascular solut neotract
manag consist open willing acquisit
comment investor confer decemb net leverag around
estim capac around billion
interestingli us manag comment investor expect tuck-in
acquisit especi within oem segment found interest sinc
segment investor typic think come
manag also comment investor expect compani accret
scale acquisit dealer direct convers late-stag technolog
essenti medic develop manta larg bore vascular closur devic use
tavr evar procedur
qt vascular enter asset purchas option agreement acquir
non-drug coat coronari product option purchas drug coat
neotract urolift minim invas system treat bph
vascular solut focus minim invas product coronari
mayo healthcar australia-bas distributor
vidacar made power driver needl devic access insid bone
lma netherland base compani special laryng mask
anesthesia emerg care
sempru develop sustain polym coat surfac medic devic
reduc thrombosi microbi growth initi applic technolog
picc vascular product
possibl question manag
outsid urolift product could help deliv top-lin growth
expect manta beyond
latest updat ez-plaz view market
opportun ez-plaz
re-launch strategi percuv still believ
outsid neotract vsi compani develop acquir sever product
offer potenti drive improv sale growth
manta vascular closur devic design closur larg bore arteriotomi
typic associ transcathet aortic valv replac tavr endovascular
aneurysm repair evar acquir product octob acquisit
essenti medic million million potenti sale regulatori
manta receiv ce mark approv juli receiv fda approv februari
launch manta unit state limit basi test
adopt price strategi discov abl obtain modest
premium product plan enter market full releas januari
manag estim market million size take
time gain share said manta includ lrp plan
manag acknowledg competitor three year away market
current use abbott perclos proglid take longer mani patient requir
secondari closur method manual compress subcutan stitch second
ez-plaz packag freeze-dri plasma polym bag store room
temperatur reconstitut steril water two minut ez-plaz
develop armi armi sponsor clinic trial treatment
battlefield trauma emerg applic resuscit plasma requir
stop uncontrol bleed prevent shock militari current freeze-dri
plasma avail howev glass bottl fragil militari medic
current plasma stock typic store frozen requir minut thaw
thaw maintain shelf life dynam coupl urgenc associ
trauma case lead plasma wast approxim expect
civilian opportun em transport hospit segment
acquir repla part acquisit vascular solut retain
estim total market size ez-plaz approxim million
govern contract repres roughli million civilian use repres
remain million
invest commun view ez-plaz potenti upsid driver lrp
forecast el-plaz receiv acceler bla approv pathway april complet
phase safeti trial initi manag plan submit bla submiss
launch product point manag includ modest sale
million lrp howev fda ask addit test
complet bla submiss delay file agre
protocol pediatr studi manag note complet test
updat invest commun updat bla submiss date
fda grant emerg use french freeze-dri plasma us
depart defens treatment hemorrhag coagulopathi militari personnel
medic emerg plasma unavail practic use french
manufactur centr de sanguin de arm french fda-
licens approv french equival fda
percuv surgic system percutan approach access inner organ
tissu achiev via needl punctur laparoscop surgeri percutan
approach reduc number trocar medic devic function portal
subsequ placement instrument provid better angl surgeon
address surgic site minim trauma patient
percuv receiv initi fda ce mark approv product made
wide avail second gener launch august
aim versatil less invas first gener system unfortun
issu voluntari recal multipl delay target return
product manag slowli roll percuv back
plan broader launch
past manag comment percuv could million
opportun manag note model million percuv
model lrp manag character percuv show-m product
would agre assess given histori
possibl question manag
potenti impact recent steril issu long impact
busi plan address disrupt
much threat competit acquir vascular solut busi
guidelin traplin etc entri medtron telescop product
still feel confid acquir vascular solut busi grow double-digit
begin octob one contract steril sterigen
oper smyrna cobb counti georgia steril facil suspend indefinit
due issu ethylen oxid emiss plant steril issu
caus disrupt surgic intermitt cathet oem product
estim suspens neg million impact sale
bp full year sale neg impact adjust ep includ
manag note start requalifi steril area
manag note clear line site facil may
guidelin cathet largest product line acquir vascular solut
acquisit guidelin cathet guid extens cathet allow
interventionalist navig diseas calcifi lesion estim sale guidelin
cathet roughli million includ bulk vsi sale
may launch compet guid cathet telescop
heavili promot product last fall tct intervent cardiolog confer
juli su alleg patent infring telescop cathet
sought preliminari perman injunct
continu grow modestli deceler
success past deal notabl
neotract urolift vsi help acceler
overal growth believ sale growth
achiev warrant premium pe
stock current reflect equal weight
upsid case could driven greater urolift
vsi sale greater improv profit
improv core busi sale growth
rate accret
downsid case could driven slowdown
urolift sale rel expect challeng
within core busi foreign exchang rate
stronger us dollar higher interest rate
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
quarterli annual ep usd
consensu number bloomberg receiv gmt
price pe perform
zimmer announc intent acquir rival biomet april initi enthusiasm around prospect combin
entiti howev compani experienc deceler sale growth trend head deal close june earli
renew enthusiasm potenti acceler growth howev prove fleet stock struggl
financi outlook remain lacklust compani announc challeng manufactur qualiti front fda decemb
zimmer biomet announc bryan hanson would next ceo intial enthusiam around appoint though
lower earn reset prompt declin stock price view recent move upward hope earn outlook
final reset initi hope fade stock under-perform stock outperform compani fundament
show sign improv
biomet hold inc equip pe ntm estim pricepric lh rel pe barclay medic suppli devic
sale product categori mo
sale geographi mo
zimmer biomet knee implant portfolio includ product instrument primari revis
procedur compani offer partial knee system total knee system person implant solut
market persona knee busi also includ capit sale rosa knee robot system
segment includ hip arthroplasti implant instrument primari revis procedur
sport extrem
product includ soft tissu injuri repair product sport medicin patient extrem repair replac
devic like plate bone nail shoulder elbow implant biolog solut enhanc recoveri
trauma surgeri
dental product includ dental implant system surgic kit surgic tool regen product
includ spinal implant devic design treat traumat injuri degen condit biolog solut
electron stimul product within spine divis cmf divis includ facial skull
reconstruct product product bone fixat stabil chest injuri cardiac surgeri
segment includ bone cement offic base technolog product like zimmer biomet spinalpak spinal fusion
zimmer biomet zb sale ep came street/our estim
constant currenc basi sale estim manag
comment first half headwind bill day off-set
estim provid tailwind also benefit buy ahead
japanes consumpt tax zb reiter full-year guidanc net/net view
result favor believ zb still long road restor compani higher
level sustain sale growth margin pressur like persist continu
addit detail quarter
million except per share data chang sale constant currenc organ basi unless otherwis note
constant currenc sale growth ahead wamgr help
sell day benefit buy ahead japanes consumpt tax growth
driven continu perform apac emea well
stabil america
knee sale ahead street/our expect rosa
acceler sequenti contribut quarter manag note
still earli half overal growth came new product base
 sale street/our estim manag
highlight suppli stabil new product launch traction special sale
channel drive result categori
hip sale street/our expect manag
note two driver potenti above-market growth longer term avenir complet
system anterior approach well eventu applic rosa hip
despit beat zb didnt rais full-year guidanc cite number benefit
quarter contribut above-wamgr growth nonetheless zb posit
growth line wamgr albeit like low end
headwind like emea rebat year ago quarter
sale report basi constant currenc
basi constant currenc growth vari knee hip
spine cmf dental
gross margin y/i driven number item includ
med-tech tax refund fx hedg ad
sg sale y/i dollar basi driven
new product launch sale forc expans
 sale y/i
oper margin y/i driven gm expans
adjust tax rate flat y/i
adjust ep street estim estim
manag expect grow line wamgr
manag reiter prior guidanc though fx expect closer high end rang sale
expect flat report basi oper margin expect adjust tax rate
expect manag expect adjust ep
zimmer biomet new manag team success
overse transit back least market growth
 could shift portfolio higher wamgr
zb share appreci past year
longer super cheap rel name
within medic devic sector also slower grow
knee rosa robot lead improv
underli growth knee busi zb largest
abil expand margin could limit need
reinvest back busi drive futur growth
sector
view appoint bryan hanson ceo posit catalyst chang believ
taken right step orchestr turnaround howev believ transform still
like take time year still like result compani grow low-to-mid singl
digit compani confin end-market growth rate opportun
margin expans believ limit take longer materi street expect
feb result guidanc
american academi orthoped surgeon aao orlando fl
possibl question topic manag
put take consid investor think
cfo suki upadhyay primari takeaway sinc take cfo
reason optim compani trajectori
investor think long-term growth profil compani
compani inflect wamgr manag target particular ep growth
rate accept reinvest certain rate
gross oper margin go time timelin look like
action compani take achiev margin goal
compani sale forc structur independ rep limit factor achiev lower
margin way term magnitud margin expans perhap timelin
achiev opportun go direct
rosa robot platform launch progress quantifi financi impact
may beyond term capit placement pull-through implant
zb close gap knee portfolio recent product launch
appropri leverag level zimmer biomet manag thought
around area view attract make market attract
dental core part compani spine
extent would compani will transact would adjac
white space diversifi revenu profil
statu remedi effort warsaw campu ultim
happen north campu facil plant ponc warn letter
could zb risk receiv corpor warn letter
possibl questions/top manag
possibl question manag
put take consid investor think
investor think compani long-term growth profil
gross oper margin go time
action compani take achiev margin goal
sale forc structur independ rep limit factor achiev
lower margin timelin achiev opportun go
cfo suki upadhyay primari takeaway sinc take
cfo reason optim compani trajectori
zimmer biomet challeng year one transit
zimmer biomet constant currenc revenu growth reflect
increas volume/mix off-set neg price rate growth
overal orthoped market oper margin year
prior year reflect lower gross margin higher level sg spend
adjust cash ep compar prior year
manag began focu stabil recoveri initi view
year step stone toward goal grow line weight averag
market growth rate wamgr howev juli manag
announc reach goal six month earli manag believ could
grow in-lin market wamgr show sequenti
improv across everi product categori rel albeit sell day help
benefit versu
zb track deliv expect novemb manag reiter full
year goal year manag expect sale flat report basi
fx expect higher end rang oper margin
expect y/i adjust ep expect
y/i
sinc earli zb note first year expect consist
durabl wamgr progress
earn manag express confid expect
respect zb note expect see pressur gross margin given price
headwind manag note would expect see slight oper margin
improv howev manag note may elect invest grow top line
well could limit margin expans
part broader margin improv plan zb initi effort address
structur challeng put downward pressur margin structur
challeng like price address last year margin
declin basi point issu like suppli remedi recent quarter
increas suppli stabil new product rosa persona revis new
product help compani drive sale forc improv result
next portion plan stabil margin cost reduct lower
cog along disciplin sg spend manag begun cost cut
initi across manufactur suppli chain defer cost increas
invest stabil busi suppli expect flow cog
line present headwind gross margin medic devic tax one-tim gain
benefit zb repeat addit aforement fx hedg
gain recur price remain headwind margin
despit headwind higher revenu growth expect help lead final
portion plan improv oper margin compani reach sustain
growth wamgr manag expect achiev consist
margin improv long-term zimmer biomet believ could cut cost
deliv margin margin expans howev expect show
signific improv would rather invest reduc cost
way support sustain top-lin growth
respect gross margin note price pressur industry-wid
consist erod zb gross margin annual sinc fx
hedg fluctuat benefit gross margin headwind
hedg gain benefit margin like zb also
benefit medic devic excis tax reoccur zb manag
note expect level hedg gain occur though gain
eventu roll present headwind presum
possibl question manag
rosa robot platform launch progress impact
growth beyond
sort up-tak investor expect term capital/robot
placement time potenti pull-through benefit implant side
zimmer biomet acquir rosa robot system juli acquisit
med-tech sa french med-tech compani origin applic rosa spine
compani iter platform use total knee arthroplasti januari
zimmer receiv fda approv total knee applic zimmer biomet began
market product march aao meet began sell system
still limit launch rosa knee posit growth close gap without
capit result posit impact knee franchis
rosa capit sale acceler sequenti serv strong contributor
knee growth though manag note launch still earli stage half
overal growth busi came product base knee busi
said manag note demand rosa high system gain traction
among surgeon manag expect continu acceler
system one primari growth engin organ
applic rosa
time acquisit med-tech sa portfolio includ rosa brain rosa spine
fda approv ce mark februari zb gain fda
clearanc next-gener rosa one brain applic compani rosa one
spine system subsequ approv march rosa one spine rosa one brain
rosa knee avail robot hardwar platform platform
clear neurosurg spinal knee patholog zb hasnt fulli launch rosa
one spine system plan full launch first part
zb manag also comment eventu applic rosa hip
extrem though formal timelin given regard hip manag
note robot system could allow compani get upper end
overal hip market growth low-single-digit
possibl question manag
appropri leverag level zimmer biomet posit
conduct
dental core part compani spine
compani will transact adjac white space
diversifi revenu profil
resolv qualiti issu return compani weight averag market
growth rate wamgr initi focu ceo bryan hanson zb
accomplish goal believ manag team focu may begin got shift
bigger pictur strateg agenda improv wamgr someth north
although manag note novemb see pathway
acceler beyond level without need
view capit alloc like critic longer term success zimmer
biomet share believ ceo bryan hanson look increas compani weight
higher growth end market manag note desir diversifi growth
engin like categori within sport extrem march wall street
journal report zimmer biomet retain advisor assess potenti
divest compani dental busi consid sale
zimmer biomet cash flow balanc sheet improv compani expect
gener billion free cash flow think cash flow
improv go forward septemb zimmer biomet net debt
billion net debt ebitda would consid extrem low there
flexibl deal make
ask investor confer interest pursu larg deal
similar acquisit wright medic manag acknowledg
compani less-than-stellar track record said would prefer smaller deal test
water pursu larger diversifi acquisit
possibl question manag
close competit gap knee need
investor think long-term mix cement versu
cementless knee recent launch persona cementless knee
earli feedback surgeon use persona
opportun streamlin number sku reduc cost
inventori improv margin
zb knee busi compani largest product categori repres
sale zb market leader low-single-digit growth billion market seen
share loss last year due suppli constraint result qualiti remedi
effort limit product innov lack robotic-assist platform
zb current knee portfolio includ flagship persona famili total partial revis
knee system nexgen famili total revis knee system vanguard total
knee oxford partial knee system acquir zb merger persona total
knee system first clear subsequ launch persona partial
cementless revis knee system help drive recent growth
robot stryker mako signific head start robotic-assist knee
replac taken share three major player zb js depuy
synth smith nephew three invest significantli
form robot end on-going launch zb rosa knee system help
stabil compani share loss knee given pull-through implant
partial knee septemb zb partial knee portfolio limit mobile-
bear oxford partial knee system gain biomet acquisit compani
launch persona partial knee system allow compani particip fixed-
bear segment partial knee market
cementless zimmer biomet launch persona cementless total knee earli
cementless segment market previous domin
triathlon cementless total knee system launch benefit
premium-pr cementless knee repres roughli quarter stryker
knee expect similar premium-pr benefit persona cementless
anticip cementless penetr within persona reach similar mix
zb cementless persona platform legaci biomet knee system
thu dont expect penetr cementless look zb broader
revis zb manag comment time import ad
revis system persona famili note absenc keep
prospect custom side-lin
septemb zb announc fda clearanc launch revis system
complet persona platform compani announc first surgeri use
revis system decemb
possibl question manag
statu remedi effort warsaw campu
ultim happen north campu
back suffici suppli level product
statu two warn letter
much spend need resolv warn letter address
manufactur defici across compani
could compani risk corpor warn letter
late fda inspect zimmer biomet north campu manufactur facil
warsaw indiana issu fda inspect observ
inspect observ issu conclus inspect fda
investig observ condit may constitut violat food drug
cosmet fd act relat act
april zimmer receiv anoth relat north campu facil
subsequ respond fda
august zimmer biomet receiv warn letter fda relat
north campu facil warn letter fda acknowledg progress
made zimmer biomet note outstand defici fda also propos
regulatori meet discuss propos correct
manufactur qualiti remedi effort initi affect zimmer biomet abil
produc adequ suppli product across knee hip busi unit
compani work improv suppli product made progress eas
constraint
earn call manag note qualiti remedi plan
remain track full remedi compani also engag independ third
parti conduct mock audit remedi effort manag note
feedback posit
north campu facil warn letter face compani may
zimmer biomet receiv warn letter fda relat observ non-
conform current good manufactur practic requir qsr
facil montreal canada septemb legaci zimmer receiv warn letter
fda cite concern relat certain process pertain product
manufactur ponc puerto rico manufactur facil ponc warn letter
equal weight view appoint
bryan hanson ceo posit catalyst chang
believ orchestr turnaround
howev believ transform need
like take multipl year see prospect
signific sale margin expans
limit near-term
upsid case could driven improv
market trend orthoped greater success
improv price trend strateg
downsid case could driven inabl
receiv and/or execut new product approv
deterior price addit fda regulatori
exchang stronger us dollar dilut
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
valuat methodolog risk
valuat methodolog set price target primarili reli forward price-to-earnings methodolog believ stock
maintain premium multipl given top line bottom line growth prospect pt appli multipl ep
risk may imped achiev barclay research valuat price abbott signific exposur
emerg market intern broadli thu chang fx rate could pressur sale ep result new product central
posit view approv adopt new product therefor anoth risk risk includ healthcar reform effort medicar
reimburs chang product recal fda warn letter govern regulatori action libr signific driver
growth chang trajectori key risk factor
valuat methodolog price target base ev/sal multipl appli multipl sale estim
arriv valuat med-tech compani substanti question growth outlook histor trade revenu
pt would equat ep
risk may imped achiev barclay research valuat price risk includ approv
abil compani sustain least mid-single-digit growth time uptak new product abil realiz cost save
target off-set strand cost chang effect tax rate foreign exchang success deploy capit dilut
valuat methodolog set price target primarili reli forward price-to-earnings methodolog pt appli target pe
ep estim
risk may imped achiev barclay research valuat price outcom account investig
key risk factor new product import baxter growth outlook therefor approv uptak new product key risk
factor gener competit particularli cyclo brevibloc could pressur earn and/or extent pressur less expect
favor impact fx rate stronger us dollar could also pressur baxter sale earn outlook risk includ signific
reimburs chang fda govern action
co
valuat methodolog set price target primarili reli forward price-to-earnings methodolog price target appli
multipl calendar ep
risk may imped achiev barclay research valuat price upsid risk factor extent becton
success integr bard see greater expect revenue/cost synergi downsid fx stronger us dollar commod
cost could greater headwind risk factor includ time success new product increas competit key product
drug-coat balloon infus pump signific chang reimburs fda govern action
valuat methodolog price target methodolog base enterpris valu sale appli multipl sale estim
billion arriv price target smid cap med-tech name similar growth outlook current trade
risk may imped achiev barclay research valuat price risk includ abil integr
transact particularli buffalo filter new product approv competit price pressur fda action abil expand oper
margin abil reduc debt
valuat methodolog set price target primarili reli forward price-to-earnings methodolog price target appli target
pe calendar ep estim slight discount med-tech compani trade
growth profil improv expect pe expand
risk may imped achiev barclay research valuat price downsid risk includ fx rate
strengthen us dollar could pressur earn stock perform new product key futur success compani
thu extent compani unabl receiv fda approv could advers impact futur outlook product includ
compani surgic robot platform expect regulatori approv outsid unit state begin key
product includ micra av interstim micro minim futur iter continu blood glucos monitor devic
transcathet valv system upsid greater success new product margin expans risk includ signific reimburs
chang competit pressur product failur fda govern action
valuat methodolog set price target primarili reli forward price-to-earnings methodolog price target appli pe
multipl ep estim
risk may imped achiev barclay research valuat price fx rate recent acquisit could
pressur earn growth competit pressur particularli area knee competitor launch compet robotic-assist
system could impact growth outlook sentiment toward stock time ultim receipt new product approv could
affect outlook risk includ signific chang reimburs potenti dilut associ acquisit product failur
fda govern action
valuat methodolog risk
valuat methodolog set price target primarili reli forward price-to-earnings methodolog price target appli pe
multipl ep estim premium market other med-tech sector believ
warrant given higher growth rate
risk may imped achiev barclay research valuat price upsid extent neotract urolift sale
higher expect could drive upsid sale earn lead higher pe downsid urolift sale disappoint core
growth fail improv fx stronger us dollar higher interest rate half debt float risk includ time receipt
new product approv competit pressur particularli key product like urolift signific chang reimburs fda
govern action
kristen stewart cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
